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Abstract
Alzheimer's disease (AD) is the most prevalent cause of senile dementia in industrialized nations. The
financial and organizational challenges it presents will increase with the projected rise in the proportion of
older people in the population. Elucidation of the causes and progression of AD and development of
effective treatments has been hampered by the lack of an animal model suitable for laboratory research.
The discovery of rare heritable AD cases coupled with the development of transgenic technology has
provided the possibility of generating powerful research tools. Resulting transgenic animal models have
already aided understanding of the disease progression and suggested possible treatments. This thesis
investigates the hippocampal electrophysiology and pathology of a rat model of the presenilin 1 gene
M146V mutation, and is the first rat model of presenilin 1 AD. This mutation causes dominant inheritance
of AD in a Finnish family. Since affected subjects show early disease onset and rapid deterioration, it was
hoped that the PS1Mm6v transgene would promote generation of a phenotype within the life-span of the
rat. In this study, extracellular field potential recordings of medial perforant pathway/dentate gyrus and
CA3/CA1 synaptic properties and plasticity have been made in the PSlMi46v transgenic rats and their non-
transgenic littermates at 6 and 18 months old. No changes were observed in the half-maximal EPSP
amplitude. At 6 months, no changes were seen in the expression of long-term potentiation, post-tetanic
potentiation or paired pulse plasticity in either pathway. Synaptic plasticity recorded in the dentate gyrus
in 18 month animals was also unchanged. However, long-term potentiation was significantly increased in
the CA3/CA1 pathway in 18 month old transgenic animals, which showed a striking difference in its
pattern of development. Paired pulse facilitation and post-tetanic potentiation were unchanged. This age-
dependent and pathway-specific change is consistent with the progression of AD in human subjects, and
results published on presenilin 1 mouse models. Intracellular sharp electrode recordings were made from
CA1 pyramidal neurones from the 18 month old animals to investigate the source of the changes in long-
term potentiation. No changes were observed in the passive membrane properties, action potential
properties, the duration or amplitude of slow, medium and fast afterhyperpolarization and action potential
adaptation. However, the half width of the EPSP was significantly increased, which may be attributable to
slower membrane repolarization. A similar lengthening of EPSP decay time has been reported for the
conditioned response during paired pulse facilitation, and this has been attributed to autoinhibition of
GABAergic interneurones via GABAb receptors. Further studies are required to establish whether
GABAergic mechanisms are responsible for the observation in the PSlMi46v rat. A preliminary
histological investigation using congo red failed to reveal amyloid deposition or neurofibrillary tangles in
the PSlMi46v rat and this has since been supported by another laboratory using more rigorous
immunohistological techniques. This observation is consistent with the findings reported in a presenilin 1
mouse model. These results support the success of the PS1Mm6v transgene in creating a phenotype with
possible use in AD research. Its future contribution would probably be in generating a double transgenic
model by cross breeding with a mutated amyloid precursor protein line, which has proved to be a





Alzheimer's disease (AD) is a fatal neurodegenerative disorder usually associated with the elderly. It
is characterized by insidious deterioration of cognitive functions, which leaves the sufferer
increasingly dependent on carers. The disease is prolonged, often lasting 8 to 12 years following
diagnosis, severely impairing quality of life for sufferers and generating a huge emotional burden on
relatives. It also causes economic and organizational challenges for both carers and society. This
burden will increase given the projected growth in the ageing population. Current treatments are
limited, and at best give only temporary alleviation of symptoms, with eventual incapacitation and
death being inevitable. These considerations make the search for the cause of AD and development of
effective treatments of great importance.
1.1 Epidemiology and Diagnosis
AD is the most common form of dementia in industrialized nations. Estimated prevalence varies
greatly, but is usually quoted between 5 to twenty per cent for the population over sixty-five years old
and twenty to fifty per cent for those over eighty-five years old (Bachman et al 1992, Rosenberg 1997,
Evans et al 1989, Skoog et al 1993). Despite the variation in figures, all studies show a trend of
increased AD prevalence from around sixty to eighty-five years of age. In men there is an
approximate doubling in incidence every decade from sixty years, reaching a plateau after eighty-five
years (Skoog et al 1993). Such a plateau is not seen in women.
The variability in prevalence figures arises from diagnostic difficulties. These are due to tire
heterogenous nature of the disease and the overlap of symptoms with other illnesses, particularly
vascular dementia and Creutzfeld Jacob disease. Mild AD is particularly hard to diagnose, and some
epidemiological studies have chosen to quantify only moderate and severe cases, creating further
discrepancy in prevalence figures.
In 1984, a task force consisting of the National Institute of Neurological and Cognitive
Disorders (USA) and the Alzheimer's Disease and Related Disorders Association developed a set of
criteria to improve diagnostic accuracy (Appendix I) (McKhann et al 1984). It was agreed that a
definite diagnosis of AD is not possible using current clinical tests. Instead, the task force decided that
diagnosis of 'probable AD' could be made upon demonstration of typical clinical symptoms according
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to their criteria, and having eliminated other dementing illnesses as the cause. Even with these clinical
criteria, the accuracy of pre-mortem diagnosis is variable, with the most experienced assessors
correctly diagnosing about ninety per cent of cases (Galasko et al 1994), and accuracy identifying the
disease in its early stages can be much lower. For this reason, the task force stated that a definite
diagnosis can only be made when the clinical assessment is combined with positive autopsy results.
For effective treatments to be developed, early diagnosis of AD is especially important.
Towards this goal, various approaches are being investigated. Computerized tomography scans and
magnetic resonance imaging can be used to identify other conditions as the source of dementia by
detecting abnormalities such as ischaemic lesions caused by stroke and tumours. These techniques
also reveal cortical atrophy and dilation of ventricles typical of AD, however, the extent of atrophy
overlaps extensively with that associated with normal ageing and is not diagnostic.
Magnetic resonance imaging is particularly sensitive and is helping to improve early diagnosis
by detecting reduced hippocampal volume (Jack et al 1999). Hippocampal cell loss is correlated to the
severity of dementia, making this test particularly relevant to the clinical condition. Increased
resolution of magnetic resonance imaging is now allowing visualization of larger senile plaques in
experimental conditions (Benveniste et al 1999), which in the future will hopefully allow definite
antemortem diagnosis. More recently, plaque stains derived from congo red have been developed that
are able to cross the blood brain barrier. It is intended that these will allow antemortem staining of
neuritic plaques to improve visualization using techniques such as magnetic resonance imaging
(Skovronsky et al 2000a).
Although there is no current antemortem test for AD, some factors strongly support a
diagnosis. Amongst these are the presence of the s4 allele at the apolipoprotein E (apoE) locus, which
is a known genetic risk factor. Cerebrospinal fluid of AD subjects consistently shows significant
elevation of tau and reduction in the Ap42 protein (Mehta et al 2000, Kanai et al 1998). Blood tests
would be more acceptable since cerebrospinal fluid tests require lumbar puncture. Recent efforts are
focussing on AD-specific changes in the forms of beta-amyloid precursor protein (ApPP) isolated
from platelets, which are correlated with the clinical severity of AD and reflect ApPP composition in
the cerebrospinal fluid (Sennvik et al 2000).
3
Although promising, most of these techniques are currently either still experimental, too
expensive or too time-consuming for a large scale epidemiological studies or general use.
1.2 Clinical Symptoms
Alzheimer's disease was first described by Alois Alzheimer in 1907. He documented the case of a
fifty-one year old woman who presented with extreme jealousy that was soon accompanied by
memory impairment and paranoid behaviour. She displayed violent outbursts and suffered from
auditory hallucinations, and was often too disturbed to be properly examined. During successful
examinations she was confused, lacked concentration and failed to perform simple verbal and writing
tasks. She showed no sign of significant motor impairment. Towards the end of her illness she was
bedridden, incontinent and apathetic. The patient declined steadily and died after 4 Vi years.
At autopsy the brain showed severe and widespread atrophy and arteriosclerosis. Histological
examination revealed intracellular fibrillar bundles, which persisted in regions of cell loss. Throughout
the cortex, extracellular deposits described as a 'peculiar substance' were observed (Alzheimer 1907).
At the time, dementia was considered a rare disease since cognitive decline in the elderly was
seen as a normal consequence of ageing. It was only later that the symptoms and pathology observed
in this middle-aged woman were linked to dementia in older subjects.
The typical early symptoms of AD are mild memory loss, particularly of anterograde
declarative memory, and subtle behavioural changes. Memory impairment gradually extends to all
forms of memory. Aphasia, manifest in difficulty naming objects and recognizing words, develops
into mutism in the late stages. Agnosia confers impaired judgement and reasoning, resulting in
difficulty planning and executing tasks. Subjects' ability to recognize objects and familiar faces
deteriorates. Apraxias involve physical inability to perform daily tasks. Subjects tend to be unaware of
their deficits (anosagnosia) and so are often reluctant to seek medical help. Sensory-motor function
tends to be spared ail though limb rigidity, coupled with extreme confusion and apathy leads to subjects
frequently becoming bedridden in the late disease stages.
Sufferers may also display a wide range of behavioural disturbances, which are often more
distressing for carers than the cognitive problems. These include verbal and physical aggression.
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paranoid delusions, hallucinations, sleep disturbances, depression, apathy, social withdrawal,
wandering and pacing, repetitive actions, incontinence and inappropriate social behaviour.
1.3 Neuropathology
Three forms of pathology are recognised as diagnostic abnormalities in AD:
• Amyloid plaques
• Neurofibrillary deposition
• Specific nerve cell loss
The brain areas most severly affected are the association areas of the neocortex, the
hippocampus, the amygdala and cholinergic neurones of the basal forebrain. This pattern of pathology
accords with the typical AD deficits in memory, analytical thought, perception, and motivation.
1.31 Amyloid Plaques
These are extracellular lesions of which there are three forms; diffuse, neuritic and dense-core. All
contain deposits of beta-amyloid (A|3; a globular protein cleaved from A(iPP). In healthy tissue, the
major cleavage product is 40 amino acids long (A(340), but some longer Ap42/43 is also produced.
Ap42/43 seems to be the important isoform in plaque formation, since it is less soluble due to its
additional N-terminal p-pleated sheet structure which increases its tendancy for fibril formation and
aggregation (Xia et al 1997). Plaques form when Ap42 levels increase in conjunction with a high
Ap42/Ap40 ratio, and in vitro studies have suggested that Ap40 hinders Ap42 deposition (Snyder 1994).
Neuritic plaques comprise a distinct Ap core surrounded by dystrophic neurites and reactive
astrocytes. Fibrillar Ap42/43 is the initial species to be deposited in neuritic plaques (Iwatsubo et al
1995), which is believed to seed the later deposition of Ap40 (Jarrett et al 1993). Other factors
associated with plaques are microglia and proteins such as ApPP, a 1-antichymotrypsin, apoE,
apolipoprotein J, heparin-sulphate proteoglycan (HSPG), butyrylcholinesterase and non-amyloid
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plaque component. Neuritic plaques are stained by congo red and show green bifringence when
observed under polarized light.
Diffuse plaques also contain aggregated Ap42/43, but have far fewer fibrils and lack the distinct
amyloid core. They are not associated with dystrophic neurites, are not stained by congo red and
attract very few astrocytes or microglia. It has been proposed that diffuse plaques are precursors to
neuritic plaques, possibly being converted by a butyrylcholinesterase-dependent mechanism, since
butyrylcholinesterase is only associated with plaques with high levels of P-sheet amyloid (Guillozet et
al 1997) and it induces Ap aggregation in vitro. However, diffuse plaques are not restricted to areas of
the brain that show degeneration in AD, for example, they are often found in the cerebellum. Also,
they occur in the brains of aged, non-demented individuals, (although this may represent preclinical
change). It has therefore been suggested that they are non-pathogenic and are either generated
independently from neuritic plaques or are converted to neuritic plaque by factors that are restricted to
limbic and association cortex areas. Alternatively, diffuse plaques are potentially pathogenic but not
all brain areas are susceptible.
Dense-core or 'burnt-out' plaques are the final stage of plaque development. Associated
neurites are degenerated and they no longer attract astrocytes. At this stage they are probably most
effectively degraded by microglia.
There are also Ap deposits in the cerebral vasculature, especially in vessels associated with the
cerebral cortex. Vascular amyloid comprises mainly of Ap40, suggesting that the vasculature is not the
source of amyloid deposited in the brain. The amount of vascular deposition is not correlated with the
degree of dementia, and so it is unlikely that it contributes to AD-related deficits.
1.32 Neurofibrillary Deposition
Neurofibrillary deposits are intracellular and mainly comprise the tandem repeat region of tau. This
microtubule binding protein undergoes various post-translational modifications, including
phosphorylation, glycosylation and glycation, which have been implicated in AD pathology.
The affinity of tau for microtubules is regulated by its level of phosphorylation. In AD, tau is
hyperphosphorylated (tau-p), which reduces its binding capacity and causes destabilizatiou of
microtubules. This may compromise neurone viability by impairing intracellular trafficking. Tau-p
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forms non-soluble paired-helical filaments, that aggregate into neurofibrillary tangles (NFT). These
build up in the cytoplasm, dislocating the nucleus and spreading into apical dendrites (but not axons)
of pyramidal cells. They are associated with vimentin, actin, ubiquitin, tau, Ap and neurofilament
proteins, which form a fuzzy coat around the tau-p paired-helical filament core.
Glycation of tau is observed in AD brain but not in age-matched non-demented controls (Ko et
al 1999b). Tau becomes an advanced glycation end-product (AGE); a protein heavily glycated by non-
enzymatic formation of covalent bonds between the amino-groups of proteins and sugars. The bonds
may be important for paired-helical filament formation; glycation can alter protein structure making
proteins inactive and increasing their stability, which may explain the persistence of tangles. In
addition, AGEs encourage formation of reactive oxygen species, which at low levels stimulate
neuroprotective NFkB activity and cytokines (Yan et al 1995) and at higher levels can cause oxidative
cell damage.
Tangles persist even when the cell is destroyed, leaving ghosts tangles that are eventually
degraded by astrocytes. Ghost tangles are prevalent in the nucleus basalis of Meynert and
hippocampus but are rare in tire neocortex, even in the presence of intracellular NFTs. This suggests
that they may only invade the neocortex in the later stages of the disease and are not the main cause of
cell loss, or that they are more effectively cleared from the neocortex. Their distribution is specific to
areas that show degeneration, such as the entorhinal cortex (LII and LIV), the subiculum, CA1, and
prosubiculum. Other areas less affected include the accessory basal nucleus of the amygdala, the
nucleus basalis of Meynert and the association neocortex, where they are mostly in LIII and LV.
Tangles are associated with other diseases such as Pick's, Down's syndrome (DS) and
progressive supranuclear palsy, however they receive special interest in AD since they have a
predictable distribution through various stages of the disease and their numbers correlate well with
levels of dementia. This pattern was recognised by Braak & Braak (1991) who used it to categorise
AD pathology into stages;
Transentorhinal Stages : Mild to severe deposition in the entorhinal cortex, targeting large stellate
neurones of the pre-a layer.
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Limbic Stages Pre-a strongly affected in the transentorhinal cortex. Some weak
deposition in the CA1 and subiculum.
Isocortical Stages : Ghost tangles in the transentorhinal and entorhinal cortices. Severe
pathology in all isocortical association and limbic areas. Primary motor
and sensory areas are spared.
Clinical changes relating to transentorhinal and limbic stages seem to be very subtle with
obvious decline observable only once tau pathology extends beyond the limbic areas in the isocortical
stage.
1.33 Specific Cell Loss
This predominantly affects large neurones in the association neocortex and limbic structures
(Bundgaard et al 2001). Cell loss is co-localized with areas affected by tangles and to a large extent,
neuritic plaques, with the level of cell loss correlating well with the severity of dementia (Gomez-Isla
et al 1997).
There is increasing evidence for apoptotic mechanisms in AD neurodegeneration. DNA
fragmentations has been identified by TUNEL labelling (Overmyer et al 2000) and brains of
Alzheimer's disease subjects show upregulation of factors linked to apoptosis such as caspase 3
(Stadelmann et al 1999) Bcl-2 interacting mediator of cell death, Bcl-2 related ovarian death gene and
p21 (Engidawork et al 2001). However, there is still controversy over whether necrotic cell death is
also involved. Evidence of necrosis and lack of apoptosis reported in some studies may be artefactual
since experimental conditions are manipulated to accelerate potential toxic effects and whilst a
cytotoxic insult may cause apoptosis when delivered chronically at a low level, the same insult often
results in necrosis when presented acutely and at a higher dose (Bonfoco et al 1995). This suggests
that apoptotic mechanisms may be more relevant to the gradual, insidious nature of AD progression.
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The following cell types are targeted in AD:
• Pyramidal neurones in the CA1 (forty per cent cell loss) and subiculum degenerate. CA3
neurones are largely spared.
• Large stellate neurones in the entorhinal cortex. This results in almost total destmction of LII and
reduced cell density in LIII. These neurones give rise to the perforant pathway, which is the major
source of cortical input into the hippocampus.
• Large multipolar neurones in LIV of the entorhinal cortex. These are the sole cortical output
targets of the hippocampal formation. Surviving cells have a high tangle load, which suggests
impaired function.
• Accessory basal nucleus cells in the amygdala, which project to the hippocampus.
• Large pyramidal cells of the neocortex association areas, especially the upper laminae.
• Cholinergic neurones of tire nucleus basalis of Meynert (forty to seventy per cent cell loss) as
well as tire medial septum and vertical limb of tire diagonal band of Broca. These form the main
cholinergic projections to tire neocortex and hippocampus and seem to be important for cognitive
function. Their loss is demonstrated by the lack of cholinergic markers in the cortex and
hippocampus.
The gross effects of cell loss are functional isolation of the hippocampus from tire neocortex
and other limbic areas and impaired cholinergic modulation of limbic and associational isocortex
activity, disrupting pathways that are important for normal cognitive function.
1.34 Other Pathological Changes
AD subjects are affected by other non-specific pathologies. Some AD subjects have Lewy bodies
without Parkinsonism, for which Lewy bodies are a typical pathological feature. These are found in
smaller pyramidal neurones in the deep cortical layers (Wakabayashi et al 1995). There seems to be a
correlation between Lewy body pathology and tire incidence of hallucinations in AD subjects,
especially in conjunction with poor eyesight (McShane et al 1995). However cases of Lewy body-
variant AD are often considered to be a distinct form of dementia since the clinical traits are specific
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enough to allow Lewy body involvement to be predicted antemortem (Liberini et al 1995). Also, there
is evidence that the neurodegenerative process is different, for example inflammatory processes do not
seem to feature in Lewy body variants of AD, which show much lower immunoreactivity for
microglia than brains from non-Lewy body AD subjects (Rozemuller et al 2000). Lewy body subjects
also lack tau immunoreactivity (Shepherd et al 2000).
In normal ageing, the apical dendrites of dentate gyrus granule cells and LII pyramidal cells of
the parahippocampal gyrus are extended, presumably to compensate for mild cell loss, allowing
maintenance of synaptic density. In AD subjects, this compensatory dendrite lengthening does not
occur (Callahan et al 1998).
Hirano bodies, which are restricted to the CA1 and subiculum, are eosinophillic rods or spindle
shaped bodies that contain actin and actin-associated proteins. Their function is unknown.
Granulovascular change is seen in hippocampal pyramidal cells coincident with tangles (Ball 1978).
They are clear, membrane-bound inclusions with a black granular core, which can distort neurone
shape and displace the nucleus. They are immunoreactive for tau and tubulin filaments (Price et al
1986, Dickson et al 1993). These lesions are considered to be secondary AD pathology since they are
found in many types of neurodegeneration, have a restricted distribution and in the case of hirano
bodies may be evident in subjects as young as twenty years old.
1.4 Genetic basis
AD has been commonly understood to be a sporadic disease occurring in the elderly. This was termed
senile dementia of the Alzheimer's type, to distinguish it from other forms of senile dementia such as
Parkinson's disease or vascular dementia. However, it was recognized that some cases of AD occur at
a much earlier age. Thus, cases in subjects under sixty years of age came to be termed pre-senile
dementia of the Alzheimer's type, with evidence that it was distinct from that observed in elderly
subjects (Pro et al 1980). It was also noted that some presenile cases are not sporadic, but are inherited
in a fully penetrant, autosomal dominant manner. This familial Alzheimer's disease (FAD) tends to be
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more aggressive than late-onset AD with subjects showing rapid cognitive decline and a shorter
survival time (Swearer et al 1996).
To date, mutations on 3 genes have been connected with FAD. These code for the ApPP,
presenilin 1 (PS1) and presenilin 2 (PS2). Mutations to PS1 are most common and may account for
about fifty per cent of all FAD (Campion et al 1999) (although estimates are as low as 18% (Cruts et
al 1998)). Late-onset FAD pedigrees exist but these are more difficult to identify. They are often
masked by family members dying from other causes before AD is evident, and so a genetic
susceptibility is not suspected. This may be especially relevant to PS2 mutations, which are not fully
penetrant and seem to cause a pattern of clinical development more typical of sporadic Alzheimer's
disease (SAD), being longer in duration and later in onset (Bird et al 1996). Conversely, it is possible
that some cases appear to be familial but are actually due to a common environmental factor, or that
since age is a risk factor for AD, familial longevity may increase the chances of SAD occuring in
multiple family members and being mistaken for FAD.
Although FAD is only thought to account for about 0.5 to 1 per cent of AD cases (Rosenberg
1997), it is hoped that studying the effects of these mutations will aid understanding of the processes
involved in the more prevalent sporadic forms. A major problem in the study of AD has been trying to
establish cause and effect. The predictable nature of FAD transmission has allowed monitoring of
preclinical family members known to carry the pathogenic mutation. This has led to identification of
preclinical abnormalities in cerebrospinal fluid, blood composition and brain volume, which help to
determine the order in which features of AD contribute to the disease and suggest possible treatments
and diagnostic tools. For example magnetic resonance imaging can detect decreased hippocampal
volume in FAD subjects up to 10 years before clinical symptoms develop.
SAD cases also seem to be influenced by genes. Although not sufficient or necessary for
causing AD, these genes may predispose individuals to the disease, making its onset more likely in
conjunction with other genetic or environmental risk factors. That genes are involved in AD concurs
with the observation that about 10 per cent of AD subjects have at least one relative who has had the
disease (Rosenberg 1997). The best understood risk factor associated with SAD is the s4 allele of
apoE. Mutations and dimorphisms in other genes have been suggested but these seem to have weaker
effects and are less well studied.
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1.41 The nature and roles of proteins involved in AD genetics
[j-Amyioid precursor protein and fj-amyioid
ApPP is an ubiquitously expressed glycosylated transmembrane protein that is especially prevalent in
the brain (Kang et al 1987, Selkoe et al 1988, Shimokawa et al 1993). The full-length protein (ApPPg)
is seven-hundred and seventy amino acids long (ApPP770) with other isoforms arising from alternative
mRNA splice variants. The most common isoform in the brain is ApPP695, which is mainly generated
in neurones (Tanaka et al 1988).
ApPP is processed by either a-secretase (Maruyama et al 1991), which is the main route in
healthy cells, or p-secretase (figure 1.1). a-Secretase is located at the cell membrane, where it cleaves
ApPP within the Ap domain to release a secreted N-terminal fragment, sApPPa and a C-terminal
stub. The C-terminal stub is further cleaved by y-secretase to release p3 (Haass et al 1993) and a
rapidly degraded C-terminal fragment. Since a-secretase cleaves ApPP within the Ap domain, this
pathway is non-amyloidogenic (Golde et al 1992).
The p-secretase amyloidogenic pathway is also active in healthy cells (Shoji et al 1992). p-
secretase is located in the endoplasmic reticulum and trans-golgi (Haass et al 1993). It cleaves ApPP
at the N-terminal of the Ap domain to release the secreted sApPPp fragment. The remaining C-100
stub is cleaved by y-secretase to release Ap (Golde et al 1992).
The identities of the secretases are as yet undetermined although there is growing evidence that
PS1 may have y-secretase activity (Li et al 2000a) and p-secretase may be the beta-amyloid
converting enzyme (Cai et al 2001).
Different lengths of Ap, varying from thirty-nine to forty-three amino acids, are produced
depending on the exact cleavage site of y-secretase. The more common forty amino acid variant is
formed in the late golgi, whilst the longer AP42/43 variants, (Ap42 being more prevalent,) are formed in
the endoplasmic reticulum, suggesting that there are two types of y-secretase with different subcellular
localizations and ApPP cleavage sites (Citron et al 1996). These y-secretases compete for the common
substrate, C-100, such that if Ap40 secretion is inhibited, the levels of intracellular AP42/43 increase











Figure 1.1 AfiPP a-secretase and j3-secretase processing pathways
The AfJ domain is highlighted.
ApPP is a house-keeping gene; an ubiquitously expressed gene that is important for non-
specialized cellular processes. As such, it is highly conserved and abundant, comprising about 0.2 per
cent of neuronal mRNA. Full length ApPP (ApPPfl) and sApPPa have recognized physiological roles
in neurite outgrowth, synaptic plasticity and neuroprotection.
sApPPa appears to protect neurones against excitotoxic insults and oxidative stress. Its
expression is increased following neurone injury and cells pretreated with physiological
concentrations of sApPPa show reduced excitotoxicity in response to glutamate or Ap. It reduces
neurone excitability by activating the high conductance charybdoxin-sensitive Ca2+-dependent K+
channel, which carries a hyperpolarizating K+ current. This may decrease the activity of voltage-gated
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Ca2+ channels and NMDA receptor channels and so lower both basal and glutamate-induced increases
in intracellular Ca2+ concentration. sApPPa also decreases NMDA receptor activity by altering its
phosphorylation state via a cGMP/PKG dependent pathway (Furukawa et al 1998). This does not
affect kainate or AMPA receptor activity. sApPPa release is stimulated by nerve growth factor,
suggesting it has a role in neurotrophic activities.
sApPPa levels are increased in the cerebrospinal fluid following in vivo induction of the
putative physiological correlate of memory; long-term potentiation, and when infused into adult rat
brains sApPPa improves performance in learning and memory tasks. Rats reared in a stimulus
enriched environment have more ApPP immunoreactive synapses and perform better in shock
avoidance and water maze behavioural tests than rats from impoverished environments (Huber et al
1997). ApPP overexpressing mice show upregulation of growth associated protein 43 (GAP-43) and
increased synapse density in the frontal cortex when examined using in situ immunohistochemistry
(Mucke et al 1994). GAP-43 is important for neurite outgrowth in synaptic remodelling, and in
healthy adult brain is expressed specifically in areas associated with AD; the association neocortex
and hippocampus. However, its levels are reduced in the hippocampus and frontal cortex in AD brain
which may contribute to cognitive impairment (Bogdanovic et al 2000, de la Monte et al 1995).
Membrane bound ApPPfl promotes neurite outgrowth and may contribute to synaptic plasticity.
It binds proteoglycans (Buee et al 1993), which mediate cell-cell and cell-matrix adhesion and neurite
extension and so may be involved in morphological changes and target finding during expression of
synaptic plasticity.
The roles of (3-secretase products; Ap, sApPPp and C100, at normal physiologically levels of
lOpM to InM are less well understood, however, micromolar doses of fibrillar Ap trigger apoptosis-
like cell death in neurone cultures (Loo et al 1993), and more recently, soluble oligomers and
protofibrils of Ap have shown neurotoxicity in culture (Lambert et al 1998, Hartley et al 1999). C100
is also neurotoxic (Yankner et al 1989). sApPPp activates cultured microglia to release potentially
cytotoxic products such as reactive oxygen species and inflammatory cytokines. Although sApPPa
has similar activity, the detrimental effects seem to be compensated by its neurotrophic properties
(Barger & Harmon 1997).
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Presenilin 1 and 2
PS1 and 2 are ubiquitously expressed in the CNS but are especially prevalent in areas most susceptible
to AD. Their distribution is similar to that of Ap and is unchanged in AD. They are found exclusively
in neurones (Kovacs et al 1996), specifically in tire cell soma, with PS1 also spreading into some
neurites. They are restricted to the early compartments of the protein secretory pathway, including the
endoplasmic reticulum, intermediate compartment and the early cis-golgi compartment (Annaert & De
Strooper 1999) although it has recently been suggested that small amounts may be found in the cell
membrane (Takashima et al 1996). Their homology lies mostly within the 8 transmembrane domains
and the large cytoplasmic loop, suggesting that these regions are particularly important for protein
function.
The level of PS is strictly regulated, possibly by calsenilin (Buxbaum et al 1998), as
demonstrated in TG mice designed to overexpress human PS1 (Thinakaran et al 1996, Thinakaran et
al 1997). In these animals, although human PS1 is expressed, the level of total PS1 is little changed.
PS is processed in the ER where the full length protein is rapidly cleaved within the cytoplasmic loop.
The resulting C-terminal and N-terminal fragments remain closely associated to form a heterodimer.
PS has aspartate protease activity and can cleave proteins within transmembrane domains. It is
involved in development, protein processing and apoptosis. Whilst the heterodimer is usually
considered to be the active form, the full length protein must also be functional since it can reverse
deficits in Caenorhabditis elegans caused by mutations in its PS homologue Sel-12.
The PS1 heterodimer is necessary for normal y-secretase processing of ApPP (Xia et al 1998)
and it is possible that PS 1 is y-secretase since it has the necessary property of being an aspartate
protease with access to cleavage sites within the membrane (Wolfe et al 1999) and it is bound by y-
secretase inhibitors (Li et al 2000a). Neurones in PS1 null animals have reduced y-secretase activity as
indicated by the accumulation of P3- and Ap-containing C-terminal stubs (De Strooper et al 1998).
However, presenilinl lacks sequence homology with know protease domains (Sherrington et al 1995)
and there is residual amyloid secretion in PS1 null animals (De Strooper et al 1998). Also, there is
increasing evidence for the existance of distinct y-secretases that result in the different lengths of Ap.
However, PS1 mutations inhibited the production of both cleavage products to an equal extent
(Murphey et al 2000). This would suggest that to be y-secretase, then it must perform both Ap42 and
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Ab42 cleavage and have two distinct active sites for these roles. Given the lack of sequence homology
with known proteases for even one domain, this is unlikely. However, it is clear that PS 1 is important
in promoting and regulating y-secretase cleavage by an as yet unresolved mechanism. FAD mutations
to PS1 result in elevated A(342/43 production, which is a possible source of AD development in affected
families.
A pro-apoptotic role is suggested for PS2. Cultured PC12 cells overexpressing human PS2
show increased vulnerability to apoptosis in response to Ap exposure and withdrawl of neurotrophins.
A similar response is seen in cells carrying normal levels of PS2 with an FAD-causing mutation
(Deng et al 1996, Janicki et al 1997). In COS-7 cells overexpressing PS2, ApPP is abnormally
processed by mechanisms suggesting apopotic, caspase-like activity and this response is heightened in
cells expressing PS2 with FAD mutations (Weidermann et al 1999). Conversely, downregulation of
PS2 is neuroprotective.
The interaction of PS1 with apoptotic pathways seems to be more complex. Upregulation of
PS1 may cause either facilitation of (Czech et al 1998) or protection against (Bursztajn et al 1998)
apoptosis whilst downregulation of PS1 has been shown to increase cell vulnerability (Roperch et al
1998).
PS1 may exert neuroprotection by interacting with the anti-apoptosis protein, P-catenin, in the
endoplasmic reticulum. Free P-catenin is phosphorylated by glycogen synthase kinase-3p and tagged
by ubiquitin for degredation. PS1 stabilizes p-catenin preventing its clearance and presumably
promotes its anti-apoptotic activity. Cells expressing FAD PS1 are more sensitive to Ap-induced
apoptosis (Tanii et al 1999, Mattson et al 2000, Guo et al 1997). This may be explained by the failure
of mutated PS1 to bind p-catenin, which is then depleted in association with an increased risk of
apoptosis (Zhang et al 1998). However, another report in which PS1 was overexpressed in COS-7
cells suggests that PS1 binding inhibits p-catenin activity (Murayama et al 1998), although it did not
show the effect of this binding on cell viability.
Where PS1 has been seen to facilitate apoptosis, identified mechanisms have included
increased Ca2+ release from the endoplasmic reticulum (Guo et al 1997), free radical production (Guo
et al 1999b), mitochondrial dysfunction (Guo et al 1998) and caspase activation (Kovacs et al 1999).
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A role for PS1 in development was suggested by its homology with the Caenorhabditis elegans
Notch signalling peptide, Sel-12. PS1 null animals have severe developmental defects, similar to those
observed in Sel-12 null nematodes, which prevent offspring from surviving beyond a few days.
However, this role does not seem to be disrupted in AD, since FAD mutations to PS in mice do not
cause loss of function during development, and indeed mutated PS can rescue PS null animals as
effectively as normal PS (Davis et al 1998).
Apolipoprotein E
ApoE is involved in plasma cholesterol and lipid homeostasis. In the cerebrospinal fluid, apoE is
invariably associated with liposomes as a lipoprotein complex, which binds cell surface receptors such
as the low density lipoprotein receptor, very low density lipoprotein receptor and the low density
lipoprotein receptor-like receptor. Binding leads to internalization of the lipoprotein complex and its
degradation by the lysosomal. Elevated apoE is associated with reduced plasma cholesterol (for
review see Nimpf & Schneider 2000).
In the CNS, apoE is mainly produced by astrocytes (Boyles et al 1985) but it is also
expressed at a lower level by selective neurones. In particular, apoE immunoreactive neurones are
found in the frontal lobe of the cerebral cortex, CA1-4 hippocampal pyramidal cell populations and
the granule cells of the dentate gyrus. ApoE is not produced in cerebellar neurones (Xu et al 1999).
This pattern of neuronal apoE production mimics the distribution of AD pathology, suggesting that it
may have a role in AD pathogenesis and confer regional specificity.
Additional roles for apoE relating to AD include modulation of A|3PP processing and clearance
(Vincent et al 2001), promotion of tau stability and microtubule formation (Benzing et al 1995, Wang
et al 1998, Scott et al 1998) and synaptic remodelling (Arendt et al 1997).
1.42 AD-related gene mutations and allelic variants
(5-Amyloid precursor protein
The first FAD mutation to be identified was on the ApPP gene. ApPP had been mapped to
chromosome twenty-one in 1987 (Goldgaber et al 1987, Tanzi et al 1987, St George-Hyslop et al
1987). Meanwhile, it had been recognised that DS subjects invariably develop pathology
indistinguishable from AD by thirty-five years (Jervis & Thiells 1948) and about seventy-five per cent
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are diagnosed with AD by sixty years (Wisniewski et al 1985, Olson & Shaw 1969). Since DS is
caused by trisomy of chromosome twenty-one it was possible that overexpression of a gene found on
this chromosome could cause AD. The association of Ap with amyloid plaques made ApPP a prime
potential locus for FAD-inducing mutations.
In 1991, a missense mutation was identified at codon 717 of ApPP, replacing valine with
isoleucine (V717I) (Goate et al 1991). This resulted in increased Ap42/43 levels in the CNS and onset
of AD at about fifty years. Eight other unrelated families have subsequently been found to carry the
same mutation. Ten other ApPP missense mutations have been found (Appendix II). They are all
located at or near the Ap domain and cause an increase in the level of AP42/43. They all cause presenile
onset at of Alzheimer's disease and an aggressive disease progression.
The most extensively studied ApPP mutation is the K670M/N671L Swedish double mutation
on exon 16, close to the P-secretase site. Age of onset is between forty-four and sixty-one years
(Axelman et al 1994). At autopsy, subjects show cortical atrophy, especially of the hippocampus, and
dilated ventricles. There are high concentrations of NFTs and amyloid plaques mainly comprising
AP42/43 (Lannfelt et al 1994, Kalaria et al 1996).
Ap levels in skin fibroblasts from living subjects are trebled (Ingelson et al 1996), suggesting
that this tissue might replicate some of the pathogenic cellular processes of affected neurones making
it a useful experimental tool. Human kidney 293 and neuroblastoma cells carrying the Swedish
mutation produce 6 to 8 times more Ap than those expressing wildtype ApPP (Citron et al 1992, Cai
et al 1993) supporting amyloid upregulation as the source of AD changes.
Presenilin 1
It is often cited that about forty per cent of early-onset FAD cases are linked to PS1 mutations (Tanzi
et al 1996) although some estimates are as low as 18 per cent (Cruts et al 1998). The involvement of
chromosome 14 in FAD was recognised in 1992 (Schellenberg 1992) and the PS1 gene was identified
in 1995 (Sherrington et al 1995) since when over seventy FAD-causing PS1 mutations have been
described (Appendix III).
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Mutations are found at many sites throughout the primary protein structure of PS1, but are
particularly focused on the highly conserved transmembrane regions with a significant cluster along
one face of an a-helix. These areas are all thought to be important for the function of the protein.
Although PS1 mutations are many and widespread, the resulting phenotypes are very similar.
They lead to especially virulent AD with a mean age of onset of forty-five years and a rapid disease
progression. In all cases, Ap42/43 is elevated without any change in Ap40, ApPPs or ApPPfl levels
(Citron et al 1997). This implies that the a- and p-secretase pathways can be independently regulated.
These observations have been made in both blood plasma and cultured skin fibroblasts from affected
individuals. More importantly, Ap42/43 is elevated in cultured cells from healthy tissue when
transfected with mutated PS1 and in transgenic mice carrying the mutated human gene (Citron 1997),
showing that altered ApPP processing in the AD subjects can be attributed exclusively to the PS1
mutation.
PS1 mutations (M146V, L286V) predispose cells to apoptosis, including that induced by Ap
toxicity. Cell viability is restored by overexpression of the Ca2+ binding protein calbindin (Guo et al
1998), suggesting that impaired Ca2+ homeostasis is involved. Cells carrying the mutations A246E,
AE10 and L286V express activated caspase 3 which is part of the classic apoptotic pathway (Kovacs
et al 1999).
The mutation that will be studied in this thesis is the methionine to valine substitution at
codon 146 (M146V). This mutation was linked to chromosome 14 in 1994 (Hardy 1994) and
subsequently identified in 3 unrelated families (Clark et al 1995). Inheritance is autosomal dominant
and the age of onset is especially low, commonly being between thirty-six and forty years and the
mean disease duration is 6 years.
A typical case study describes a thirty-nine year old woman who presented with mild memory
deficit. Medical examination revealed moderate deficits in other cognitive functions; spatial
orientation, visual agnosia, constructional apraxias and agraphia in conjunction with cortical atrophy
and ventricular dilation. The patient also had mild myoclonic jerking, which seems to be particular to
M146V FAD. Her cognitive and physical problems worsened rapidly and she died 4 years after
diagnosis in a bedridden state. Autopsy showed the expected pattern of amyloid plaques, NFTs and
cell loss. Unusually, there was also mild vacuolar change, which suggested a form of prion disease but
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this was discounted by the presence of AD pathology and a lack of altered prion protein (Hardy et al
1994).
Plasma and fibroblasts from Ml46V subjects showed a specific increase in Ap42/43 (Scheuner et
al 1996). HK293 cells and transgenic mice expressing human PSlMi46V both showed elevated levels of
AP42/43 when compared to controls carrying the wildtype human gene (Ancolio et al 1997, Duff et al
1996), and transfected cells also show increased sensitivity to AP42/43 toxicity.
Presenilin 2
Six FAD-causing mutations have been described in the PS2 gene on chromosome 1 (Appendix IV).
The time course of the disease resembles SAD, showing a later age of onset and longer disease
duration than FAD attributed to PS 1 and ApPP. The timing is also less predictable suggesting that
environmental factors are significant modifiers of disease expression (Sherrington et al 1996).
One pedigree is the Volga-German line N141I found in 8 families with a common ancestor.
The mean age of onset is fifty-five years and the duration is eleven years (Iwatsubo et al, 1998). A
second mutation, in an Italian family (M239V) has a mean onset of over sixty years and lasts up to
twenty years although commonly the duration is much shorter. AP42/43 levels are elevated but as in
SAD the total Ap level is unchanged. Cells transfected with N141I produce 5 times more AP42/43
(Citron et al 1997) and show increased susceptibility to apoptosis (Janicki & Monteiro 1997).
Apolipoprotein E
Apos was identified as the SAD-linked chromosome 19 gene in 1993 (Strittmatter et al 1993), which
marked a significant discoveiy towards understanding the nature of the most prevalent cases of AD.
The three allelic variants of apoe differ at two loci (table 1.1).
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Table 1.1 Allelic variants ofapoE




Amongst AD cases, the s4 allele occurs at a higher than expected frequency. The risk conferred by e4
is dose dependent with homozygotes being the most likely to develop AD. s4 promotes early disease
onset, rapidly deteriorating neurone function and A|3 over-production. It also seems to increase the
chance of developing AD in conjunction with other risk factors, for example, Ap deposition in
response to traumatic head injury is more severe in e4 carriers (Nicholl et al 1995). Conversely, AD
subjects carrying the s2 allele occur at a frequency lower than would be expected suggesting that this
allele is protective.
The apoe genotype also interacts with FAD mutations in ApPP. In the ApPP V717F and
K670M/N671L pedigrees, apos4 carriers have a significantly earlier age of AD onset (Noguchi et al
1993). It does not seem to interact with PS mutations (Houlden et al 1998). A polymorphism in tire
apos promoter also affects AD susceptibility. There is a higher prevalence of alanine homozygotes at
the -491 ATT locus in AD cases regardless of the apoe genotype (Wang et al 2000).
The apoE protein may influence ApPP processing, clearance of extracellular ApPP and Ap and
plaque formation. Carriers of the e4 allele have lower apoE levels, which leads to impaired lipid and
cholesterol catabolism and elevated levels of total cholesterol and triglycerides (Tiret et al 1994, Luc
et al 1994). This may explain tire perceived link between AD and cardiovascular disease. Inhibiting
cholesterol production in cultured cells by seventy per cent impairs Ap production without affecting
the level of ApPP (Simons et al 1998). Therefore, elevated cholesterol levels in s4 subjects may
increase Ap production.
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ApoE binds A(3PP, which allows it to be internalized for degradation by the low density
lipoprotein receptor-like receptor. However, in AD, apoE associated with senile plaques may impair
Ap clearance and contribute to plaque development (Namba et al 1991). ApoE4 binds Ap with higher
affinity than E3 or E2 and promotes Ap aggregation and fibrillogenesis (Wisniewski et al 1994). One
study reported that apoE4 reduces Ap polymerization and toxicity in culture (Evans et al 1995),
however they used free apoE, which may act differently to apoE in its usual lipoprotein complex.
Ap (and especially Ap42/43,) promotes apoE binding to hippocampal neurones in culture, which
leads to internalization of the Ap/apoE complex. This suggests a putative pathway for plaque
formation whereby Ap42/43 is preferentially internalized by neurones, generating intracellular
concentrations that promote aggregation. This Ap aggregate is released when the neurone dies and
seeds plaque formation. This process would be accelerated in apoe4 carriers since apoE4 is much
more readily bound and internalized by neurones in response to Ap.
ApoE binds tau to promote microtubule formation and stability. The E2 and E3 isoforms have
the highest affinity for tau, suggesting that microtubule stabilization may be impaired in s4 carriers. In
vitro, apoE prevents tau hyperphosphorylation and tangle formation (Flaherty et al 1999) and s:4
carriers exhibit elevated cerebrospinal fluid tau levels (Kanai et al 1999), which in AD cases correlate
with disease duration and level of cognitive deficit.
ApoE4 may potentiate pro-inflammatory mechanisms in AD, since cultured microglia are
activated by sera from apos4 AD subjects, but not by sera from other AD patients or healthy apoe4
subjects (Lombardi et al 1998). Also, apoE3 hinders microglial activation by sApPP, whilst apoE4 is
far less effective (Barger & Harmon 1997).
ApoE is expressed in response to injury (Snipes et al 1986) may have a role in synaptic
plasticity (Krugers et al 1997, Arendt et al 1997). ApoE3 enhances neurite outgrowth in cultured
dorsal root ganglion neurones, whilst apoE4 reduces outgrowth (Nathan et al 1994) which may
indicate impaired reinnervation and formation of new synaptic connections following cell loss in vivo.
This could explain the early age of AD-onset in e4 carriers who could have impaired compensatory
mechanisms for preclinical cell loss, and may also explain the lack of age-associated neurite extention
in AD neurones (Callahan et al 1998).
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Alzheimer's disease (AD) is a fatal neurodegenerative disorder usually associated with the elderly. It
is characterized by insidious deterioration of cognitive functions, which leaves the sufferer
increasingly dependent on carers. The disease is prolonged, often lasting 8 to 12 years following
diagnosis, severely impairing quality of life for sufferers and generating a huge emotional burden on
relatives. It also causes economic and organizational challenges for both carers and society. This
burden will increase given the projected growth in the ageing population. Current treatments are
limited, and at best give only temporary alleviation of symptoms, with eventual incapacitation and
death being inevitable. These considerations make the search for the cause of AD and development of
effective treatments of great importance.
1.1 Epidemiology and Diagnosis
AD is the most common form of dementia in industrialized nations. Estimated prevalence varies
greatly, but is usually quoted between 5 to twenty per cent for the population over sixty-five years old
and twenty to fifty per cent for those over eighty-five years old (Bachman et al 1992, Rosenberg 1997,
Evans et al 1989, Skoog et al 1993). Despite the variation in figures, all studies show a trend of
increased AD prevalence from around sixty to eighty-five years of age. In men there is an
approximate doubling in incidence every decade from sixty years, reaching a plateau after eighty-five
years (Skoog et al 1993). Such a plateau is not seen in women.
The variability in prevalence figures arises from diagnostic difficulties. These are due to the
heterogenous nature of the disease and the overlap of symptoms with other illnesses, particularly
vascular dementia and Creutzfeld Jacob disease. Mild AD is particularly hard to diagnose, and some
epidemiological studies have chosen to quantify only moderate and severe cases, creating further
discrepancy in prevalence figures.
In 1984, a task force consisting of the National Institute of Neurological and Cognitive
Disorders (USA) and the Alzheimer's Disease and Related Disorders Association developed a set of
criteria to improve diagnostic accuracy (Appendix I) (McKhann et al 1984). It was agreed that a
definite diagnosis of AD is not possible using current clinical tests. Instead, the task force decided that
diagnosis of "probable AD' could be made upon demonstration of typical clinical symptoms according
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to their criteria, and having eliminated other dementing illnesses as the cause. Even with these clinical
criteria, the accuracy of pre-mortem diagnosis is variable, with the most experienced assessors
correctly diagnosing about ninety per cent of cases (Galasko et al 1994), and accuracy identifying the
disease in its early stages can be much lower. For this reason, the task force stated that a definite
diagnosis can only be made when the clinical assessment is combined with positive autopsy results.
For effective treatments to be developed, early diagnosis of AD is especially important.
Towards this goal, various approaches are being investigated. Computerized tomography scans and
magnetic resonance imaging can be used to identify other conditions as the source of dementia by
detecting abnormalities such as ischaemic lesions caused by stroke and tumours. These techniques
also reveal cortical atrophy and dilation of ventricles typical of AD, however, the extent of atrophy
overlaps extensively with that associated with normal ageing and is not diagnostic.
Magnetic resonance imaging is particularly sensitive and is helping to improve early diagnosis
by detecting reduced hippocampal volume (Jack et al 1999). Hippocampal cell loss is correlated to the
severity of dementia, making this test particularly relevant to the clinical condition. Increased
resolution of magnetic resonance imaging is now allowing visualization of larger senile plaques in
experimental conditions (Benveniste et al 1999), which in the future will hopefully allow definite
antemortem diagnosis. More recently, plaque stains derived from congo red have been developed that
are able to cross the blood brain barrier. It is intended that these will allow antemortem staining of
neuritic plaques to improve visualization using techniques such as magnetic resonance imaging
(Skovronsky et al 2000a).
Although there is no current antemortem test for AD, some factors strongly support a
diagnosis. Amongst these are the presence of the s4 allele at the apolipoprotein E (apoE) locus, which
is a known genetic risk factor. Cerebrospinal fluid of AD subjects consistently shows significant
elevation of tau and reduction in the A(i12 protein (Mehta et al 2000, Kanai et al 1998). Blood tests
would be more acceptable since cerebrospinal fluid tests require lumbar puncture. Recent efforts are
focussing on AD-specific changes in the forms of beta-amyloid precursor protein (ApPP) isolated
from platelets, which are correlated with the clinical severity of AD and reflect ApPP composition in
the cerebrospinal fluid (Sennvik et al 2000).
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Although promising, most of these techniques are currently either still experimental, too
expensive or too time-consuming for a large scale epidemiological studies or general use.
1.2 Clinical Symptoms
Alzheimer's disease was first described by Alois Alzheimer in 1907. He documented the case of a
fifty-one year old woman who presented with extreme jealousy that was soon accompanied by
memory impairment and paranoid behaviour. She displayed violent outbursts and suffered from
auditory hallucinations, and was often too disturbed to be properly examined. During successful
examinations she was confused, lacked concentration and failed to perform simple verbal and writing
tasks. She showed no sign of significant motor impairment. Towards the end of her illness she was
bedridden, incontinent and apathetic. The patient declined steadily and died after 4 Zi years.
At autopsy the brain showed severe and widespread atrophy and arteriosclerosis. Histological
examination revealed intracellular fibrillar bundles, which persisted in regions of cell loss. Throughout
the cortex, extracellular deposits described as a 'peculiar substance' were observed (Alzheimer 1907).
At the time, dementia was considered a rare disease since cognitive decline in the elderly was
seen as a normal consequence of ageing. It was only later that the symptoms and pathology observed
in this middle-aged woman were linked to dementia in older subjects.
The typical early symptoms of AD are mild memory loss, particularly of anterograde
declarative memory, and subtle behavioural changes. Memory impairment gradually extends to all
forms of memory. Aphasia, manifest in difficulty naming objects and recognizing words, develops
into mutism in the late stages. Agnosia confers impaired judgement and reasoning, resulting in
difficulty planning and executing tasks. Subjects' ability to recognize objects and familiar faces
deteriorates. Apraxias involve physical inability to perform daily tasks. Subjects tend to be unaware of
their deficits (anosagnosia) and so are often reluctant to seek medical help. Sensory-motor function
tends to be spared although limb rigidity, coupled with extreme confusion and apathy leads to subjects
frequently becoming bedridden in the late disease stages.
Sufferers may also display a wide range of behavioural disturbances, which are often more
distressing for carers than the cognitive problems. These include verbal and physical aggression.
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paranoid delusions, hallucinations, sleep disturbances, depression, apathy, social withdrawal,
wandering and pacing, repetitive actions, incontinence and inappropriate social behaviour.
1.3 Neuropathology
Three forms of pathology are recognised as diagnostic abnormalities in AD:
• Amyloid plaques
• Neurofibrillary deposition
• Specific nerve cell loss
The brain areas most severly affected are the association areas of the neocortex, the
hippocampus, the amygdala and cholinergic neurones of the basal forebrain. This pattern of pathology
accords with the typical AD deficits in memory, analytical thought, perception, and motivation.
1.31 Amyloid Plaques
These are extracellular lesions of which there are three forms; diffuse, neuritic and dense-core. All
contain deposits of beta-amyloid (AP; a globular protein cleaved from ApPP). In healthy tissue, the
major cleavage product is 40 amino acids long (Ap40), but some longer Ap42/43 is also produced.
Ap42/43 seems to be the important isoform in plaque formation, since it is less soluble due to its
additional N-terminal p-pleated sheet structure which increases its tendancy for fibril formation and
aggregation (Xia et al 1997). Plaques form when Ap42 levels increase in conjunction with a high
Ap42/Ap40 ratio, and in vitro studies have suggested that Ap40 hinders Ap42 deposition (Snyder 1994).
Neuritic plaques comprise a distinct Ap core surrounded by dystrophic neurites and reactive
astrocytes. Fibrillar Ap42/43 is the initial species to be deposited in neuritic plaques (Iwatsubo et al
1995), which is believed to seed the later deposition of Ap40 (Jarrett et al 1993). Other factors
associated with plaques are microglia and proteins such as ApPP, al-antichymotrypsin, apoE,
apolipoprotein J, heparin-sulphate proteoglycan (HSPG), butyrylcholinesterase and non-amyloid
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plaque component. Neuritic plaques are stained by congo red and show green bifringence when
observed under polarized light.
Diffuse plaques also contain aggregated Ap42/43, but have far fewer fibrils and lack the distinct
amyloid core. They are not associated with dystrophic neurites, are not stained by congo red and
attract very few astrocytes or microglia. It has been proposed that diffuse plaques are precursors to
neuritic plaques, possibly being converted by a butyrylcholinesterase-dependent mechanism, since
butyrylcholinesterase is only associated with plaques with high levels of p-sheet amyloid (Guillozet et
al 1997) and it induces Ap aggregation in vitro. However, diffuse plaques are not restricted to areas of
the brain that show degeneration in AD, for example, they are often found in the cerebellum. Also,
they occur in the brains of aged, non-demented individuals, (although this may represent preclinical
change). It has therefore been suggested that they are non-pathogenic and are either generated
independently from neuritic plaques or are converted to neuritic plaque by factors that are restricted to
limbic and association cortex areas. Alternatively, diffuse plaques are potentially pathogenic but not
all brain areas are susceptible.
Dense-core or 'burnt-out' plaques are the final stage of plaque development. Associated
neurites are degenerated and they no longer attract astrocytes. At this stage they are probably most
effectively degraded by microglia.
There are also Ap deposits in the cerebral vasculature, especially in vessels associated with the
cerebral cortex. Vascular amyloid comprises mainly of Ap40, suggesting that the vasculature is not the
source of amyloid deposited in the brain. The amount of vascular deposition is not correlated with the
degree of dementia, and so it is unlikely that it contributes to AD-related deficits.
1.32 Neurofibrillary Deposition
Neurofibrillary deposits are intracellular and mainly comprise the tandem repeat region of tau. This
microtubule binding protein imdergoes various post-translational modifications, including
phosphorylation, glycosylation and glycation, which have been implicated in AD pathology.
The affinity of tau for microtubules is regulated by its level of phosphorylation. In AD, tau is
hyperphosphorylated (tau-p), which reduces its binding capacity and causes destabilization of
microtubules. This may compromise neurone viability by impairing intracellular trafficking. Tau-p
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forms non-soluble paired-helical filaments, that aggregate into neurofibrillary tangles (NFT). These
build up in the cytoplasm, dislocating the nucleus and spreading into apical dendrites (but not axons)
of pyramidal cells. They are associated with vimentin, actin, ubiquitin, tau, Ap and neurofilament
proteins, which form a fuzzy coat around the tau-p paired-helical filament core.
Glycation of tau is observed in AD brain but not in age-matched non-demented controls (Ko et
al 1999b). Tau becomes an advanced glycation end-product (AGE); a protein heavily glycated by non-
enzymatic formation of covalent bonds between the amino-groups of proteins and sugars. The bonds
may be important for paired-helical filament formation; glycation can alter protein structure making
proteins inactive and increasing their stability, which may explain the persistence of tangles. In
addition, AGEs encourage formation of reactive oxygen species, which at low levels stimulate
neuroprotective NFkB activity and cytokines (Yan et al 1995) and at higher levels can cause oxidative
cell damage.
Tangles persist even when the cell is destroyed, leaving ghosts tangles that are eventually
degraded by astrocytes. Ghost tangles are prevalent in the nucleus basalis of Meynert and
hippocampus but are rare in the neocortex, even in the presence of intracellular NFTs. This suggests
that they may only invade the neocortex in the later stages of the disease and are not the main cause of
cell loss, or that they are more effectively cleared from the neocortex. Their distribution is specific to
areas that show degeneration, such as the entorhinal cortex (LII and LIV), the subiculum, CA1, and
prosubiculum. Other areas less affected include the accessory basal nucleus of the amygdala, the
nucleus basalis of Meynert and the association neocortex, where they are mostly in LIII and LV.
Tangles are associated with other diseases such as Pick's, Down's syndrome (DS) and
progressive supranuclear palsy, however they receive special interest in AD since they have a
predictable distribution through various stages of the disease and their numbers correlate well with
levels of dementia. This pattern was recognised by Braak & Braak (1991) who used it to categorise
AD pathology into stages;
Transentorhinal Stages : Mild to severe deposition in the entorhinal cortex, targeting large stellate
neurones of the pre-a layer.
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Limbic Stages Pre-a strongly affected in the transentorhinal cortex. Some weak
deposition in the CA1 and subiculum.
Isocortical Stages : Ghost tangles in the transentorhinal and entorhinal cortices. Severe
pathology in all isocortical association and limbic areas. Primary motor
and sensory areas are spared.
Clinical changes relating to transentorhinal and limbic stages seem to be very subtle with
obvious decline observable only once tau pathology extends beyond the limbic areas in the isocortical
stage.
1.33 Specific Cell Loss
This predominantly affects large neurones in the association neocortex and limbic structures
(Bundgaard et al 2001). Cell loss is co-localized with areas affected by tangles and to a large extent,
neuritic plaques, with the level of cell loss correlating well with the severity of dementia (Gomez-Isla
et al 1997).
There is increasing evidence for apoptotic mechanisms in AD neurodegeneration. DNA
fragmentations has been identified by TUNEL labelling (Overmyer et al 2000) and brains of
Alzheimer's disease subjects show upregulation of factors linked to apoptosis such as caspase 3
(Stadelmann et al 1999) Bcl-2 interacting mediator of cell death, Bcl-2 related ovarian death gene and
p21 (Engidawork et al 2001). However, there is still controversy over whether necrotic cell death is
also involved. Evidence of necrosis and lack of apoptosis reported in some studies may be artefactual
since experimental conditions are manipulated to accelerate potential toxic effects and whilst a
cytotoxic insult may cause apoptosis when delivered chronically at a low level, the same insult often
results in necrosis when presented acutely and at a higher dose (Bonfoco et al 1995). This suggests
that apoptotic mechanisms may be more relevant to the gradual, insidious nature of AD progression.
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The following cell types are targeted in AD:
• Pyramidal neurones in the CA1 (forty per cent cell loss) and subiculum degenerate. CA3
neurones are largely spared.
• Large stellate neurones in the entorhinal cortex. This results in almost total destruction of LII and
reduced cell density in LIII. These neurones give rise to the perforant pathway, which is the major
source of cortical input into the hippocampus.
• Large multipolar neurones in LIV of the entorhinal cortex. These are the sole cortical output
targets of the hippocampal formation. Surviving cells have a high tangle load, which suggests
impaired function.
• Accessory basal nucleus cells in the amygdala, which project to the hippocampus.
• Large pyramidal cells of the neocortex association areas, especially the upper laminae.
• Cholinergic neurones of the nucleus basalis of Meynert (forty to seventy per cent cell loss) as
well as the medial septum and vertical limb of the diagonal band of Broca. These form the main
cholinergic projections to the neocortex and hippocampus and seem to be important for cognitive
function. Their loss is demonstrated by the lack of cholinergic markers in the cortex and
hippocampus.
The gross effects of cell loss are functional isolation of the hippocampus from the neocortex
and other limbic areas and impaired cholinergic modulation of limbic and associational isocortex
activity, disrupting pathways that are important for normal cognitive function.
1.34 Other Pathological Changes
AD subjects are affected by other non-specific pathologies. Some AD subjects have Lewy bodies
without Parkinsonism, for which Lewy bodies are a typical pathological feature. These are found in
smaller pyramidal neurones in the deep cortical layers (Wakabayashi et al 1995). There seems to be a
correlation between Lewy body pathology and the incidence of hallucinations in AD subjects,
especially in conjunction with poor eyesight (McShane et al 1995). However cases of Lewy body-
variant AD are often considered to be a distinct form of dementia since the clinical traits are specific
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enough to allow Lewy body involvement to be predicted antemortem (Liberini et al 1995). Also, there
is evidence that the neurodegenerative process is different, for example inflammatory processes do not
seem to feature in Lewy body variants of AD, which show much lower immunoreactivity for
microglia than brains from non-Lewy body AD subjects (Rozemuller et al 2000). Lewy body subjects
also lack tau immunoreactivity (Shepherd et al 2000).
In normal ageing, the apical dendrites of dentate gyrus granule cells and LII pyramidal cells of
the parahippocampal gyrus are extended, presumably to compensate for mild cell loss, allowing
maintenance of synaptic density. In AD subjects, this compensatory dendrite lengthening does not
occur (Callahan et al 1998).
Hirano bodies, which are restricted to the CA1 and subiculum, are eosinophillic rods or spindle
shaped bodies that contain actin and actin-associated proteins. Their function is unknown.
Granulovascular change is seen in hippocarnpal pyramidal cells coincident with tangles (Ball 1978).
They are clear, membrane-bound inclusions with a black granular core, which can distort neurone
shape and displace the nucleus. They are immunoreactive for tau and tubulin filaments (Price et al
1986, Dickson et al 1993). These lesions are considered to be secondary AD pathology since they are
found in many types of neurodegeneration, have a restricted distribution and in the case of hirano
bodies may be evident in subjects as young as twenty years old.
1.4 Genetic basis
AD has been commonly understood to be a sporadic disease occurring in the elderly. This was termed
senile dementia of the Alzheimer's type, to distinguish it from other forms of senile dementia such as
Parkinson's disease or vascular dementia. However, it was recognized that some cases of AD occur at
a much earlier age. Thus, cases in subjects under sixty years of age came to be termed pre-senile
dementia of the Alzheimer's type, with evidence that it was distinct from that observed in elderly
subjects (Pro et al 1980). It was also noted that some presenile cases are not sporadic, but are inherited
in a fully penetrant, autosomal dominant manner. This familial Alzheimer's disease (FAD) tends to be
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more aggressive than late-onset AD with subjects showing rapid cognitive decline and a shorter
survival time (Swearer et al 1996).
To date, mutations on 3 genes have been connected with FAD. These code for the ApPP,
presenilin 1 (PS1) and presenilin 2 (PS2). Mutations to PS1 are most common and may account for
about fifty per cent of all FAD (Campion et al 1999) (although estimates are as low as 18% (Cruts et
al 1998)). Late-onset FAD pedigrees exist but these are more difficult to identify. They are often
masked by family members dying from other causes before AD is evident, and so a genetic
susceptibility is not suspected. This may be especially relevant to PS2 mutations, which are not fully
penetrant and seem to cause a pattern of clinical development more typical of sporadic Alzheimer's
disease (SAD), being longer in duration and later in onset (Bird et al 1996). Conversely, it is possible
that some cases appear to be familial but are actually due to a common environmental factor, or that
since age is a risk factor for AD, familial longevity may increase tire chances of SAD occuring in
multiple family members and being mistaken for FAD.
Although FAD is only thought to account for about 0.5 to 1 per cent of AD cases (Rosenberg
1997), it is hoped that studying the effects of these mutations will aid understanding of the processes
involved in the more prevalent sporadic forms. A major problem in the study of AD has been trying to
establish cause and effect. The predictable nature of FAD transmission has allowed monitoring of
preclinical family members known to carry the pathogenic mutation. This has led to identification of
preclinical abnormalities in cerebrospinal fluid, blood composition and brain volume, which help to
determine the order in which features of AD contribute to the disease and suggest possible treatments
and diagnostic tools. For example magnetic resonance imaging can detect decreased hippocampal
volume in FAD subjects up to 10 years before clinical symptoms develop.
SAD cases also seem to be influenced by genes. Although not sufficient or necessary for
causing AD, these genes may predispose individuals to the disease, making its onset more likely in
conjunction with other genetic or environmental risk factors. That genes are involved in AD concurs
with the observation that about 10 per cent of AD subjects have at least one relative who has had the
disease (Rosenberg 1997). The best understood risk factor associated with SAD is the s4 allele of
apoE. Mutations and dimorphisms in other genes have been suggested but these seem to have weaker
effects and are less well studied.
11
1.41 The nature and roles of proteins involved in AD genetics
fj-Amyioid precursor protein and fl-amyloid
ApPP is an ubiquitously expressed glycosylated transmembrane protein that is especially prevalent in
the brain (Kang et al 1987, Selkoe et al 1988, Shimokawa et al 1993). The full-length protein (A(3PPfl)
is seven-hundred and seventy amino acids long (ApPP770) with other isoforms arising from alternative
mRNA splice variants. The most common isoform in the brain is ApPP695, which is mainly generated
in neurones (Tanaka et al 1988).
ApPP is processed by either a-secretase (Maruyama et al 1991), which is the main route in
healthy cells, or p-secretase (figure 1.1). a-Secretase is located at the cell membrane, where it cleaves
ApPP within the Ap domain to release a secreted N-terminal fragment, sApPPa and a C-terminal
stub. The C-terminal stub is further cleaved by y-secretase to release p3 (Haass et al 1993) and a
rapidly degraded C-terminal fragment. Since a-secretase cleaves ApPP within die Ap domain, diis
pathway is non-amyloidogenic (Golde et al 1992).
The p-secretase amyloidogenic pathway is also active in healthy cells (Shoji et al 1992). p-
secretase is located in die endoplasmic reticulum and trans-golgi (Haass et al 1993). It cleaves ApPP
at the N-terminal of the Ap domain to release the secreted sApPPp fragment. The remaining C-100
stub is cleaved by y-secretase to release Ap (Golde et al 1992).
The identities of the secretases are as yet undetermined although there is growing evidence tiiat
PS1 may have y-secretase activity (Li et al 2000a) and p-secretase may be the beta-amyloid
converting enzyme (Cai et al 2001).
Different lengths of Ap, varying from thirty-nine to forty-three amino acids, are produced
depending on the exact cleavage site of y-secretase. The more common forty amino acid variant is
formed in the late golgi, whilst die longer AP42/43 variants, (Ap42 being more prevalent,) are formed in
the endoplasmic reticulum, suggesting diat diere are two types of y-secretase with different subcellular
localizations and ApPP cleavage sites (Citron et al 1996). These y-secretases compete for the common
substrate, C-100, such that if Ap40 secretion is inhibited, the levels of intracellular Ap42/43 increase












Figure 1.1 ApPP a-secretase and p-secretase processing pathways
The Ap domain is highlighted.
ApPP is a house-keeping gene; an ubiquitously expressed gene that is important for non-
specialized cellular processes. As such, it is highly conserved and abundant, comprising about 0.2 per
cent of neuronal rnRNA. Full length ApPP (ApPPfl) and sApPPot have recognized physiological roles
in neurite outgrowth, synaptic plasticity and neuroprotection.
sApPPa appears to protect neurones against excitotoxic insults and oxidative stress. Its
expression is increased following neurone injury and cells pretreated with physiological
concentrations of sApPPa show reduced excitotoxicity in response to glutamate or Ap. It reduces
neurone excitability by activating the high conductance charybdoxin-sensitive Ca2+-dependent K+
channel, which carries a hyperpolarizating K+ current. This may decrease the activity of voltage-gated
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Ca2+ channels and NMDA receptor channels and so lower both basal and glutamate-induced increases
in intracellular Ca2+ concentration. sApPPa also decreases NMDA receptor activity by altering its
phosphorylation state via a cGMP/PKG dependent pathway (Furukawa et al 1998). This does not
affect kainate or AMPA receptor activity. sApPPa release is stimulated by nerve growth factor,
suggesting it has a role in neurotrophic activities.
sApPPa levels are increased in the cerebrospinal fluid following in vivo induction of the
putative physiological correlate of memory; long-term potentiation, and when infused into adult rat
brains sApPPa improves performance in learning and memory tasks. Rats reared in a stimulus
enriched environment have more ApPP immunoreactive synapses and perform better in shock
avoidance and water maze behavioural tests than rats from impoverished environments (Huber et al
1997). ApPP overexpressing mice show upregulation of growth associated protein 43 (GAP-43) and
increased synapse density in tire frontal cortex when examined using in situ immunohistochemistry
(Mucke et al 1994). GAP-43 is important for neurite outgrowth in synaptic remodelling, and in
healthy adult brain is expressed specifically in areas associated with AD; the association neocortex
and hippocampus. However, its levels are reduced in the hippocampus and frontal cortex in AD brain
which may contribute to cognitive impairment (Bogdanovic et al 2000, de la Monte et al 1995).
Membrane bound ApPPfl promotes neurite outgrowth and may contribute to synaptic plasticity.
It binds proteoglycans (Buee et al 1993), which mediate cell-cell and cell-matrix adhesion and neurite
extension and so may be involved in morphological changes and target finding during expression of
synaptic plasticity.
The roles of p-secretase products; Ap, sApPPp and C100, at normal physiologically levels of
lOpM to InM are less well understood, however, micromolar doses of fibrillar Ap trigger apoptosis-
like cell death in neurone cultures (Loo et al 1993), and more recently, soluble oligomers and
protofibrils of Ap have shown neurotoxicity in culture (Lambert et al 1998, Hartley et al 1999). C100
is also neurotoxic (Yankner et al 1989). sApPPp activates cultured microglia to release potentially
cytotoxic products such as reactive oxygen species and inflammatory cytokines. Although sApPPa
has similar activity, the detrimental effects seem to be compensated by its neurotrophic properties
(Barger & Harmon 1997).
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Presenilin 1 and 2
PS1 and 2 are ubiquitously expressed in the CNS but are especially prevalent in areas most susceptible
to AD. Their distribution is similar to that of Ap and is unchanged in AD. They are found exclusively
in neurones (Kovacs et al 1996), specifically in the cell soma, with PS1 also spreading into some
neurites. They are restricted to the early compartments of the protein secretory pathway, including the
endoplasmic reticulum, intermediate compartment and the early cis-golgi compartment (Annaert & De
Strooper 1999) although it has recently been suggested that small amounts may be found in the cell
membrane (Takashima et al 1996). Their homology lies mostly within the 8 transmembrane domains
and the large cytoplasmic loop, suggesting that these regions are particularly important for protein
function.
The level of PS is strictly regulated, possibly by calsenilin (Buxbaum et al 1998), as
demonstrated in TG mice designed to overexpress human PS1 (Thinakaran et al 1996, Thinakaran et
al 1997). In these animals, although human PS1 is expressed, the level of total PS1 is little changed.
PS is processed in the ER where the full length protein is rapidly cleaved within the cytoplasmic loop.
The resulting C-terminal and N-terminal fragments remain closely associated to form a heterodimer.
PS has aspartate protease activity and can cleave proteins within transmembrane domains. It is
involved in development, protein processing and apoptosis. Whilst the heterodimer is usually
considered to be the active form, the full length protein must also be functional since it can reverse
deficits in Caenorhabditis elegans caused by mutations in its PS homologue Sel-12.
The PS1 heterodimer is necessary for normal y-secretase processing of ApPP (Xia et al 1998)
and it is possible that PS1 is y-secretase since it has the necessary property of being an aspartate
protease with access to cleavage sites within the membrane (Wolfe et al 1999) and it is bound by y-
secretase inhibitors (Li et al 2000a). Neurones in PS 1 null animals have reduced y-secretase activity as
indicated by the accumulation of P3- and Ap-containing C-terminal stubs (De Strooper et al 1998).
However, presenilinl lacks sequence homology with know protease domains (Sherrington et al 1995)
and there is residual amyloid secretion in PS1 null animals (De Strooper et al 1998). Also, there is
increasing evidence for the existance of distinct y-secretases that result in the different lengths of Ap.
However, PS1 mutations inhibited the production of both cleavage products to an equal extent
(Murphey et al 2000). This would suggest that to be y-secretase, then it must perform both Ap42 and
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Ab42 cleavage and have two distinct active sites for these roles. Given the lack of sequence homology
with known proteases for even one domain, this is unlikely. However, it is clear that PS 1 is important
in promoting and regulating y-secretase cleavage by an as yet unresolved mechanism. FAD mutations
to PS 1 result in elevated Ap42/43 production, which is a possible source of AD development in affected
families.
A pro-apoptotic role is suggested for PS2. Cultured PC12 cells overexpressing human PS2
show increased vulnerability to apoptosis in response to Ap exposure and withdrawl of neurotrophins.
A similar response is seen in cells carrying normal levels of PS2 with an FAD-causing mutation
(Deng et al 1996, Janicki et al 1997). In COS-7 cells overexpressing PS2, ApPP is abnormally
processed by mechanisms suggesting apopotic, caspase-like activity and this response is heightened in
cells expressing PS2 with FAD mutations (Weidermann et al 1999). Conversely, downregulation of
PS2 is neuroprotective.
The interaction of PS1 with apoptotic pathways seems to be more complex. Upregulation of
PS1 may cause either facilitation of (Czech et al 1998) or protection against (Bursztajn et al 1998)
apoptosis whilst downregulation of PS 1 has been shown to increase cell vulnerability (Roperch et al
1998).
PS1 may exert neuroprotection by interacting with the anti-apoptosis protein, p-catenin, in the
endoplasmic reticulum. Free p-catenin is phosphorylated by glycogen synthase kinase-3p and tagged
by ubiquitin for degradation. PS1 stabilizes p-catenin preventing its clearance and presumably
promotes its anti-apoptotic activity. Cells expressing FAD PS1 are more sensitive to Ap-induced
apoptosis (Tanii et al 1999, Mattson et al 2000, Guo et al 1997). This may be explained by the failure
of mutated PS1 to bind p-catenin, which is then depleted in association with an increased risk of
apoptosis (Zhang et al 1998). However, another report in which PS1 was overexpressed in COS-7
cells suggests that PS1 binding inhibits P-catenin activity (Murayama et al 1998), although it did not
show the effect of this binding on cell viability.
Where PS1 has been seen to facilitate apoptosis, identified mechanisms have included
increased Ca2+ release from the endoplasmic reticulum (Guo et al 1997), free radical production (Guo
et al 1999b), mitochondrial dysfunction (Guo et al 1998) and caspase activation (Kovacs et al 1999).
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A role for PS 1 in development was suggested by its homology with the Caenorhabditis elegans
Notch signalling peptide, Sel-12. PS1 null animals have severe developmental defects, similar to those
observed in Sel-12 null nematodes, which prevent offspring from surviving beyond a few days.
However, this role does not seem to be disrupted in AD, since FAD mutations to PS in mice do not
cause loss of function during development, and indeed mutated PS can rescue PS null animals as
effectively as normal PS (Davis et al 1998).
Apolipoprotein E
ApoE is involved in plasma cholesterol and lipid homeostasis. In the cerebrospinal fluid, apoE is
invariably associated with liposomes as a lipoprotein complex, which binds cell surface receptors such
as the low density lipoprotein receptor, very low density lipoprotein receptor and the low density
lipoprotein receptor-like receptor. Binding leads to internalization of the lipoprotein complex and its
degradation by the lysosomal. Elevated apoE is associated with reduced plasma cholesterol (for
review see Nimpf & Schneider 2000).
In the CNS, apoE is mainly produced by astrocytes (Boyles et al 1985) but it is also
expressed at a lower level by selective neurones. In particular, apoE immunoreactive neurones are
found in the frontal lobe of the cerebral cortex, CA1-4 hippocampal pyramidal cell populations and
the granule cells of the dentate gyrus. ApoE is not produced in cerebellar neurones (Xu et al 1999).
This pattern of neuronal apoE production mimics the distribution of AD pathology, suggesting that it
may have a role in AD pathogenesis and confer regional specificity.
Additional roles for apoE relating to AD include modulation of A(3PP processing and clearance
(Vincent et al 2001), promotion of tau stability and microtubule formation (Benzing et al 1995, Wang
et al 1998, Scott et al 1998) and synaptic remodelling (Arendt et al 1997).
1.42 AD-related gene mutations and allelic variants
p-Amyloid precursor protein
The first FAD mutation to be identified was on the ApPP gene. AfiPP had been mapped to
chromosome twenty-one in 1987 (Goldgaber et al 1987, Tanzi et al 1987, St George-Hyslop et al
1987). Meanwhile, it had been recognised that DS subjects invariably develop pathology
indistinguishable from AD by thirty-five years (Jervis & Tliiells 1948) and about seventy-five per cent
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are diagnosed with AD by sixty years (Wisniewski et al 1985, Olson & Shaw 1969). Since DS is
caused by trisomy of chromosome twenty-one it was possible that overexpression of a gene found on
this chromosome could cause AD. The association of Ap with amyloid plaques made ApPP a prime
potential locus for FAD-inducing mutations.
In 1991, a missense mutation was identified at codon 717 of ApPP, replacing valine with
isoleucine (V717I) (Goate et al 1991). This resulted in increased Ap42/43 levels in the CNS and onset
of AD at about fifty years. Eight other unrelated families have subsequently been found to carry the
same mutation. Ten other ApPP missense mutations have been found (Appendix II). They are all
located at or near the Ap domain and cause an increase in tire level of Ap42/43. They all cause presenile
onset at of Alzheimer's disease and an aggressive disease progression.
The most extensively studied ApPP mutation is the K670M/N671L Swedish double mutation
on exon 16, close to the p-secretase site. Age of onset is between forty-four and sixty-one years
(Axelman et al 1994). At autopsy, subjects show cortical atrophy, especially of the hippocampus, and
dilated ventricles. There are high concentrations of NFTs and amyloid plaques mainly comprising
Ap42/43 (Lannfelt et al 1994, Kalaria et al 1996).
Ap levels in skin fibroblasts from living subjects are trebled (Ingelson et al 1996), suggesting
that this tissue might replicate some of the pathogenic cellular processes of affected neurones making
it a useful experimental tool. Human kidney 293 and neuroblastoma cells carrying tire Swedish
mutation produce 6 to 8 times more Ap than those expressing wildtype ApPP (Citron et al 1992, Cai
et al 1993) supporting amyloid upregulation as the source of AD changes.
Presenilin 1
It is often cited that about forty per cent of early-onset FAD cases are linked to PS1 mutations (Tanzi
et al 1996) although some estimates are as low as 18 per cent (Cruts et al 1998). The involvement of
chromosome 14 in FAD was recognised in 1992 (Schellenberg 1992) and the PS1 gene was identified
in 1995 (Sherrington et al 1995) since when over seventy FAD-causing PS1 mutations have been
described (Appendix III).
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Mutations are found at many sites throughout the primary protein structure of PS1, but are
particularly focused on the highly conserved transmembrane regions with a significant cluster along
one face of an a-helix. These areas are all thought to be important for the function of the protein.
Although PS 1 mutations are many and widespread, the resulting phenotypes are very similar.
They lead to especially virulent AD with a mean age of onset of forty-five years and a rapid disease
progression. In all cases, Ap42/43 is elevated without any change in Ap40, ApPPs or ApPPfl levels
(Citron et al 1997). This implies that the a- and p-secretase pathways can be independently regulated.
These observations have been made in both blood plasma and cultured skin fibroblasts from affected
individuals. More importantly, Ap42/43 is elevated in cultured cells from healthy tissue when
transfected with mutated PS1 and in transgenic mice carrying the mutated human gene (Citron 1997),
showing that altered ApPP processing in the AD subjects can be attributed exclusively to the PS1
mutation.
PS1 mutations (M146V, L286V) predispose cells to apoptosis, including that induced by Ap
toxicity. Cell viability is restored by overexpression of the Ca2+ binding protein calbindin (Guo et al
1998), suggesting that impaired Ca2+ homeostasis is involved. Cells carrying the mutations A246E,
AE10 and L286V express activated caspase 3 which is part of the classic apoptotic pathway (Kovacs
et al 1999).
The mutation that will be studied in this thesis is the methionine to valine substitution at
codon 146 (M146V). This mutation was linked to chromosome 14 in 1994 (Hardy 1994) and
subsequently identified in 3 unrelated families (Clark et al 1995). Inheritance is autosomal dominant
and the age of onset is especially low, commonly being between thirty-six and forty years and the
mean disease duration is 6 years.
A typical case study describes a thirty-nine year old woman who presented with mild memory
deficit. Medical examination revealed moderate deficits in other cognitive functions; spatial
orientation, visual agnosia, constructional apraxias and agraphia in conjunction with cortical atrophy
and ventricular dilation. The patient also had mild myoclonic jerking, which seems to be particular to
M146V FAD. Her cognitive and physical problems worsened rapidly and she died 4 years after
diagnosis in a bedridden state. Autopsy showed the expected pattern of amyloid plaques, NFTs and
cell loss. Unusually, there was also mild vacuolar change, which suggested a form of prion disease but
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this was discounted by the presence of AD pathology and a lack of altered prion protein (Hardy et al
1994).
Plasma and fibroblasts from Ml46V subjects showed a specific increase in A(342/43 (Scheuner et
al 1996). HK293 cells and transgenic mice expressing human PSlMi46v both showed elevated levels of
Ap42/43 when compared to controls carrying the wildtype human gene (Ancolio et al 1997, Duff et al
1996), and transfected cells also show increased sensitivity to Ap42/43 toxicity.
Presenitin 2
Six FAD-causing mutations have been described in tire PS2 gene on chromosome 1 (Appendix IV).
The time course of the disease resembles SAD, showing a later age of onset and longer disease
duration than FAD attributed to PS 1 and ApPP. The timing is also less predictable suggesting that
environmental factors are significant modifiers of disease expression (Sherrington et al 1996).
One pedigree is the Volga-German line N141I found in 8 families with a common ancestor.
The mean age of onset is fifty-five years and the duration is eleven years (Iwatsubo et al, 1998). A
second mutation, in an Italian family (M239V) has a mean onset of over sixty years and lasts up to
twenty years although commonly the duration is much shorter. Ap42/43 levels are elevated but as in
SAD the total Ap level is unchanged. Cells transfected with N141I produce 5 times more Ap42/43
(Citron et al 1997) and show increased susceptibility to apoptosis (Janicki & Monteiro 1997).
Apolipoprotein E
Apoe was identified as the SAD-linked chromosome 19 gene in 1993 (Strittmatter et al 1993), which
marked a significant discovery towards understanding the nature of the most prevalent cases of AD.
The three allelic variants of apos differ at two loci (table 1.1).
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Table 1.1 Allelic variants of apoE




Amongst AD cases, the s4 allele occurs at a higher than expected frequency. The risk conferred by s4
is dose dependent with homozygotes being the most likely to develop AD. s4 promotes early disease
onset, rapidly deteriorating neurone function and A|3 over-production. It also seems to increase the
chance of developing AD in conjunction with other risk factors, for example, Ap deposition in
response to traumatic head injury is more severe in s4 carriers (Nicholl et al 1995). Conversely, AD
subjects carrying the e2 allele occur at a frequency lower than would be expected suggesting that this
allele is protective.
The apos genotype also interacts with FAD mutations in ApPP. In the ApPP V717F and
K670M/N671L pedigrees, apoe4 carriers have a significantly earlier age of AD onset (Noguchi et al
1993). It does not seem to interact with PS mutations (Houlden et al 1998). A polymorphism in the
apos promoter also affects AD susceptibility. There is a higher prevalence of alanine homozygotes at
the -491 A/T locus in AD cases regardless of the apos genotype (Wang et al 2000).
The apoE protein may influence ApPP processing, clearance of extracellular ApPP and Ap and
plaque formation. Carriers of the s4 allele have lower apoE levels, which leads to impaired lipid and
cholesterol catabolism and elevated levels of total cholesterol and triglycerides (Tiret et al 1994, Luc
et al 1994). This may explain the perceived link between AD and cardiovascular disease. Inhibiting
cholesterol production in cultured cells by seventy per cent impairs Ap production without affecting
the level of ApPP (Simons et al 1998). Therefore, elevated cholesterol levels in s4 subjects may
increase Ap production.
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ApoE binds ApPP, which allows it to be internalized for degradation by the low density
lipoprotein receptor-like receptor. However, in AD, apoE associated with senile plaques may impair
Ap clearance and contribute to plaque development (Namba et al 1991). ApoE4 binds Ap with higher
affinity than E3 or E2 and promotes Ap aggregation and fibrillogenesis (Wisniewski et al 1994). One
study reported that apoE4 reduces Ap polymerization and toxicity in culture (Evans et al 1995),
however they used free apoE, which may act differently to apoE in its usual lipoprotein complex.
Ap (and especially Ap42/43,) promotes apoE binding to hippocampal neurones in culture, which
leads to internalization of the Ap/apoE complex. Tliis suggests a putative pathway for plaque
formation whereby Ap42/43 is preferentially internalized by neurones, generating intracellular
concentrations that promote aggregation. This Ap aggregate is released when the neurone dies and
seeds plaque formation. This process would be accelerated in apos4 carriers since apoE4 is much
more readily bound and internalized by neurones in response to Ap.
ApoE binds tau to promote microtubule formation and stability. The E2 and E3 isoforms have
the highest affinity for tau, suggesting that microtubule stabilization may be impaired in s4 carriers. In
vitro, apoE prevents tau hyperphosphorylation and tangle formation (Flaherty et al 1999) and s4
carriers exhibit elevated cerebrospinal fluid tau levels (Kanai et al 1999), which in AD cases correlate
with disease duration and level of cognitive deficit.
ApoE4 may potentiate pro-inflammatory mechanisms in AD, since cultured microglia are
activated by sera from apoe4 AD subjects, but not by sera from other AD patients or healthy apoe4
subjects (Lombardi et al 1998). Also, apoE3 hinders microglial activation by sApPP, whilst apoE4 is
far less effective (Barger & Harmon 1997).
ApoE is expressed in response to injury (Snipes et al 1986) may have a role in synaptic
plasticity (Krugers et al 1997, Arendt et al 1997). ApoE3 enhances neurite outgrowth in cultured
dorsal root ganglion neurones, whilst apoE4 reduces outgrowth (Nathan et al 1994) which may
indicate impaired reinnervation and formation of new synaptic connections following cell loss in vivo.
This could explain the early age of AD-onset in s4 carriers who could have impaired compensatory
mechanisms for preclinical cell loss, and may also explain the lack of age-associated neurite extention
in AD neurones (Callahan et al 1998).
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1.5 Predisposition and protection for Alzheimer's disease
1.51 Risk Factors
The commonly accepted risk factors for AD are old age and family history. Many other risk factors
have been proposed but most are poorly substantiated, or have been refuted by subsequent studies. In
1991, the importance of some major potential risk factors was reassessed by collating data from
numerous studies, on the premise that the subject groups in many individual studies were too small to
give the statistical power required to provide conclusive results (Graves et al 1991). Large subject
groups are especially important in these studies since individual cases will only be associated with a
subset of the proposed risk factors.
Age is the most obvious risk. AD is rare in subjects below sixty-five years old, but prevalence
increases over the following decades reaching upto fifty per cent in the over eighty-five age group.
Maternal age also seems to be important since a dispropotionate number of AD subjects are born to
mothers over forty years old (Rocca et al 1991) although another study failed to find a significant
correlation (Dewey et al 1988).
Genetic predisposition for AD is suggested by the high frequency of dementing illness
(including Parkinson's disease) in first degree relatives of SAD subjects (van Duijn et al 1991). AD
also seems to be preferentially transmitted down the maternal line, which suggests genetic
susceptibility factors on the X-chromosome or in mitochondrial DNA. In the rare FAD cases,
mutations cause autosomal dominant transmission of AD with close to full penetrance.
DS and diabetes are also linked with AD. DS subjects commonly develop pathology
indistinguishable from AD by around thirty years of age and show clinical signs of AD by about forty
years (Jervis & Thiells 1948, Wisniewski et al 1985). A weaker link is made with adult-onset diabetes
on the basis of traits shared with AD such as amyloid deposition, impaired glucose metabolism, AGE
formation, energy depletion and oxidative stress (Ott et al 1996, Leibson et al 1997). Amyloid
deposits in diabetes are formed from amylin, which has little sequence homology with Ap but does
form p-enriched fibrils. Amylin activates microglia with interleukin-p and tumour necrosis factor a
release kinetics identical to fibrillar Ap. (Yates et al 2000). Presumably, deficits in diabetes are
potentially capable of activating AD-causing pathways.
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Between 1.5 and 3 times more women have AD as men, and this cannot be explained by the
higher life-expectancy of women. This gender bias may be related to reduced oestrogen levels in post¬
menopausal women (Fratiglioni et al 1997).
However, studies of monozygotic twins with discordant incidence of AD or varied age of onset
demonstrate the importance of environmental influences in SAD. This is supported by a study of
communities of African origin in the USA, who had a higher incidence of AD than people living in
Africa (Hendrie et al 1995). Also, there is a higher incidence of AD in urban compared to rural
populations (Prince et al 1994).
Clinical depression has been sited as a cause, especially in cases where it occurs more than 10
years before diagnosis of AD and so is not merely an early symptom of dementia (Jorm et al 1991).
Traumatic head injury, defined as an incident causing loss of consciousness, induces elevation
of the plaque-associated Ap42/43 in the cerebrospinal fluid within a week of the impact. Boxers often
develop dementia pugilistica, which although distinct from AD, does involve NFT formation, Ap
deposition and loss of cholinergic function. That traumatic head injury does not consistently lead to
AD in later life may be due to variability in the site of Ap deposition depending on the site of impact
and the observation that Ap deposition following head injury is usually reversed (Mortimer et al 1991,
Raby et al 1998)
Exposure to aluminium as a cause for AD became a popular theory when tangles were
observed in the brains of animals that had received aluminium injections. However, these tangles were
later found to comprise normal, and not hyperphosphoiylated tau and much of the supporting research
has since been discredited. AD subjects do not have elevated plasma aluminium and high exposure to
the metal either through working environment or frequent use of antacids is not a risk factor (Munoz
1998). Other metals such as copper, zinc and iron may have a role in AD, but it has been recognised
that endogenous levels of metal ions are high enough to be neurotoxic and possible pathogenic roles
are likely to involve impaired regulation of metal ion storage and transport rather than exposure to
exogenous sources.
Physical underactivity is particularly connected to early onset AD and this may link with
hypothyroidism being a risk factor (Breteler et al 1991).
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1.52 Protective Factors
There has been an equal interest in identifying environmental factors that might protect against AD. It
was noticed that tire incidence of AD is lower amongst arthritis sufferers (McGeer et al 1996). Anti¬
inflammatories used to treat arthritis have been cited as the probable reason for this and several
antiinflammatory drugs are currently being trialled as treatments for AD.
Low oestrogen levels following the female menopause are a risk factor and AD prevalence is
reduced in post-menopausal women on hormone replacement therapy (Kawas et al 1998). Oestrogen
has many potentially neuroprotective activities such as increasing cerebral blood flow, augmenting
glucose use, promoting neurite outgrowth and synapse formation and as an antioxidant. Oestrogen
replacement improves cognitive performance in healthy post-menopausal women (Henderson 1997)
and some female AD subjects.
Use of the antioxidants, vitamins E and C, to treat AD subjects reflects the importance of
oxidative processes in the disease (Morris et al 1998). Vitamin E seems to have some efficacy,
particularly in alleviating behavioural symptoms.
The protective effects of smoking in AD are controversial. Whilst demonstrated in some
studies (Graves et al 1991), and supported by improved cognitive performance in demented subjects
treated with nicotine patches, many studies have found smoking to either have no influence or to
potentiate the risk for AD (Launer et al 1999, Merchant 1999).
Folic acid is depressed in the plasma of AD subjects (Clarke et al 1998), and folic acid deficits
are linked to impaired performance on cognitive tests (Riggs et al 1996), suggesting a potential line of
investigation.
Higher levels of education have been proposed as a protective factor. The observed link
between AD and education may be due to increased synapse density or elevated expression of
neuroprotective factors; however, this is speculative. Suggestions that the correlation may be due to
subjects with poorer education coming from a lower social strata are refuted by a study of an Italian
population with low education but good socio-economic status. They confirmed a link between AD
and lack of education, regardless of social status, particularly amongst subjects in their sixties (De
Ronchi et al 1998).
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There is a low incidence of severe headaches and migraines in AD subjects (Dewey et al 1988,
Heyman et al 1984). During a phase of severe headaches, cerebral blood flow is increased suggesting
a possible protective mechanism.
1.6 Alzheimer's disease pathogenesis
Elucidating the mechanisms of AD pathogenesis is complicated by the heterogeneity of the possible
causative and risk factors and the diversity of clinical symptoms. The variety of characteristic
abnormalities in AD brain have inspired different theories of disease progression, emphasizing in turn
the potential roles of abnormal proteins, genetic mutations and polymorphisms, inflammatory
processes, oxidising agents, metal ions, neurotransmitter deficits and metabolic defects, all of which
are likely to contribute to some extent.
A full theory of AD should explain how the different risk factors feed into a common pathway
resulting in the observed complement of pathologies and clinical symptoms. It must also explain why
only certain brain areas are targeted to generate the specific cognitive deficits characteristic of this
disease, and why it is predominantly a disease of ageing.
The current prevailing theoiy of AD pathogenesis is the amyloid cascade hypothesis.
According to this view, pathogenic changes in the processing and accumulation of Ap comprise the
common pathway into which risk and causative factors feed and from which the full range of
pathology develops. In particular, the non-soluble, fibrillar form of Ap associated with plaques is seen
as the primary pathogenic species.
There is strong evidence that Ap plays a central role in disease progression. This was initially
suggested by the invariable appearance of fibrillar Ap in AD brains, forming amyloid plaques and
vascular deposits. The occurance of AD in DS subjects supports a role for Ap since this condition
leads to ApPP over-production. FAD mutations on the ApPP and PS genes all cause an increase in
either total Ap or the Ap42/43/Ap40 ratio Fibrillar Ap can induce neurotoxicity in vitro (Yankner et al
1989, Pike et al 1993) and this has been attributed to its additional p-sheet structure, the significance
of which is consolidated by the link between other p-sheet enriched proteins and neurodegenerative
diseases such as prion protein in transmissible spongiform encephalopathies, huntingtin protein in
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Huntington's disease and a-synuclein in Parkinson's disease.
Figure 1.61 Amyloid toxicity in Alzheimer's disease
The pathways showing development of A/3 toxic species and plaques are highlighted. ?
indicates insufficient evidence to attribute various types of pathology with specific states of
A/3 aggregation.
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PS mutations cause disruption of Ca2+ homeostasis. Cultured cells expressing mutated PS1
have an elevated Ca2+ response to depolarization and the source of this Ca2+ is the endoplasmic
reticulum (Guo et al 1997), where PS1 is localized. Altered Ca2+ regulation in the ER could disrupt
normal gene expression and protein processing and elevated Ca2+ promotes Ap production (Querforth
& Selkoe 1994).The major arguments against a central role for fibrillar Ap are the poor correlation
between neuritic plaque density and the severity of dementia cited by many studies (Gomez-Isla et al
1997, Bierer et al 1995), which has been explained by microglial clearance of plaques; and the
transgenic mouse models of FAD that show amyloid deposition in the absence of neurodegeneration.
This has been explained by species differences in sensitivity to human Ap fibrils, which induce
neurodegeneration, microglial activation and tau phosphorylation when injected into aged primates
but do not generate pathology in rats when injected in plaque-equivalent doses (Geula et al 1998b). A
further suggestion is that tire transgenic animals were not allowed to age sufficiently since Ap is toxic
when injected into the brain of aged but not young adult primates (Geula et al 1998b). These
explanations have however not yet satisfied critics of the amyloid hypothesis.
Recently, a more convincing explanation of these discrepancies has emerged that continues to
support Ap toxicity but questions the amyloid hypothesis assumption that it is only highly aggregated
fibrils of Ap that are toxic (figure 1.61). Whilst soluble Ap monomers are benign, small oligomers
(usually comprising 3-6 Ap units) and protofibrils (precursors to fibrils) are toxic (Lambert et al 1998,
Hartley et al 1999). Both are more readily formed by the P-sheet enriched Ap42/43, but whilst
protofibrils tend to evolve into fibrillar deposits, the small oligomers are quite stable.
Levels of soluble Ap are elevated in AD (McLean et al 1999) and correlate well with synapse
loss (Lue et al 1999). This implies a correlation with dementia levels, which are linked to the degree
of cell loss. Similar observations have been made in transgenic mouse FAD models (Mucke et al
2000). Soluble Ap toxicity may also explain cell loss in the absence of plaque formation reported in
some FAD mouse models (Chui et al 1999, Mucke et al 2000). Elevated levels of soluble Ap are not
seen in brain from non-demented subjects with AD-equivalent plaque density, suggesting that plaque
Ap is less pathogenic. Deposited amyloid in the form of diffuse plaques may even be neuroprotective
by depleting reservoirs of soluble Ap. This is not to ignore a possible pathogenic role for plaque-
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associated fibrillar Ap but suggests that it may be unavailable to damage neurones directly.
A second distinguishing feature of non-demented subjects with high levels of AD-like
pathology is the lack of inflammatory markers, which are a significant feature of AD brain. The AD
brain may provide conditions that allow fibrillar Ap to exert indirect toxicity by activating microglia
and astrocytes, leading to neuritic plaque formation and chronic, cytotoxic inflammation.
Since many papers do not indicate the state of Ap used in toxicity studies, or use 'aged' fibrillar
Ap without ruling out the possible presence of protofibrils and oligomers, it is not possible to predict
which forms contribute to the various modes of toxicity, although the evidence cited above does
suggest that soluble Ap aggregates may be the predominant species, especially regarding direct
toxicity. These ambiguities should be considered in the following sections where results are often
cited as being specific to fibrillar Ap, which in fact may not be the case.
Ap can exert direct toxicity by activating fyn tyrosine kinase (Lambert et al 1998), which
induces apoptosis by increasing the rectifying potassium channel current Ik (Yu et al 1998) (although
excitotoxicity has also been recorded due to Ap-induced inactivation of Ik (Good et al 1996)), free-
radical generation, calcium influx via L-type voltage sensitive channels, and PKA-mediated
impairment of mitochondrial activity (Ueda et al 1994). Ap facilitates glutamate excitotoxicity (Koh
et al 1990) by impairing glutamate uptake by astrocytes both directly and by reducing glucose uptake,
which creates a deficit of ATP and so impairs glutamate sequestration (Parpura-Gill et al 1997).
As well as increasing levels of toxic Ap, altered ApPP processing in AD decreases levels of
the neuroprotective sApPPa (Sennvik et al 2000). sApPPa is upregulated in healthy neurones in
response to metabotropic glutamate receptor activation (Stephenson & Clemens 1998) and confers
protection against excitotoxicity. It acts through the membrane-associated cGMP to dephosphorylate
charybdotoxin-sensitive K+ channels and NMDA receptor channels. This selectively suppresses
NMDA currents, attenuating Ca2+ influx in response to high levels of presynaptic activity, and
activating charybdotoxin-sensitive K+ channels in a Ca2+-independent manner (Furukawa et al 1996,
Barger et al 1995), which carry a hyperpolarizing current, reducing neurone excitability.
29
1.61 Neurofibrillary tangles
The potential for NFTs to play a pathogenic role in AD was largely overlooked as the amyloid
hypothesis gained increasing support and abnormal amyloid protein became the focus of research.
NFTs were seen as a largely irrelevant by-product of the disease process. Interest in NFTs was
rekindled by the discovery of tau gene mutations that are responsible for the heritable fronto-temporal
dementias with parkinsonism (FTDP-17). Patients with FTDP-17 show similar clinical presentation to
AD, although behavioural deficits are more prevalent. Brains from FTDP-17 subjects contain
hyperphosphorylated tau which either forms paired helical filaments as in AD or ribbons depending
on the mutation. These cases demonstrate that tau dysfunction can cause neurodegeneration and
dementia in the absense of aberrant Ap.
Fibrillar A[ican induce hyperphosphorylation of tau in vitro, in the absence of amyloid
deposition (Busciglio et al 1995). This may explain how A(3 can induce NFT formation before plaques
develop. A[3 causes tau hyperphosphorylation by activating tau protein kinase I (TPKI). TPKI is
upregulated in AD brain and in hippocampal cells incubated with Ap, and blockers of TPKI reduce
Ap toxicity (Takashima et al 1993). Tau-p has reduced capacity for binding microtubules, which leads
to microtubule destabilization. This impairs intracellular trafficking and maintenance of neuronal
polarity. Dephosphoiylation of tau restores microtubule binding function (Busciglio et al 1995). Tau is
usually localized in distal axons, but fibrillar Ap treatment results in tau-p accumulation in the
somatodendritic compartment, possibly due to impaired axonal transport (Busciglio et al 1995).
Tau is not the only microtubule associated protein in cells and it has been questioned why
others fail to compensate for the loss of tau function. The primary candidates for assuming the role of
tau are MAP-1 and MAP-2. MAP-2 has a tandem repeat sequence similar to tau that could possibly
also be hyperphosphorylated, reducing its binding efficiency (Zhang et al 1996). Also, tau-p directly
prevents MAP-1 and MAP-2 from compensating for loss of tau function by binding to them in
competition with microtubules (Alonso et al 1997). MAP-2 is phosphorylated by a nitric oxide
synthase-dependent pathway in response to NMDA receptor activity (Llansola et al 2001) and so may
contribute to synaptic plasticity by inducing microtubule destabilisation to allow remodelling of the
synapse. Loss of MAP activity would therefore be expected to destabilise existing synapses and
prevent the establishment of new synaptices in response to induction stimuli for synaptic plasticity.
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Figure 1.62 Pathogenic actions of hyperphosphorylated tau.
—► indicate possible positive feedback into the pathogenic Ap pathway. Major
consequences of tau hyperphosphorylation are highlighted.
Tau-p is both glycated and glycosylated. Glycated tau is capable of causing oxidative stress
which results in cytokine activation and Ap release (Takashima et al 1993, Yan et al 1995).
Glycosylation of tau-p seems to stabilize the helical structure of paired helical filaments (Wang et al
1996a) and promote hyperphosphorylation. Deglycosylation leads to the formation of tau ribbons as
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seen in FTDP-17 brain, and facilitates release of normal tau upon treatment with phosphatases (Wang
et al 1996a).
Tau is also involved in the cell cycle. It binds the mitosis regulating protein prolyl isomerase
(Pinl) (Lu et al 1999a), and is upregulated during mitosis in neuronal cultures (Nelson et al 1996).
Although most neurones are post-mitotic, other cell cycle proteins are detected in AD, the purpose or
consequences of which are unclear. Pinl restores the microtubule binding activity of tau-p. It has been
suggested that high levels of tau-p in AD brain may sequester Pinl depleting soluble reserves and that
this might have adverse consequences for cell viability (Lu et al 1999a).
Tau-p may promote fibril formation since paired helical filaments extracted from human AD
subjects causes Ap deposition when injected into the cerebral cortex and hippocampus of rats (Shin et
al 1993). Injection of the phosphatase inhibitor, okadaic acid, into rat brain causes tau
phosphorylation, amyloid plaque formation and memory impairment (Arendt et al 1995).
1.62 Inflammation
Interest in a possible role for inflammatory mechanisms in AD, long neglected due to the view that the
brain holds an immuno-privileged status, came with the recognition that long-term users of anti¬
inflammatory drugs have a lower risk of developing AD (McGeer et al 1996). Inflammation is
confined to areas affected by AD and is localized around plaques and NFTs (Oka et al 1998). Ap is
capable of triggering inflammatory responses (Bournemann et al 2001). Also, several polymorphisms
are now being identified in genes for proteins involved in inflammation that co-segregate with cases
of late-onset AD (Collins et al 2000).
Inflammation in the CNS is mediated by microglia and astrocytes that are attracted to sites of
tissue damage or foreign material where they act to both remove abnormal material and protect
healthy tissue. Activated glia become phagocytic and release inflammatory proteins, including
cytokines, chemokines, complement and acute phase proteins, that interact in complex cascades. In
normal circumstances, the upregulation of inflammatory proteins is transient and beneficial (for
reviews see Eddelston and Mucke 1993, Zielasek & Hartung 1996). In AD these pathways become
chronically activated so may become neurotoxic (Marty et al 1991). The inflammatory mechanisms in
the CNS are poorly understood and the protective and pathological actions of individual inflammatory
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proteins in AD remain ambiguous. However, this section will highlight some of the mechanisms that
possibly contribute to AD pathology (figure 1.63).
Glia and plaque development
Inflammation occurs early in the disease process and may be important for transforming diffuse
A|3 deposits into neuritic plaques. Inflammation could be crucial for initiating neurotoxicity, since
brains from non-demented subjects with AD-like levels of diffuse plaques and NFTs have far fewer
inflammatory markers than AD brains and have no neuritic plaques or cell loss (Lue et al 1996).
Ap acts as a chemotactic signal, triggering the initial migration of microglia and astrocytes to
sites of Ap aggregation. Microglia phagocytose plaques and generate proteolytic enzymes to degrade
Ap fibrils, however, microglia may be disabled by plaque toxins (Korotzer et al 1993). Astrocytes
gather around the periphery of plaques and shield surrounding tissue from plaque-associated toxins.
However, they also impede clearance of amyloid by microglia, which allows plaques to persist and
induce chronic inflammation (DeWitt et al 1998).
Ap activates microglia, possibly by binding the receptor for advanced glycation end-products
(RAGE) or scavenger receptors, both of which are upregulated in microglia from AD brain, and this is
enhanced by numerous cytokines (Meda et al 1995). sApPPp also induces microglia activation and
cytotoxicity in culture, which can be blocked by pre-incubating microglia with apoE3. ApoE4 is
ineffective (Barger & Harmon 1997). Microglia are fully activated in AD, showing MHCII
immunoreactivity. Astrocytes are reactive rather than fully activated, showing elevated GFAP but no
MHCII expression. They are stimulated by cytokines released from activated microglia (Akama & van
Eldic 2000).
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Figure 1.63 Immune responses to A/3 fibrils
^ Indicate possible positive feedback
consequences of inflammation are highlighted.
into the pathogenic Ap pathway. Major
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Glia contribute to plaque development by producing ApPP, promoting Ap fibrillogenesis, attracting
neurites and improving plaque stability. Although neurones are the major source of Ap, elevated
levels of the cytokine TGF-p in AD (Gray & Patel 1993) may promote astrocyte expression of ApPP.
Astrocytes release HSPGs, which promote p-secretase processing of ApPP (Leveugle et al 1997) and
formation of Ap fibrils (McLaurin et al 1999) as well as protecting Ap aggregates from degradation
(Verbeek et al 1999). Microglia release nerve growth factor in response to Ap25.35, the complement
protein C3a and the synergistic actions of cytokines IL-ip and TNFa (Heese et al 1988), which could
attract neurites to areas of Ap accumulation where they are exposed to neurotoxins.
Cytokines and Chemokines
All cytokines and chemokines so far investigated are centrally generated (Licastro et al 2000) and are
elevated in brain areas showing AD pathology (Luterman et al 2000). A variety of cytokines and
chemokines are released from cultured microglia in response to Ap, including MCP-1 and TNFa, IL-
6, IL-la and IL-ip (Szczepanik et al 2001).
In the periphery, chemokines provide chemotactic signals for leucocytes, and in the CNS of
AD subjects they may promote migration of microglia and astrocytes towards plaques, degenerating
neurones and NFTs. The chemokine MCP1 induces peripheral monocyte migration across the blood-
brain barrier and can also stimulate cytokine activity and superoxide radical formation.
The inflammatory cytokines best studied in AD are IL-1, IL-6, TGFp, TNFa and S100p. IL1
immunoreactive microglia are present during the early stages of plaque formation and IL-1 levels
increase as dystrophic neurites become associated with the plaque. IL-1 triggers S100P release from
astrocytes.
S100P promotes dendritic outgrowth and may attract neurites to tire site of Ap accumulation,
leading to the formation of neuritic plaques. Indeed there is a strong correlation between S100P levels
and the number of plaque-associated dystrophic neurites. An early role for S100P in plaque
development is supported by the ApPPV7nF mouse model of AD (Sheng et al, 2000). In this model,
activation of cytokine S100P preceded Ap deposition. This suggests that accumulation of soluble Ap
oligomers in the early (prc-clinical) stages of AD could attract microglia and activate expression of
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IL-1. SlOOp release from astrocytes would attract neurites to form neuritic plaques, which degenerate
in the absence of neuronal targets and presence of inflammatory cytotoxins.
SlOOp upregulates neuronal expression of IL-6 (Li et al 2000b). Elevated IL-6 levels may
promote cognitive impairment since chronic expression in mice interferes with avoidance learning
(Heyser et al 1997) and human individuals expressing the C allele of the IL-6 gene show decreased
IL-6 activity and delayed AD development (Papassotiropoulos et al 1999).
Cytokines also affect Ap production. Although TGFp can protect against ischaemia and
excitotoxicity and has been shown to facilitate plaque clearance by microglia in transgenic mice
(Wyss-Coray et al 2001), it can also induce increased ApPP release from astrocytes (Gray & Patel
1993). TNFa and INFy act synergistically on neurones to increase Ap and decrease sApPPa
production (Blasko et al 1999). The factors that determine the role TGFp plays in AD have not been
determined.
Complement
The classical complement pathway is an amplifying cascade mainly comprising serine proteases. The
pathway starts with activation of Clq and terminates with the formation of the membrane attack
complex (figure 1.64). An alternative pathway of complement activation requires covalent bonding of
a stimulating molecule to C3. Membrane attack complex units combine to form transmembrane
channels capable of conducting ions and disrupting cellular homeostasis. Intermediate complement
components trigger the release of cytokines from microglia, tag material for phagocytosis and act as
glia chemoattractants.
Non-demented elderly subjects show little CNS complement activity but in AD brain full
complement activation is seen in areas affected by pathology (Yasojima et al 1999). In the
hippocampus and temporal cotex, neurones are the main source of complement (Yasojima et al 1999)
and plaque-associated dystrophic neurites express membrane attack complex.
Ap stimulates the classical complement pathway by binding to Clq, which has 6 homologous
subunits each with a binding site for Ap. Ap42 binds more effectively than Ap40 and fibrillar Ap is
more effective at activating the complement cascade (Webster et al 1997). Clq protects bound Ap
from phagocytosis by microglia (Webster et al 2000) and promotes fibrillogenesis (Webster & Rogers
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1996). It is possible that difficulty generating plaques in rodent models of AD overexpressing
muApPP or huPSl carrying FAD mutations is due to the lower affinity of rodent A(3 for Clq
(Webster et al 1999). Clq can also be activated by DNA released from damaged neurones, which
binds the same domain as Ap (Jiang et al 1992). This could amplify complement activation as
neurones degenerate and accelerate cognitive decline. Ap42 also forms covalent bonds with C3 and so
is capable of activating the alternative complement pathway (Bradt et al, 1998).
Figure 1.64 The classical complement pathway
Factors referred to in the text are highlighted.
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Complement is active early in tire development of AD. In a study using Down's syndrome
brains as a temporal model of AD, diffuse plaques and Ap42 immunoreactivity were observed in a 12
year old in the absense of complement activity or AD pathology. In a 15 year old, Ap42 was
colocalized with Clq, C3 and apoJ in neuritic plaques in addition to reactive astrocytes and activated
microglia leading to full AD patholgy and complement immunoreactivity by the late 20s. Brains from
thirty to forty year old subjects showed Clq and C3 mostly in neuritic plaques with C5b-9 also
associated with dystrophic neurites, some neurones and NFTs. Therefore, complement becomes
activated in conjunction with neuritic plaque formation, which leads to MAC formation and
neurodegeneration. (Stoltzner et al 2000).
Fibrillar Ap is opsonized by C3b which attracts microglia and stimulates the production C5a.
C5a potentiates Ap-induced release of cytokines IL-6 and IL-ip from cultured microglia (O'Barr &
Cooper 2000).
To avoid inappropriate opsonization by complement, healthy endogenous cells have
membrane-bound complement regulators that block the complement cascade either at the C3/C5
convertase level (membrane cofactor protein, decay accelerating factor and complement receptor 1) or
at the level of MAC formation (CD59). These regulators are highly expressed in peripheral tissue. In
the brain, cultured astrocytes express CD59, membrane cofactor protein and at a lower level, decay
accelerating factor. Neurones have low levels of CD59 and membrane cofactor protein and lack decay
accelerating factor and complement receptor 1 therefore may be more susceptibly to damage by
complement, which could explain the neuritic damage in the vicinity of AD plaques (Singhrao et al
1999).
Acute phase protein
Plaques are associated with Ap-binding acute phase proteins such as a2-macroglobulin and al-
antichymotrypsin. a2-macroglobin can have either neuroprotective of neurotoxic actions. It binds and
inactivates neuroprotective NGFp, which can lead to cell death (Fabrizi et al, 1999). However, it also
contributes to Ap clearance (Qui et al 1996). Both of these acute phase proteins reduced neurone loss
under the same culture conditions, but whilst a2-macroglobin prevented fibril formation, this was
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promoted by al-antichymotrypsin (Du et al 1988) The authors suggest that al-antichymotrypsin
obscures the Ap active site to prevent toxicity (Du et al 1988). However, it may be that both al-
antichymotrypsin and a2-macroglobin prevented Ap toxicity by interferring with the toxic actions of
soluble Ap and the presence or absence of fibrils was largely irrelevant to neurone viability.
1.63 Mitochondrial dysfunction
The main role of mitochondria is energy production. Neurones have an exceptionally high energy
demand making it particularly vulnerable to ATP deficiency. This is reflected in the large number of
neurological disorders amongst diseases caused by mitochondrial dysfunction (Schoffner & Wallace,
1994).
Mitochondria metabolise pyruvate, the end-product of glycolysis, in the Krebs cycle and
electron transport chain. The electron transport chain is especially important since it releases the
majority of the ATP produced by aerobic respiration by the process of oxidative phosphorylation (for
review see Sherratt 1991). The electron transport chain substrates are NADH and FADH2, which are
formed during glycolysis and the Krebs cycle. In the electron transport chain the pair of high energy
electrons carried by NADH or FADH2 are passed through a series of protein complexes (I to IV) of
decreasing energy levels, to drive the movement of protons across the inner mitochondrial membrane
from the matrix into the intermembrane space. The inner membrane is highly impermeable and so
holds protons against their electrochemical gradient, generating a proton-motive force, which drives
the release of ATP.
As well as producing energy, mitochondria buffer cytosolic Ca2+ and so are important for
maintaining Ca2+homeostasis (Budd & Nicholls 1996). However, extreme or prolonged increases in
cytosolic Ca2+ can saturate mitochondrial buffering capacity. These conditions cause tire opening of
mitochondrial permeability transition pores that span both inner and outer membranes (Dubinsky and
Levi 1998). In their partially open state, these non-specific channels allow release of Ca2+ and
exchange of other small molecules. More seriously, when fully open, they cause mitochondrial
swelling (Puka-Sundvall et al 2000) and may also allow release of NADH, FADH2 and GSH,
depleting substrate availability for the electron transport chain.
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Free radicals are formed during oxidative phosphorylation. Electrons escape the electron
transport chain, and react with molecular oxygen to form the superoxide radical. This is converted into
oxygen and hydrogen peroxide by superoxide dismutase. Hydrogen peroxide can be converted by
catalase into water and oxygen or by glutathione peroxidase into water (reviewed in Boveris &
Cadenas 1982). Deficits in this antioxidant system or increases in the production of reactive oxygen
species in a dysfunctional electron transport chain lead to oxidative stress, which damages proteins,
lipids and DNA.
Oxidative stress leads to tire opening of mitochondrial transition pores and disrupts the electron
transport chain, creating a cellular energy deficit and promoting further production of reactive oxygen
species. Oxidants stimulate mitochondrial permeability transition pores to open either directly or by
activating phospholipase A to produce free fatty acids (Wieckowski et al 2000).
Mitochondria carry their own DNA that codes for some components of the electron transport
chain complexes. Damage to mitochondrial DNA or disfunction in the transcription pathways reduces
the efficiency of oxidative phosphorylation and ATP production and increases the release of reactive
oxygen species. Since these are produced in the mitochondria, this organelle is a prime target for
oxidative damage. Mitochondrial DNA is especially fragile since it lacks histones and has less
efficient DNA repair enzymes than nuclear DNA. Impaired mitochondrial function encourages further
reactive oxygen species production, generating a positive feedback loop of escalating damage.
Resulting energy deficits disrupt ion homeostasis and membrane potential, cell excitability and
increase the availability of free metal ions.
Mitochondria from AD subjects show impaired activity in the electron transport chain
complexes I (NADH dehydrogenase) and IV (cytochrome oxidase) (Aksenov et al 1999) and in
pyruvate dehydrogenase (Gibson et al 1998). One of the complex I subunits, normally coded by
mitochondrial DNA, appears to be missing in AD. Complex I dysfunction is also seen in Parkinson's
disease and Huntington's disease.
Complex IV function is decreased by about fifty per cent in AD. This is not observed in
healthy aged subjects or in subjects with other neurodegenerative diseases such as Parkinson's
disease. The loss of function is observed in AD-affected brain areas but not in the cerebellum
(Aksenov et al 1999).
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Pyruvate dehydrogenase is deactivated by TPKI. Mitochondria have their own form of TPKI
which is more sensitive to activation by Ap than cytosolic TPKI (Imahori et al 1998). In
mitochondria, pyruvate dehydrogenase converts pyruvate, the product of glycolysis, into acetyl CoA.
In AD, its activity is depleted, leading to reduced glucose metabolism and increased lactate
production. This causes acetyl CoA depletion and consequent decrease in ATP production. Acetyl
CoA depletion may also be a source of the cholinergic deficit typical of AD.
Some cases of SAD are linked to mutations in mitochondrial DNA coding subunits COl and
C02 of cytochrome oxidase (complex IV). SAD cases show preferential transmission down the
maternal line, which may be explained by AD susceptibility genes in the maternally transmitted
mitochondrial DNA.
1.64 Metal Ions
Metal ions are abundant in healthy brain, where they bind metalloproteins to facilitate enzyme
function. Free metal ions are highly toxic; iron, copper, zinc and manganese all have redox activity
and can cause oxidative damage. Therefore, free metal ion concentrations are strictly controlled by
ATPase pumps and high capacity storage proteins.
Many studies have measured levels of metal ions in healthy and AD brain with poor
replicability. An early report measured increased zinc and iron and decreased copper levels in the
hippocampus and amygdala but no change in the cerebellum of AD brain (Deibel et al 1996). A
further study confirmed the increase of zinc and iron (Cornett et al 1998). Others have failed to
measure changes in cerebrospinal fluid levels of iron or zinc or have measured a decrease in zinc
(Molina et al 1998, Rulon et al 2000). Serum levels of metal ions are affected by apoE genotype.
Carriers of the SAD-linked apos4 allele have elevated levels of serum copper and zinc (Gonzalez et al
1999). However, these studies have measured total metal levels rather than levels of the potentially
toxic free metal ions. Increased amounts of the iron storage protein, ferritin, have also been recorded
(Kuiper et al 1994), suggesting that any increase in iron in the AD brain can be accommodated safely.
More convincing evidence for the involvelment of metal ions in AD is their association with
pathological markers. Zinc is strongly associated with amyloid plaques, NFT-bearing neurones and
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vascular amyloid (Suh et al 2000). Iron and copper are also associated with plaques (Lovell et al
1998).
Conditions in the AD brain could promote metal ion availability. The AD brain shows cerebral
acidosis (Yates et al 1990). This could be caused by lactate generation in response to energy deficit
and by chronic inflammation. Mild acidosis causes release of metal ions from metalloproteases and so
could free a variety of enzyme associated metal ions. Energy depletion could impair control of metal
ion compartmentalisation by inactivating ATPase ion pumps. Zinc is released in neurotransmitter
vesicles from some glutamatergic synaptic terminals. Excitotoxicity, associated with AD, could cause
excessive release of zinc, elevating it to toxic levels. Elevated zinc levels may suppress synaptic
plasticity. Zinc can modulate the kinetics of GABAa (Smart 1992), NMDA and non-NMDA
glutamate receptors (Xie et al 1993), and blocks LTP in both mossy fibre/CA3 and Schaffer
collateral/CAl hippocampal pathways (Xie & Smart 1994). Therefore, elevated zinc concentration in
the hippocampus could contribute to impaired cognitive function in AD prior to severe levels of cell
loss.
These metals may actually contribute to the formation of plaques and tangles. Ap has binding
sites for copper (Atwood et al 2000) and zinc (Yang et al 2000a). Copper II binds Ap and induces
aggregation, especially of Ap42 (Atwood et al 2000) and this is enhanced under acidic conditions
(Atwood et al 1998). It also binds ApPP, and is reduced to Cul with the release of free radicals
(Multhaup et al 1996). Zinc causes Ap aggregation but preferentially of a-helix conformation Ap
(Huang et al 2000). As well as promoting aggregation, copper and zinc also defibrillize established
Ap aggregates (Chauhan et al 1997) and so the interaction between Ap and metal ions promotes the
formation of non-fibrillar Ap aggregates.
Metal ions can also cause aggregation of tau protein. Calcium and magnesium selectively
aggregate tau-p whereas aluminium and iron both induce aggregation of tau and tau-p. Copper and
zinc have no effect (Yang et al 1999a).
Binding of copper (and iron) to Ap generates hydrogen peroxide (Huang et al 1999b) and
peptide-bound redox metal ions (Huang et al 1999c, Sayre et al 2000) which can both cause oxidative
damage. Bound metal ions can react with hydrogen peroxide to release the highly reactive hydroxyl
ion, making metalloproteins particularly susceptible to oxidative damage. Zinc prevents the
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production of hydrogen peroxide caused by the interaction of Ap with iron and copper. Therefore,
although zinc contributes to Ap deposition, it may then act to resist plaque-associated production of
reactive oxygen species (Huang et al 2000b).
The copper/iron binding protein and antioxidant, ceruloplasmin, is expressed in the neurones of
healthy brain, but in AD it is preferentially upregulated in the neuropil (Loeffler et al 1996, Castellani
et al 1999). It has been suggested diat this reflects a lack of ability in neurones to upregulate
ceruloplasmin in response to elevated metal ion levels in AD and this represents a deficit in AD
antioxidative activity that contributes to oxidative stress (Castellani et al 1999). This suggestion is
supported by observations of low ceruloplasmin, as well as superoxide dismutase, activity in the
plasma of AD subjects (Snaedal et al 1998).
1.65 Oxidative Stress
The previous sections have shown the possible mechanisms by which changes in a single protein, Ap,
could generate the wealth of pathological features recorded in cases of AD. The culmination of these
changes must ultimately be cell death, and evidence is growing that the primary mechanism of
neurotoxicity is oxidative stress. This is caused by an imbalance between the production of harmful
reactive oxygen species, such as the hydroxyl radical, the superoxide radical, hydrogen peroxide and
peroxynitrate and the availability of protective antioxidants. Ap aggregates, NFTs, inflammation,
dysfunctional mitochondria and free metal ions all have the capacity to generate reactive oxygen
species. Antioxidant activity decreases with age and neurones are especially susceptible to oxidative
damage having relatively poor antioxidant activity and in general being post-mitotic. The AD brain
shows typical signs of oxidative damage; oxidation of proteins and release of carbonyl peptides,
peroxidation of lipids, production of 4-hydroxynonenal and acrolein and oxidative damage causing
fragmentation of DNA, especially in mitochondria. This section will summarize the sources of
reactive oxygen species in AD pathology and suggest some mechanisms by which these can cause
neurodegeneration.
Ap can be directly neurotoxic by binding metal ions to produce hydrogen peroxide and
peptide-bound redox metal ions. Ap targets the cell membrane, where it damages the Na+/K+/ATPase
leading to ion imbalance (Mark et al 1997). It oxidises the astrocyte glutamate transporter, impairing
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glutamate clearance from the synaptic cleft (Keller et al 1997). It also inactivates glutamine synthase
that converts glutamate into glutamine (Pike et al 1997). These actions all contribute to excitotoxicity.
Ap oxidises lipids forming lipid free radicals and the by-products of lipid peroxidation, HNE and
acrolein (Mark et al 1997, Keller et al 1997). Although these are less toxic than Ap, they have a longer
half-life and so can act at greater distances from the initial site of free radical formation. Ap reacts
non-enzymatically with carbohydrates by the Maillard reaction to release free radicals and form
advanced glycation end-products. Glycated Ap can bind RAGE, a receptor that mediates cellular
oxidative stress in glia, endothelial cells and neurones (Yan et al 1996) and can stimulate apoptosis.
Ap can indirectly induce iNOS from astrocytes by stimulating ILip release from microglia. IL-
ip binds astrocyte interleukin receptors to activate the TNFa receptor associated factor 6, which
stimulates iNOS expression and NO release (Akama & van Eldic, 2000). NO has potentially
neurotoxic and neuroprotective roles in AD. It can exert toxicity indirectly by reacting with
superoxide radicals to form peroxynitrate. However, its direct roles seem to be protective. It has a
putative neurotransmitter/retrograde messenger role in synaptic plasticity, promotes vasodilation and
may protect against excitotoxicity. In AD brain, the level of cerebrospinal fluid NO is inversely
correlated to the level of dementia and glutamate toxicity is attenuated in cerebellar granule cells
which produce iNOS and are spared in AD (Tarkowski et al, 2000) supporting a predominantly
protective role.
The mitochondrial electron transport chain releases superoxide radicals. Mitochondria are
especially prone to oxidative damage due to their proximity to this significant source of free radical
production and the vulnerability of their DNA, and such damage potentiates further superoxide radical
formation making mitochondria a site of potential amplification of oxidative stress. Cells exposed to
Afi42/43 produce increased levels of reactive oxygen species, have impaired mitochondrial function and
eventually become apoptotic. This is prevented by the Ca2+ binding agent, calbindin, suggesting that
Ca2+ influx is an early event in the pathway (Guo et al 1998).
Oxidative stress activates a PKC-dependent increase in Ap production (Paolo et al 2000). This
specifically increases the intracellular Ap pool and may be an important positive feedback loop in AD,
contributing to the formation of toxic Ap42/43 aggregates.
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Whether neurodegeneration in AD is primarily a necrotic or apoptotic event, or is subserved by
some distinct mechanism, is still a matter for debate. In experimental conditions, chronic, low level
toxic insults are more likely to induce apoptosis, whilst the same insult applied acutely may induce
necrosis. This possibly explains reports of both necrosis (Sutton et al 1997, Suzuki 1997) and
apoptosis (Ohyagi et al 2000, Li et al 1996) in different studies on Ap toxicity in cell cultures. Since
AD is a chronic illness, apoptosis may be the more likely mechanism but identifying apoptotic cells in
AD tissue is difficult since only a very small proportion of cells will be undergoing apoptosis at any
time. Oxidative stress has been cited as a likely cause of neurodegeneration in AD, and this is
commonly linked to apoptosis.
1.66 Age-dependence
The brain becomes increasingly vulnerable to Ap-mediated toxicity with age as shown by Ap
injections into primate brain that causes neurodegeneration in aged but not young animals (Geula et al
1998b). The ageing brain has impaired defences against excitotoxicity and oxidative stress (Clementi
et al 1996) and so may accumulate toxins that make it more susceptible to disease. In women, risk of
AD with age is increased at the menopause with the associated decrease in oestrogen levels
(Fratiglioni et al 1997).
The age-dependence of AD could be caused by accumulation of mutations in mitochondrial
DNA. Mitochondria divide independently of cell mitosis. Mutations to mtDNA occur more frequently
than in nuclear DNA (Richter et al 1988). This is exacerbated in AD brain in which the rate of
mitochondrial DNA mutation is 15 times greater than in healthy age-matched controls (Corral-
Debrinski et al 1994). Cells develop a heteroplasmic population of mitochondria (ie having
mitochondria with differences in their complement of mutations) and those carrying mutations
proliferate either by increased division or persistence (de Grey 1997). In post-mitotic cells, such as
neurones, this unfortunately encourages proliferation of dysfunctional mitochondria tending towards
homoplasmy for deliterious mutations, and this gradual build-up of impaired mitochondria contributes
to the observed decrease in ETC efficiency and increase in reactive oxygen species production with
age. This would make the aged brain more susceptible to illnesses such as AD that are linked to
energy deprivation and oxidative stress.
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Polyunsaturated fats are more prone to oxidative damage than other membrane bound lipids
(Laganiere & Yu 1993). Mitochondrial and neuronal membranes become more vulnerable to Ap
toxicity with ageing as the levels of polyunsaturated fats (already relatively high in these membranes)
increases (Huber et al 1991).
Chronic inflammation has a major role in AD. Basal and stimulus-induced levels of
inflammatory cytokines are increased in the ageing brain (Ershler 1993, Saurwein-Teissl 2000)
facilitating the excessive immune response to amyloid deposition that leads to the sustained and toxic
activity of inflammatory proteins.
1.67 Site specificity
AD pathology is focussed on the hippocampus and association cortices. There is also significant
neurodegeneration of cholinergic pathways from the basal forebrain nuclei to the hippocampus and
neocortex.
The importance of inflammation in AD partly explains the site-specificity of neurone loss since
the hippocampus and the entorhinal cortex are especially sensitive to inflammatory cytotoxins.
Chronic low-dose infusion of the inflammogen, bacterial lipopolysaccharide, into the ventricles of
experimental animals result in increased ApPP and cytokine (ILip and TNFa) expression and atrophy
limited to the hippocampus and entorhinal cortex, and the animals show memory impairment (Hauss-
Wegrzyniak et al 1998).
Soluble Ap oligomers are selectively toxic to neurones in the hippocampus CA1, dentate
gyrus, and entorhinal cortex and spare cerebellar neurones and some CA3 neurones. ApoE is more
strongly expressed in brain areas that are sensitive to damage in AD (Xu et al 1999).
Cytokine activation often involves nuclear factor-icB (NFkB) -dependent transcription. In most
cells, NFkB exists in an inactivated form in the cytoplasm. However, in some cortical and
hippocampal cells it is constitutively active (Kaltschmidt 1994), which may explain why these areas
suffer high levels of pathology and cell loss in AD. NFkB mediates both neuroprotective and
cytotoxic pathways, and is central to apoptosis, and so may act as a discriminator of incoming signals
to decide cell fate.
The influence of apoE in AD may confer site specificity since this protein is expressed in the
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cerebral cortex and hippocampus, but not in the cerebellum (Xu et al 1999).
There are two possible explanations for specific loss of cholinergic projections from the basal
forebrain nuclei to the hippocampus and cerebral cortex. First, Ap-induced oxidative stress disrupts
G-protein signalling of muscarinic receptors. Second, Ap activates tau protein kinase, which impairs
pyruvate dehydrogenase function. This depletes levels of acetyl CoA, required to produce
acetylcholine. Disruption of cholinergic transmission in the hippocampus and neocortex may then
cause retrograde degeneration of neurones in the medial septum and nucleus basalis of Meynert. The
loss of cholinergic fibres correlates with density of NFTs suggesting a link between the two





The study of AD is hampered by the lack of a naturally occurring animal model. Post-mortem
examination of AD brain allows the affected areas to be identified and patterns of pathological
markers to be described, but disease progression cannot be studied and components of the
pathological markers do not reliably indicate factors that are of primary importance in pathogenesis.
An animal model would allow the progression of changes in the AD brain to be plotted from the
earliest stages and provide a tool for testing new treatments. In recent years, transgenic technology,
coupled with the discovery of genetic mutations that cause FAD, has provided a possible means of
generating animals that express AD.
Transgenic technology involves the introduction of foreign genetic material into an animal's
genome and the subsequent transmission of this mutation in a stable maimer to offspring, creating a
sustainable pedigree of animals carrying the donated DNA in all their cells. Transgenic technology
has the benefit of allowing human genes to be expressed in laboratory animals, so overcoming some
of the species-difference problems faced when studying human conditions in animals. Transgenic
animals can be used to examine gene control sequences and their activity in disease development. The
function of proteins can be studied by inference of the effects of overexpressing or inhibiting the
expression of the gene. The consequences of disease-causing mutations can be studied by inserting
human genes carrying a known disease-related mutation into laboratory animals.
2.1 Historical overview
The first step in the development of transgenic technology was to show that foreign cells could be
incorporated into tire tissues of a host. Rather than producing a transgenic animal; one which carries a
copy of donor DNA in every cell, tliis generated chimaeric animals, in which some tissues contained
cells of both host and donor origin. Two 8-cell stage embryos were cultured together until they formed
a single blastocyst, which was then implanted into pseudopregnant mice to develop to term
(Tarkowski 1961). SuccessM contribution of both cell lines to the offspring was demonstrated by sex-
chimaerism, in about half of the offspring. Production of chimaeric mice was developed by Gardner,
(1968) who used a blastocyst as the host into which foreign cells from the iimer mass of a blastocyst
of the same age were injected. Brinster (1974) used teratocarcinoma cells as the donor material to
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confirm that cells from different developmental stages could participate in embryonic development.
The advantage of using teratocarcinoma cells was that they could be maintained in culture making
them available for genetic manipulation prior to insertion. However, the use of teratocarcinoma cells
precluded the production of sustainable lines of genetically altered animals since tire offspring often
developed fatal tumours which prevented them from reaching adulthood and progeny of chimaeric
mice seldom carried tire donor cells, suggesting that teratocarcinoma cells rarely contribute to the
germline (Papaioannou et al 1975). Evans and Kaufman (1981), succeeded in finding suitable culture
conditions for maintaining embryonic stem cell lines. Using embryonic stem cells instead of
teratocarcinoma cells gave higher rates of success in generating chimaeras, mid these mice
successfully transmitted the donor cells to their offspring, giving the first evidence that lines of
animals carrying foreign genetic material could be reliably sustained (Bradley et al 1984). Transgenic
lines were generated from the first generation progeny of the chimeric animals, by selecting those
offspring derived from gametes containing tire donor DNA.
Transgenic animals can also be generated directly by injection of donor DNA into the fertilized
egg at tire 1 -cell (pronuclear) stage, as was first shown by Gordon et al (1980). This is the method of
choice for production of transgenic rats since culture conditions for maintaining rat embryonic stem
cells have still not been devised. Al tire pronuclear stage, within a few hours of fertilization, tire male
and female nuclei have not yet fused. The DNA of the transgene is injected into the male nucleus of
tire fertilized egg (figure 2.1). The male nucleus is larger than the female nucleus mid is usually closer
to the surface of the oocyte (Riilicke & Hribscher 2000). It is incorporated into the nucleus of the
zygote as tire male mrd female nuclei fuse and so will be present in all the cells of the offspring. The
manipulated zygote is then inserted into a pseudopregnant female to develop to term.
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2.2 Limitations of transgenic technology
Although transgenic animals have already been very useful in scientific research and their
contribution continues to expand, the technology has pitfalls that can affect the reliability of protein
expression and activity.
2.21 Genetic background
Transgenes are usually expressed in inbred strains of laboratory animal. These are lines of animals
which are homozygous at every gene locus as a result of consecutive brother/sister matings over more
than twenty generations. This provides a background free of genetic variability suitable for assessing
the specific effects of the transgene.
Some inbred lines show abnormalities due to homozygosity of deleterious mutations and these
may affect assessment of the effects of the transgene. The olal29 mouse strain shows particularly
severe abnormalities such as deficits in behavioural tests and in the development of the corpus
collosum, which make it a poor choice for studying the effects of a transgene on development or on
learning and memoiy.
The same transgene can show qualitative or quantitative differences in phenotype depending on
the background upon which it is expressed and so it is often worth examing a transgene in more than 1
strain.
2.22 Co-segregation
Unfortunately, olal29 is often the strain of choice for generating a transgenic line since embryonic
stem cells from these animals are cultured with the greatest success. The resulting transgenic animals
are often backcrossed onto another strain such as C57B, which confers a more normal physiological
background and more robust breeding. With each generation of back-crossing, the transgenic
offspring lose more of the ola genome. However, even after many generations, the transgene will
continue to be associated with neighbouring olal29 genes. It is possible that any differences seen in







2.23 Limits to insert size
Bacterial plasmid DNA is the usual vectors for cloning a transgene. However, they can only handle
gene fragments of about one hundred kilobase pairs; much smaller than most of the genes being
studied. Also, longer DNA fragments are more prone to damage from the shearing forces exerted
during purification and pronuclear injection. As a result, the non-coding introns are omitted from the
transgene. This allows cloning of sufficient DNA for successful expression of the full protein.
However, the introns can be important for efficient gene transcription, which may explain the
difficulties often experienced in generating high levels of protein expression (Brinster et al 1988).
Introns control splicing of mRNA into gene product variants and so functionally important isoforms
may not be produced. Introns can also signal transport of 111RNA to the cytoplasm, therefore their
omission may result in abnormal intracellular distribution of the protein.
The introduction of larger DNA fragments has been made possible by the use of yeast artificial
chromosomes, which have the potential to carry up to 2 megabase-pairs of genetic material. Also,
endogenous mechanisms for gene rearrangement in yeast can be exploited to introduce mutations of
the transgene before cloning. Lamb et al (1993) used yeast artificial chromosomes to transfer an entire
human gene, ApPP (about four hundred kilobase pairs), to mice, this being the first example of yeast
artificial chromosomes being used to transfer considerably longer DNA fragments.
2.24 Variable insertion site
Although a transgene usually only has one insertion site in the host genome, its position is
unpredictable. Therefore, two transgenic lines may carry the same transgene but in different parts of
the genome. Neighbouring genes can affect the expression of the transgene mid so the two lines may
exhibit different phenotypes. These positional effects are often only quantitative, so a number of lines
me generated mid the one with the strongest protein expression or most robust phenotype is chosen for
maintaining a permanent line. Creating multiple lines allows false positives, caused by unusual
interactions between the transgene and the host DNA or by rare cases of the transgene disrupting mi
endogenous gene, to be identified.
Positional effects are overcome by directing the transgene to a specific part of the
chromosome. This is known as homologous recombination and involves the transgene recognizing its
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analogous sequence in the host DNA and inserting at that locus, simultaneously removing or
disrupting the endogenous gene. This technique has also allowed the production of gene knockout
animals.
2.25 Redundancy
Many genes, especially those fundamental for cell function, have homologues with similar
capabilities. The effect of knockout or loss of function mutations can be masked by the recruitment of
homologues to restore function and leads to false-negative results.
2.26 Problems with homozygous mutations
Knockout of or loss of function mutations to a gene that is important for development is usually
developmentally lethal. Therefore, heterozygote animals are often used as the experimental group, and
so some normal gene function remains, possibly masking the phenotype of the transgene.
More recent developments are allowing increasing control over the tissues in which or at what
developmental stage a mutation is effected. This conditional mutagenesis commonly uses an intrinsic
plasmid gene rearrangement mechanism using two 34-base pair lox-p sequences to mark the target
gene and the 'causes recombination' CRE effector, which recognises lox-p and makes cither a reversal
or removal of the target gene, depending on the orientation of the lox-p markers. A line of animals can
be generated that carry lox-p marking the gene of interest. A second line of animals carries the CRE
gene with a promotor which confers upon it site or time specific expression. When the two lines are
crossed, offspring will express the mutation in the tissues or at the developmental stage as determined
by the CRE promotor. Other similar genes capable of performing these alterations have been
subsequently identified.
2.27 Variable copy number
Although there is usually only one transgene insertion site, this may carry multiple copies of the
transgene in a head-to-tail array. Not all copies are necessarily complete, therefore, although a higher
copy number gives a greater chance of transcribing the full length transgene, the expression levels of
the gene does not necessarily reflect the copy number. If each copy has its own direct control region
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then they each appear to be independently regulated and copy number is reflected by expression level
(Stiefetal 1989).
2.28 Changes in expression of other genes
Transgenic animals can show altered expression of proteins other than those targeted by transgenesis.
This may be due to the transgene directly interfering with transcription of endogenous genes or
indirectly by the transgene product (or lack of a protein in the case of knockout transgenic animals)
leading to modified expression of other genes.
2.3 Animal models of Alzheimer's disease
Transgenic approaches have been a focus of recent AD research. Some AD-like pathology has been
reported in apes and dogs, but these animals are not suitable for extensive scientific studies due to
ethical, financial and time constraints. Ideally, an AD model would be a traditional laboratory animal,
however, aged rodents do not naturally show any AD-type of illness.
Rodents transgenic for human genes carrying FAD-causing mutations have been produced in
an attempt to provide an AD model. A perfect animal model would show all aspects of the human
condition. In AD this is perhaps unlikely due to the cognitive focus of the disease. It affects mostly
phylogenetically recent brain areas, wliich underlie cognition and are particularly well developed in
the human brain. Since rodents do not posses such sophisticated cognitive traits, it is likely that some
of the systems affected by AD are not developed in rodent brain. However, it is possible that many of
the traits of AD can be recreated, and that cognitive dysfunction can be studied in relation to normal
rodent behaviour.
Potential AD models are typically studied for signs of pathology and alterations in their
behaviour, levels of neurochemicals, electrophysiology and biochemistry. A perfect model should
show amyloid plaques, neurofibrillary tangles and specific nerve loss. This should be focussed in the
neocortex, hippocampus, amygdala and basal forebrain nuclei.
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Since AD pathology is especially concentrated in tire hippocampus of AD subjects, animal
models should show deficits in forms of memory subserved by the hippocampus. In rodents, the
hippocampus subserves spatial memory, and so impaired performance in maze tests is expected.
AD brain shows particularly severe loss of cholinergic innervation to the hippocampus and
neocortex from the cholinergic forebrain nuclei. An AD model would be expected to show a reduction
in cholinergic markers in these brain areas, reflecting synapse loss and degeneration of cells in the
forebrain nuclei.
Electrophysiological studies can detect changes in the activity of neurones and in the properties
of pathways, such as expression of synaptic plasticity in the hippocampus and neocortex. Altered
expression of synaptic plasticity would be particularly interesting in an AD model, since these
mechanisms are believed to underly memory storage and retrieval.
A major effect of FAD mutations in human subjects is increased Ap production. ApPP
mutations cause an increase in total Ap whilst presenilin FAD mutations cause a selective increase in
Ap42/43, therefore, any FAD model of AD should show the appropriate change in Ap levels.
Transitional metals such as iron and copper should be colocalized with plaques and tangles and the
activity of protein kinases and phosphatases could be altered. Markers of apoptosis should be
upregulated, along with signs of oxidative damage such as lipid peroxidation, protein oxidation and
DNA fragmentation.
2.31 Transgenic rodent models of ApPP familial Alzheimer's disease
The ApPP mutations used most to generate transgenic models of FAD are Indiana V717F and
Swedish K670N/M671L, both of which have successfully recapitulated some important features of
human AD.
A popular model for studying the Indiana mutation is the PDAPP mouse, which shows
dramatic upregulation of Ap, and in particular Ap42 in the hippocampus and cerebral cortex but not in
the cerebellum (Games et al 1995, Johnson-Wood et al 1997). This leads to Ap deposition and plaque
formation in the neocortex and hippocampus from about 6 months onwards. The density of plaques
increases with age and they become associated with dystrophic neurites (Games et al 1995, Johnson-
Wood 1997). Dentate gyrus synaptic and dendritic density are lower in the transgenic mice (Games et
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al 1995), however, this does not correlate with amyloid load and in fact liigh A(3 levels can
accompany decreased synaptic density in the absence of AJ3 deposition (Mucke et al 2000). This is
supported by another PDAPP study that revealed deficits in synaptic transmission and reduced
synaptic density in the absence of plaques (Hsia et al 1999). NFTs have not been observed in this
model (Games et al 1995).
The amyloid plaques of PDAPP mice are surrounded by microglia and astrocytes (Games et al
1995). Microglia are strongly activated and have increased expression of macrophage colony-
stimulating factor receptors, that can modulated interactions between Ap and glia (Murphy et al
2000).
Impaired cognition increases with age and plaque load as shown using the water maze (Chen et
al 2000). This is accompanied by altered neurone excitability and synaptic plasticity. The maximum
EPSP amplitude of hippocampal pyramidal neurones from PDAPP mice is decreased. Young (4 to 5
month old) mice show increased paired pulse facilitation and decreased long-term potentiation whilst
aged (twenty-seven to twenty-nine month old) mice show decreased paired pulse facilitation and
increased long-term potentiation suggesting that synaptic transmission can be compromised prior to
amyloid deposition, and that the mechanisms of cognitive impairment differ in young and aged
animals (Larson et al 1999).
Indiana mutation mice show age-dependent deficiencies in glucose metabolism, that concurs
with the energy deficit observed in human AD brain (Dodart et al 1999).
The main Swedish mutation models are TG2576 and APP23. Swedish mutation mice show
increased [3-cleavage of ApPP that results in Ap elevation and sApPPa depletion (Moechars et al
1999). The level of Ap42 is the most strongly enhanced (Hsiao et al 1996). As Ap accumulation
progresses, the proportion of insoluble Ap increases and CSF and plasma Ap levels drop
(Kawarabayashi et al 2001). Mice show age-dependent amyloid deposition and plaque formation in
the neocortex and limbic areas (Hsiao et al 1996, Chapman et al 1999, Phinney et al 1999). Plaques
develop more rapidly in female mice (Sturchler-Pierrat & Staufenbiel 2000) and so this model may be
useful for studying the reasons for increased AD susceptibility in women.
APP23 mice at 14 to 18 months show selective cell loss in brain areas affected by congophillic
plaques, which are localized in the neocortex and hippocampus (Sturchler-Pierrat et al 1997, Calhoun
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et al 1998), although a study of a different line; TG2576 mice failed to show significant cell loss
(Yang et al 2000b). That plaques can induce neurodegeneration is supported by the positive
correlation between loss of CA1 pyramidal neurones and plaque load and the signs of degeneration
seen in some neurons that are near to plaques. There was qualitative evidence for cell loss in tire
neocortex although no significant global cell loss was measured (Calhoun et al 1998). These findings
concur with studies of human AD brain. Some plaque-associated neurites were positive for a-
synuclein (Yang et al 2000b), as is observed in human AD brain. A(i deposits of APP23 mice were
associated with neurites that show ectopic projections and swollen axons resembling dystrophic
neurites of AD (Sturchler-Pierrat et al 1997, Phinney et al 1999). Aged APP23 mice show dystrophy
of cholinergic fibres (Sturchler-Pierrat & Staufenbiel 2000).
Paired helical filaments of tau have not been observed (Yang et al 2000b) although tau-p was
detected in the APP23 line (Sturchler-Pierrat et al 1997, Sturchler-Pierrat & Staufenbiel 2000).
Congophyllic (but not diffuse) plaques from APP23 mice are associated with activated
microglia and reactive astrocytes (Sturchler-Pierrat et al 1997). The microglia are found on the plaque
periphery and are associated with amyloid fibrils and dystrophic neurites. Microglia exhibit signs of
phagocytic activity when associated with neurites but not amyloid fibrils suggesting that Ap fails to
stimulate microglia to phagocytose amyloid deposits (Stalder et al 1999). Ap probably activates
microglia via scavenger receptor A, which was upregulated in these mice, rather than by RAGE,
which was absent from the majority of plaques. The activated microglia express major
histocompatibility complex II but fail to activate B and T lymphocytes (Bornemann et al 2001), which
do not seem to be involved in the immune response in human AD. Rather, Swedish mutation mice do
have microglia that are positive for the cytokines IL-ip and TNFa and astrocytes that are positive for
IL-6, and it is such inflammatory factors that appear to be activated in human AD brain (Benzing et al
1999) (although a further study only managed to detect IL-1 p activity (Mehlhorn et al 2000)).
An age-dependent deficit in long-term potentiation was recorded both at the Schaffer
collateral/CAl and perforant pathway/DG synapses. Paired pulse facilitation and post-tetanic
potentiation were unchanged (Moechars et al 1999, Chapman et al 1999). There was no change in the
amplitude of the EPSP and no reduction in synaptophysin labelling suggesting that the decrease in
long-term potentiation was not due to altered synaptic transmission (Chapman et al 1999).
57
Swedish mutation mice show altered behaviour in tire home cage; alternate aggression, anxiety
and hyperactivity behaviour emerges in mice from about 8 weeks old. They have impaired
performance in the water maze (Hsiao etal 1996), and in tire T-nraze when aged sufficiently to show
impaired long-term potentiation expression (in the absense of cell loss) (Chapman et al 1999). The
performance level in the maze correlates well with the size of the long-term potentiation response.
Therefore, cognitive impairment can occur before cell loss, due to dysfunction of neuronal activity.
Some tests reveal cognitive impairment in transgenic mice even prior to amyloid deposition (King et
al 1999), suggesting that soluble Ap rather than amyloid fibrils could alter neuronal activity. Gender
differences in cognitive impairment have also been recorded, with females being more susceptible,
which may be relevant to tire gender bias in human AD (King et al 1999).
Models of other ApPP mutations have confirmed observations of elevated AP42 and sApPPp,
abnormal honrecage behaviour, impaired glucose metabolism and impaired perfomance in behavioural
tests (Moechars et al 1999, Pedersen et al 1999). Transgenic mouse brain has also shown signs of
apoptotic cell death in die absense of plaque formation (Kumar-Singh et al 2000) supporting a toxic
role for soluble Ap and apoptosis as the mechanism for cell death in AD. Amyloid deposition has
been observed in die cerebral vasculature (Van Dorpe et al 2000).
2.32 Transgenic rodent models of presenilin familial Alzheimer's disease
Levels of presenilin are very tightly regulated and so it has not been possible to generate PS transgenic
animals widi die high levels of mutated protein expression achieved in ApPP transgenic models.
However, lines of mutated presenilin mice have still successfully expressed some AD-like padiology.
Mice expressing human PS 1 carrying a variety of FAD-causing mutations show a selective
increase in Ap42 production (Duff et al 1996, Citron et al 1997) confirming diat PS1 influences ApPP
processing and substantiating die theory that all FAD mutations discovered so far probably cause AD
by interfering with Ap expression. Altiiough no amyloid plaques develop in these mice, neurones
show increased intracellular Ap load and cell loss in the hippocampus, neocortex and cerebellum
(Chui et al 1999), supporting a role for soluble Ap aggregates in neurotoxicity. PS1 mutations caused
impaired Ca2+ homeostasis and mitochondrial function in synaptosomes from transgenic mice (Begley
et al 1999), which could be responsible for the observed hypersensitivity to excitotoxins shown by
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neurones from these mice (Guo et al 1999a). Cell death was prevented by treatment with antioxidants
that prevent Ca2+ influx (Guo et al 1999b) supporting a role for Ca2+ in PS 1-mediated neurotoxicity.
Altered Ca2+ regulation has been recorded in electrophysiological studies that observed
enlarged medium and late afterhyperpolarising potentials, increased Ca2+ influx in response to cell
depolarisation and elevated long-term potentiation in neurones from mice expressing PS1 mutations
(Barrow et al 2000).
FAD mutations to PS 1 do not impair its developmental role. This is confirmed by the ability of
mutated PS1 to prevent the developmental defects usually observed in PS1 null animals with almost
equal efficacy to wildtype PS1 (Qian et al 1998, Davis et al 1998). This supports the view that PS1
mutations initiate AD via altered A(3PP processing and impairment of Ca2+ homeostasis rather than by
influencing development.
2.33 Double mutation transgenic rodent models Alzheimer's disease
The most robust rodent models of AD have been produced by cross-breeding existing single
transgenic lines to generate double transgenic lines, co-expressing tire A(3PP Swedish mutation and a
PS1 mutation. Borchelt et al (1996) combined the A|3PPswe model, with high over-production of Ap
with a PS 1A246e model that showed an increased proportion of the putatively more pathogenic Ap42, to
generate a mouse that at 2 to 3 months old already expressed a much higher level of Ap42 than either
of the single transgenic lines. By 12 months old, tire brains of double transgenic mice were positive
for amyloid deposits, gliosis and neuritic dystrophy mainly in the hippocampus and neocortex
(Borchelt et al 1997). Similar substantial elevation of Ap42 levels and speed of amyloid deposition
have been reported by studies using other PSlnrutations (Holcomb et al 1998, Lamb et al 1999,
McGowan et al 1999, Wengenack et al 2000). Expression of tire double mutations did not
significantly increase tire level of neurone loss (Takeuchi et al 2000) but did result in the basal
forebrain cholinergic nuclei forming smaller and less dense synapses in the cortex and hippocampus
(Wong et al 1999). The double mutation mice also replicated deficits in the Y-maze seen in PS1 but
not ApPPswedlsh transgenic lines (Holconrb et al 1998).
The novel approach of immunizing double-transgenic mice with Ap42/43 shows that even these
imperfect models are providing valuable insights into possible treatments for AD. Immunization prior
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to development of pathology prevented development of plaques. Animals immunized once Ap
deposition was apparent retarded the development of further pathology (Schenk et al 1999).
Behavioural tests have further shown the vaccine to alleviate cognitive deficits (Janus et al 2000a,
Morgan et al 2000).
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Chapter 3
Synaptic Plasticity in the Hippocampus
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The regular cytoarchitecture of the hippocampus has made it popular for extracellular studies of
synaptic function and in particular synaptic plasticity. The basic tri-synaptic circuit of the
hippocampus is preserved in transverse sections (figure 3.1) and the clearly defined cell body layers
allow reliable electrode placement. The line of PSlMi46v rats described in this thesis have been tested
for altered expression of synaptic plasticity, focussing on paired-pulse facilitation (PPF), paired-pulse
depression (PPD), post-tetanic potentiation (PTP) and long-term potentiation (LTP).
In addition, short-term potentiation, long-term depression and short-term depression can all be
generated in the hippocampus.
Figure 3.1 The Hippocampal Trisynaptic Pathway
This diagram shows the trisynaptic pathway in a transverse section of the hippocampus. The
perforant pathway (1) projects from the entorhinal cortex to the dentate gyrus granule cells.
Axons from the granule cells form the mossy fibres (2), which synapse onto CA3 pyramidal
neurones. Axons from CA3 pyramidal neurones form the Schaffer collaterals (3), which
synapse onto CA1 pyramidal neurones.
62
3.1 Paired pulse plasticity
When two stimuli me given to presynaptic neurones with a short interpulse interval (<2 seconds), the
postsynaptic response to the second stimulus may be either depressed (PPD) or facilitated (PPF) with
respect to the response to the first stimulus. When studied using field potential recordings, a specific
synaptic connection tends to reliably show plasticity in one direction. For example, PPF is commonly
observed in CA1 pyramidal neurones in response to Schaffer collateral stimulation and in dentate
gyrus granule cells in response to lateral perforant pathway stimulation, whereas stimulating the
medial perforant pathway generates PPD in dentate gyrus cells. When recorded intracellularly both
PPF and PPD can be generated by the same cell. If the response to the first pulse is large then the then
the response to the second pulse is depressed (PPD). Conversely, if the first response is small, the
second response is facilitated (PPF) (Debanne et al 1996).
3.11 Paired pulse facilitation
Paired pulse facilitation is believed to be presynaptically generated by mechanisms that control the
level of neurotransmitter release. Katz and Miledi described the Residual Calcium Hypothesis ofPPF
in 1968, which states that the influx of Ca2+ into the presynaptic bouton in response to the second
stimulus is supplemented by calcium remaining in the bouton from the first stimulus. This elevated
concentration of Ca2+ increases the release probability of available neurotransmitter vesicles (Katz &
Miledi 1968). CA3/CA1 glutamatergic synapses have an average of 5 vesicles ready for release
(Dobrunz & Stevens 1997) but only one active zone (Sorra & Harris 1993) and so they release either 1
or no vesicles in response to an action potential. If the probability of release is low then many
synapses will fail to release neurotransmitter in response to the first stimulus, generating a small
EPSP. However, the probability of release in response to the second stimulus is greater due to the
elevated Ca2+ concentration so more synapses release neurotransmitter and the second response is
larger. The low probability of neurotransmitter release in response to the first stimulus may be due to
the lower density of neurotransmitter vesicles observed in synapses that express PPF (Bower and
Haberly 1986).
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It takes less than 1 second for the concentration of cytosolic Ca2+ in the presynaptic terminal to
return to normal following a single action potential (Regelir et al 1994). That PPF can outlast the
elevation of Ca2+ suggests additional mechanisms are involved, and these may not necessarily be
presynaptic. Postsynaptic calcium-calmodulin kinase Hot (CaMKIIa) may contribute, since mice
lacking this protein show weaker PPF (Silva et al 1992).
3.12 Paired pulse depression
The mechanisms of PPD in dentate granule cells are not well understood due to the paucity of
intracellular studies on these relatively small neurones, however, the tri-phasic change in PPD
magnitude with changing interpulse interval (figure 3.2) suggests that the situation is more complex
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Figure 3.2 Dentate Gyrus Granule Cell Paired Pulse Depression
The level of depression decreases dramatically between interpulse intervals of about 50-
100ms after which it increases gradually until a plateau of depression is achieved from
intervals of about 200ms.
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Depression at short interpulse intervals (up to about one-hundred milliseconds) has been
attributed to GABAergic feed-forward inhibition (Burdette & Gilbert 1995). It appears that only
GABAa receptors tire active on dentate gyrus granule cells, generating IPSPs that peak at about forty
milliseconds and last for about two-hundred milliseconds in single cell recordings (Steffensen &
Henriksen 1991). This could account for tire inhibition at short interpulse intervals, perhaps slightly
longer than two-hundred milliseconds when imperfect synchronicity of neuronal firing in field studies
is considered.
However, other mechanisms are needed to explain the persistance of PPD well beyond the time
scale of a GABAa IPSP. It is possible that PPD is also mediated by the slow potassium-dependent
afterhyperpolarization that has been observed following perforant pathway stimulation (Rausche et al
1989). This lasts for over a second and so might become the dominant influence of PPD at longer
interpulse intervals. The mechanisms that generate PPD must exert strong inhibition to override the
events that lead to PPF generation.
3.2 Post-tetanic potentiation
Following a transient, high intensity burst of stimuli (or tetanus) the postsynaptic response increases
rapidly, often to 2 or 3 times the resting level. This potentiation reaches its peak typically within 2
minutes and lasts for less than 10 minutes. Like paired pulse facilitation, it is generated by elevated
Ca2+ concentrations in the presynaptic bouton. Mitochondria allow potentiation to persist by
sequestering Ca2+ during the tetanus. This is gradually released back into the cytosol, retarding the rate
of Ca2+ buffering (Tang & Zucker 1997).
3.3 Long-term changes in synaptic strength
Paired-pulse plasticity and post-tetanic potentiation only account for changes in synaptic strength that
last for seconds or minutes. More persistent synaptic modifications, LTP and LTD, last for at least an
hour and can persist for several days in vivo (Bliss & Lomo 1973) and involve far more complex
mechanisms involving both presynaptic and postsynaptic sites, which are as yet only partially
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understood. Potentiation that obviously outlasts PTP but decays before 1 hour is termed short-term
potentiation (STP) and is normally evoked by smaller conditioning trains of stimuli than those that
induce LTP, which has a higher tlireshold for induction, and may involve different expression
mechanisms (Schultz & Fitzgibbons 1997b).
LTP in the dentate gyrus was tire first long-lasting form of synaptic plasticity to be described
(Bliss & Lomo 1973), since when similar modifications have been observed in many excitatory and
inhibitory synapses throughout the brain. LTP is generated experimentally by a high frequency burst
of stimuli (HFS), usually comprising a one-hundred Hertz burst lasting for 1 second or multiple bursts
(for example, 10 bursts of 4 pulses at 100 Hertz every two-hundred milliseconds) termed theta burst
stimulation (TBS), argued to mimic more physiological patterns of hippocampal activity. Long-term
depression (LTD) in the liippocampus is best induced by low frequency stimulation (LFS) of around 1
Hertz for 10 to 15 minutes.
Various types of LTP and LTD have been described as it has become apparent that there are
pathway- and stimulation protocol-specific differences in the mechanisms of induction and
expression. Long-term synaptic plasticity in the perforant pathway/dentate gyrus and CA3/CA1
pathways are commonly described as NMDA-dependent (although non-NMDA components have
been isolated) wliilst mossy fibre/CA3 LTP is NMDA-independent. The following discussion relates
to NMDA-depcndent long-term synaptic plasticity recorded in the dentate gyrus and CA1. NMDA-
independent LTP mechanisms are described at the end of the chapter.
3.31 Properties of long-term plasticity
LTP exhibits the properties of cooperativity, persistence, associativity, input specificity and
metaplasticity. LTP is induced when excitation of a postsynaptic cell reaches a physiologically
determined threshold. This requires multiple inputs to be active together and/or to fire with a certain
pattern (McNaughton et al 1978). In experimental conditions, the stimulus used to induce LTP is often
as little as 1 second long, but potentiation can persist for hours. LTP can be induced in synapses
receiving a sub-threshold input when an LTP-inducing stimulus is given simultaneously onto the same
neurone (Levy & Steward 1979). Such a mechanism may underly associational learning during
classical conditioning. Formally, it was believed that only synapses that are active during induction
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are able to express LTP (Andersen et al 1977, Lynch et al 1977). This allows much greater capacity
for storing memories since plasticity occurs at the level of the synapse rather than at the level of the
neurone. However, more recently it has been found that specificity may not be absolute.
Superperfusion techniques developed by Engerg and Bonhoeffer allow activation of synapses to be
restricted to within approximately thirty micrometres from the electrode. However, synapses within
seventy micrometres were potentiated by tetanic stimulation in the CA1 (Engert and Bonhoeffer
1997). This suggests that localized groups of synapses rather than individual synapses may be the unit
of memory formation. The threshold for inducing LTP is not fixed, but can change in response to the
histoiy of synaptic activity. As a pathway becomes more potentiated, its threshold increases whereas a
relatively quiet pathway has a lower threshold (Ngezahayo et al 2000). This metaplasticity could
function to preserve responsiveness in quiet pathways and prevent saturation and seizure activity in
more active pathways. LTD in the adult hippocampus has also been shown to exhibit cooperativity,
persistence, associativity, input specificity and metaplasticity (Ngezahayo et al 2000).
3.32 Induction of NMDA-dependent plasticity
LTP induction in the CA1/CA3 pathway is dependent on Ca2+ influx through NMDA receptor-linked
ion channels (Collingridge ct al 1983). During low level synaptic activity, the NMDA receptor
contributes little to the EPSP. Its ion channel is blocked by a magnesium ion that is only removed
once the postsynaptic membrane is depolarized. Therefore, the NMDA receptor acts as a detector of
coincident presynaptic and postsynaptic activity. Due to the channel's slow activation kinetics, any
contribution made by NMDA receptor-mediated currents are swamped by feedforward and feedback
GABAergic inhibition.
During and after an LTP-inducing tetanus, NMDA receptor activity makes a greater
contribution to postsynaptic depolarization. EPSP summation during the tetanus prolongs postsynaptic
membrane depolarization, which removes the magnesium block. Also, GABAb autoreceptors inhibit
GABAergic interneurone activity by approximately 10 milliseconds into the tetanus (Davies et al
1991). Indeed, activation of presynaptic GABAb receptors is necessary for LTP (Davies et al 1991).
Slow NMDA receptor inactivation allows efficient EPSP summation during the tetanus, which
facilitates the build-up of Ca2+ in dendritic spines. There is evidence that this is supplemented by Ca2+
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released from intracellular stores, stimulated by metabotropic glutamate receptor activation and also
by Ca2+ itself.
The potential for LTP to subserve memory was realized early on with the recognition of
similarities between LTP properties and the theoretical mechanism of memory formation devised by
the psychologist Donald Hebb (Hebb 1949). The rule for Hebbian learning states that;
'When an axon of cell A ... excite(s) cell B and repeatedly or persistently takes part in firing it, some
growth process or metabolic change takes place in one or both cells so that A's efficiency as one of
the cells firing B is increased.'
Ca2+ is thought to induce LTP by binding calmodulin, creating a complex capable of activating
kinases such as CaMKIIcc, PKC and tyrosine kinases. CaMKIIa is essential for both induction of LTP
(Liu et al 1999) and spatial learning as demonstrated by deficits in CaMKIIa null mice (Silva et al
1992). During LTP induction, the increase in postsynaptic Ca2+ concentration stimulates CaMKIIa
autophosphorylalion within 15 minutes of the LTP-inducing stimulus (Barria et al 1997). Its activity is
prolonged for over an hour (Fukunaga et al 1993) and so it may serve as a memory of the transient
increase in Ca2+ concentration. It is possible that CaMKIIa levels in active dendritic spines are
increased by protein synthesis in the dendrites since CaMKIIa levels increase within 5 minutes of an
induction stimulus, which precludes transport of new protein from the soma, and CaMKIIa mRNA is
abundant in forcbrain neurone dendrites (Ouyang et al 1999).
Activated CaMKIIa is translocated to the postsynaptic density where it forms a complex with
the NMDA NR2B subunit (Strack & Colbran 1998). The formation of this complex may allow
CaMKIIa to remain active when Ca2+ levels have returned to normal by holding it near a site of Ca2+
influx. Persistent phosphorylation of CaMKIIa may also be facilitated by suppression of protein
phosphatases. A stimulus that is subtlireshold for LTP generation coupled with phosphatase inhibitors
or adenylate cyclase activators leads to CaMKIIa autophosphorylation and induction of LTP
(Makhinson et al 1999).
LTD induction is also dependent on Ca2+ influx through NMDA receptor-linked ion channels
(Dudek & Bear 1992) but this leads to enhanced phosphatase rather than kinase activity (Mulkey et al
1993). The calcium calmodulin complex is formed as in LTP, but to generate LTD it activates the
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phosphatase calcineurin. This can release protein phosphatase 1 from inhibition by suppressing
inhibitor-1 activity (Mulkey et al 1994).
STP is NMDA-dependent and probably represents early plastic changes that are necessary but
not always sufficient for initiating further mechanisms responsible for more sustained potentiation.
3.33 Bidirectional synaptic modification
Synaptic potentiation is not a permanent state. Both LTP and LTD can be induced in the same
population of synapses and are mutually reversing. The first experimental evidence for bidirectional
synaptic modification was described in dentate gyrus granule cells. HFS induction of LTP could be
reversed by LFS induction of LTD (Xie et al 1992). Both LTP and LTD were NMDA receptor-
dependent and were impaired by chelating intracellular Ca2+ with BAPTA, showing that they required
postsynaptic Ca2+ influx (Xie et al 1992).
Applying stimuli of different frequencies to a modifiable pathway exposes the bidirectional
nature of synaptic plasticity. In vitro, six-hundred pulse stimulation of the Schaffer collaterals at <5Hz
generated LTD at CA1 pyramidal cell synapses whilst stimulation at >15Hz generated LTP.
Stimulation at around 10Hz failed to generate lasting synaptic plasticity (Steel and Mauk 1999).
The nature of plasticity generated by a stimulus depends on the level of postsynaptic
depolarization and the resulting increase in Ca2+ concentration. It is differences in these parameters
that allows either LTP or LTD to be generated using different frequencies or strengths of stimulation.
Postsynaptic depolarization and Ca2+ concentration increase must be strong to induce LTP and milder
to induce LTD and manipulating these variables allows different responses to be generated by the
same stimulus. In the CA1, LTD can be induced by HFS that usually generates LTP if it is paired with
partial block of NMDA receptors (Cummings et al 1996), partial buffering of intracellular Ca2+
(Brocher et al 1992) or by perfusing tissue with low Ca2+ aCSF (Mulkey & Malenka 1992).
Stimulation of around 10Hz, which usually fails to induce lasting synaptic plasticity, induces LTD
when coupled with postsynaptic hyperpolarization (Xie et al 1992) or in tissue perfused with low Ca2'
buffer and LTP in tissue perfused with high Ca2+ buffer (Coussens & Teyler 1996).
The nature of synaptic plasticity may be influenced by the pattern as well as the magnitude of
Ca2+ elevation. Under stimulus conditions that generate LTP and LTD with near-equal probability,
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simultaneous release of caged Ca2+ to increasing the magnitude of Ca2+ concentration elevation
generates LTP, wliilst increasing the duration of Ca2+ elevation generates LTD (Yang et al 1999b).
These observations are described by the Bienenstock, Cooper & Munro model (reviewed in Bear
1996) where the transition between LTD and LTP inducing levels of postsynaptic depolarization/Ca2+
accumulation occurs at the modification threshold ©m (Figure 3.3).
The NMDA receptor was a possible candidate for gating Ca2+ influx and so determining the
value of ©m. LTD would be induced by stimuli that were too weak to activate NMDA receptors whilst
strong stimuli would activate NMDA receptor-mediated Ca2+ influx and induce LTP. However, it was
found that LTD is NMDA receptor-dependent (Dudek & Bear 1992). Also, stimulation of CA1
pyramidal neurones can cause NMDA receptor activation and NMDA-induced release of Ca2+ from
intracellular stores without inducing synaptic plasticity (Emptage et al 1999).
Figure 3.3 The Bienenstock, Cooper & Munro Model of Bidirectional Synaptic
Modification
Postsynaptic depolarization below 0m generates LTD and above 0m generates LTP. The
value of 0m can change depending on the history of synaptic activity.
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Induction of LTP leads to protein kinase activity (Huang & Hsin 1999a) whilst LTD involves
phosphatase activity (Mulkey et al 1993). It was proposed that failure of 10Hz stimulation to induce
synaptic plasticity was due to a balance between tire induction of kinase and phosphatase activity.
10Hz stimulation of CA3/CA1 synapses treated with the protein kinase inhibitor, H-7 expressed LTD
whilst those treated with the phosphatase inliibitor, tautomycin expressed LTP (Coussens & Tyler
1996) suggesting that the gating mechanisms for bidirectional synaptic modification regulate the
relative activities of kinases and phosphatases in response to Ca2+ influx.
3.34 The modifiable threshold
The value of ©m is sensitive to the liistory of synaptic activity and so subserves metaplasticity. This is
important since a static ©m would lead to persistent potentiation in some synapses and depression in
others. A modifiable ©m allows for bidirectional synaptic modification and maintenance of synaptic
sensitivity.
Modification of ©m can be generated by stimuli even if they fail to induce synaptic plasticity.
The CA1 response to HFS varies following priming stimuli of six-hundred conditioning pulses at
either 3, 10 or 30Hz. HFS generated no potentiation after 3Hz priming, weak transient potentiation
following 10Hz priming and gradually developing, stable potentiation following 30Hz (Wang &
Wagner 1999b).
LTP induction is enhanced by mGluR activation (Raymond et al 2000) and impaired by weak
NMDA receptor activation. mGluR priming establishes a lasting threshold for LTP induction by a
PKC-dependent mechanism (Bortolotto & Collingridge 2000) that results in local protein synthesis
(Raymond et al 2000). PKC may act through the mitogen activated protein kinase p42 MAPK (Sweatt
2001) to increase local protein synthesis. A possible target would be CaMKIIa mRNA which is
abundant in dendrites and CaMKIIa is upregulated and activated during LTP.
GABAa activity may modify 0m. GABAa agonists facilitate LTD induction by shifting the
threshold to a more depolarized membrane potential whilst GABAa antagonists facilitate LTP by
shifting the threshold to a more polarized postsynaptic membrane potential (Steel & Mauk 1999).
Transgenic mice that express constitutively active Jyn tyrosine kinase have depressed GABA activity.
LTP can be generated in hippocampal slices from these mice using stimuli that fail to induce synaptic
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modification in wild-type mice (Lu et al 1999b). In the CA1, pyramidal neurone activity is suppressed
by recurrent GABAergic inliibition. The strength of the inhibition is proportional to the activity in
pyramidal neurones and so may provide a mechanism of keeping the pathway within a functional
range of activity (Steel & Mauk 1999).
3.35 Site of expression of long-lasting plasticity
The expression mechanisms of synaptic modification are still poorly understood. Elucidating these
mechanisms has involved extensive research over nearly thirty years aimed at identifying the site of
expression, whether presynaptic or postsynaptic. The methods most commonly employed are
investigation of the interaction between long-term plasticity and PPF and quantal analysis.
PPF analysis of site of expression
PPF is believed to be presynaptically generated, and is weakened by manipulations that increase the
probability of neurotransmitter release (for example, increased extracellular Ca2+ concentration
(Creager et al 1980)). It is therefore suggested that putative presynaptic LTP expression would involve
an increase in the probability of neurotransmitter release and so result in PPF depression whilst PPD
would involve a decrease in neurotransmitter release and so result in PPD. McNaughton first studied
LTP-linked changes in PPF at the lateral perforant pathway/dentate gyrus synapse (McNaughton
1982). He found that whilst PPF was initially depressed, it recovered to baseline levels by the end of
the PTP phase. Similar results were recorded in the CA1 (for example Manabe et al 1993). However,
more persistent depression of PPF dnring strong LTP expression has been observed in both pathways
(for example in the CA1, Kuhnt & Voronin 1994 and in the DG, Christie & Abraham 1994).
Kleschevnikov and collcgucs recognised that PPF depression is not observed during weak LTP
expression, and in some cases PPF actually strengthened slightly, which may explain the negative
results reported in the earlier papers (Kleschevnikov et al 1997).
Strong pre-tetanic PPF predicts strong LTP and a greater and more persistent decrease in PPF
magnitude following LTP-inducing stimulation (Kleschevnikov et al 1997). During the first thirty
minutes following a high frequency tetanus, the magnitude of LTP is most strongly correlated with the
decrease in PPF strength, indicating a strong role for presynaptic mechanisms. By sixty minutes post-
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tetanus, the magnitude of LTP correlates only weakly with the change in PPF strength, suggesting that
postsynaptic mechanisms are more prominent. However, the magnitude of LTP correlates strongly
with the strength of pre-tetanic PPF (Kleschevnikov et al 1997). Large PPF may reflect a greater
capacity for plastic change in a pathway. This accords with the BCM model of synaptic modification
since large PPF would reflect low probability of transmitter release associated with depressed
synapses, in which Qm would be shifted to a more liypcrpolarized level, facilitating LTP.
Therefore, results from PPF studies suggest that presynaptic mechanisms may be important for
the first thirty minutes of LTP with postsynaptic or intermediate changes becoming more influential as
stable LTP becomes established.
QuantaI analysis of site of expression
Quantal analysis is based on tire theory that neurotransmitter is released in discrete units of uniform
quantity, termed quanta. Spontaneous miniture postsynaptic potentials are assumed to represent single
synaptic events and arc equivalent in amplitude to quantal size. Quantal size is determined by the
amount of transmitter per quanta (which is often assumed to be constant), the proportion of transmitter
that reaches postsynaptic receptors and the sensitivity of those receptors, and can therefore be
influenced by postsynaptic and intermediate changes in synaptic transmission. The number of
neurotransmitter vesicles released in response to a stimulus is termed quantal content, which is
determined by the number of vesicle release sites and the average release probability. Therefore,
changes in quantal content are usually assumed to reflect presynaptic alterations.
The parameters often measured during quantal anaylsis of LTP are transmission failure rate,
which is measured directly as the proportion of stimuli that do not generate a postsynaptic response;
quantal size, which is equivalent to the miniture excitatory postsynaptic potential (mEPSP) or current
(mEPSC) amplitude and quantal content that can be calculated as the evoked EPSP amplitude divided
by the mEPSP amplitude.
mEPSC amplitude has been observed to increase during LTP without a change in frequency
(Cormier & Kelly 1996), which suggests a postsynaptic increase in receptor sensitivity or an increase
in the number of functional receptors. However, in another study the frequency of mEPSCs increased
without a change in amplitude (Sastry and Bhagavatula, 1996) when LTP was induced using a
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different method, suggesting increased presynaptic probability of transmitter release or up-regulation
of functional release sites, although it might also reflect postsynaptic activation of receptors where
transmission failure was due to lack of receptors rather than failure of transmitter release.
LTP induction leads to a decrease in the transmission failure rate (Strieker et al 1996, Sastry &
Bhagavatula 1996, Kulint & Voronin 1994). This may reflect an increased probability of transmitter
release. There is evidence that in the hippocampus, a single quantum of glutamate saturates the
available postsynaptic receptors. However, the average probability of transmitter release is thought to
be low (Hessler et al 1993), which suggests that a decrease in the transmission failure rate involves
activation of transmitter release from previously inactive syanpses or activation of postsynaptic
receptors that were previously either absent or not functional.
Both quantal content and quantal size increased in response to LTP inducing stimuli in one
study (Strieker et al 1996), which failed to determine whether presynaptic or postsynaptic mechanisms
had been recruited, whilst another study showed a significant change in quantal content with quantal
size increase making only a small contribution to LTP (Voronin et al 1992), suggesting a presynaptic
locus. Many studies have concluded that both presynaptic and postsynaptic mechanisms are
responsible for LTP expression.
Kullmann et al (1992) concluded that various mechanisms could contribute to LTP expression,
since they were able lo generate LTP that increased cither quantal content, quantal size or both
parameters. Involvement of both presynaptic and postsynaptic mechanisms was also suggested by
Larkmanand collegues (Larkman et al 1992).
A more sophisticated study measured tire changes in PPF quantal parameters before and after
an LTP-inducing tetanus (Khunt & Voronin, 1994). Before the tetanus, the second stimulus for PPF
had a larger quantal content value only, supporting a presynaptic locus for PPF. For twenty minutes
following the tetanus, PPF was reduced and both quantal size and content increased in proportions
that suggested both pre and postsyanptic changes were active. Synaptic transmission during LTP has
been studied between individual pairs of CA3 and CA1 neurones, showing a post-tetanic decrease in
failure of transmission and increase in quantal size (Malinow 1991). Therefore, as in the PPF studies,
quantal analysis supports involvement of both presynaptic and postsynaptic mechanisms in LTP
expression.
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It is becoming clear that complex time-dependent synaptic alterations accompany the
development of LTP expression. Early LTP expression (1 to 2 hours following induction) involves
protein kinase activity and protein synthesis from existing rnRNA, and is now distinguished from late
LTP expression (over 10 hours) that requires gene expression. The complex development of these
expression mechanisms may make the results of PPF and quantal analysis studies highly dependent on
the time following the tetanus during which they are recorded.
3.36 Possible mechanisms of long-term synaptic modification
Possible mechanisms for LTP and LTD include mobilization of AMPA receptors to and from the
postsynaptic density, morphological changes, receptor phosphorylation or dephosphorylation, altered
glutamate release and retrograde messengers.
AMPA receptors and the silent synapse hypothesis
It has been assumed that both AMPA and NMDA receptors are present at all glutamatergic synapses.
In fact, some hippocampal synapses fail to express AMPA mediated currents (Gomperts et al 1998)
and following LTP induction the number of such so-called silent synapses decreases. This suggests
that expression of LTP is dependent on an increase in AMPA mediated currents, either by activation
of receptors that were previously present but not functional or by insertion of new receptors into the
postsynaptic density. The conversion of silent synapses to active synapses is a postsynaptic event, but
in quantal analysis would be detected as an increase in the frequency of mEPSCs, which would be
interpreted as presynaptic. This highlights how the assumptions upon which quantal analysis is based
can generate misleading conclusions.
The AMPA receptor, and the form containing the GluRl subunit in particular, is required for
LTP expression. Receptors consisting of GluRl/GluR2 heteromers are concentrated in the
hippocampus. Mice lacking the GluRl receptor develop normally, as other subunit types combine
with GluR2 to maintain normal synaptic transmission, but these animals fail to express LTP in the
CA1 and have impaired DG LTP (Zamanillo et al 1999).
The migration of new receptors into the postsynaptic density as a mechanism for LTP
expression was hypothesized by Xie et al (1997b) to explain the differential contribution of NMDA
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receptor- and AMPA receptor-mediated currents to LTP in dentate gyrus granule cells. Computer
modelling showed that whilst changes in NMDA receptor conductance may be explained by increased
receptor sensitivity, changes in AMPA receptor conductance were best explained by migration of
receptors closer to the site of presynaptic transmitter release. Recent evidence has supported the
importance of new AMPA receptors. NMDA-dependent LTP resulted in upregulation of AMPA
receptors as was shown by ELISA to detect AMPA receptor proteins in the membrane fraction (Lu et
al 2001). Immunostaining showed AMPA receptors to have clustered at the postsynaptic density (Lu
et al 2001). AMPA insertion was blocked by tetanus toxin suggesting SNARE-dependent exocytosis
(Lu et al 2001). GIuRl tagged with green fluorescent protein was shown to be concentrated in
dendrites near the base of spines and to migrate into the spines following LTP induction (Shi et al
1999). AMPA receptor insertion explains the increase in quantal size measured at tetanized synapses,
and concurs with the idea that neurotransmitter availability is not a limiting factor in the size of the
postsynaptic response. The migration of GluRl in response to a tetanus was dependent on NMDA
receptor activation, further supporting the link between NMDA receptor activity and LTP. GluRl was
inserted into both silent and AMPA receptor-containing synapses and some of the new receptors were
detected at tire cell surface suggesting that they were available to participate in neurotransmission.
Therefore phosphorylation of GluRl possibly mediates AMPA receptor migration to the postsynaptic
density to allow LTP expression.
Brefeldin, an inhibitor of protein trafficking, impaired NMDA-dependent LTP and western
analysis of the membrane fraction showed it to have prevented an LTP-associated increase in
membrane bound-GluRl (Broutman and Baudry 2001).
This receptor migration occurred within about 15 minutes of the tetanus (Shi et al 1999),
concurring with the observation that potentiation is stabilized within an hour of LTP induction. An
increase in AMPA receptor sensitivity has been measured starting a few minutes after the tetanus but
taking about an hour to reach a plateau, which may reflect the gradual addition and activation of new
receptors at the postsynaptic density. Early increases in AMPA receptor sensitivity may be attributed
to phosphorylation and increased conductance of active AMPA receptors, whilst increases after 15
minutes and more could involve the insertion of new receptors into silent synapses.
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AMPA receptor insertion and removal from tire postsynaptic density may be mediated by the
interaction between GluR2 and the membrane fusion protein N-ethyl-maleimide-sensitive fusion
protein (NSF). AMPA receptors are stabilized at the cell membrane by association of the GluR2
subunit with NSF. Impeding GluR2 association with NSF with pep2m leads to a decrease in the
intracellular pyramidal CA1 response to locally applied AMPA and a decrease in cell surface GluR2
immunoreactivity. Neurones treated with pcp2nr showed no reduction in the level of dendritic GluR2,
but less of the protein was located in the cell membrane suggesting that AMPA receptors can be
removed from the postsynaptic density and held in a dendritic pool (Noel et al 1999).
LTD may be mediated by removal of AMPA receptors from the postsynaptic density. CA1
pyramidal neurones perfused intracellular^ with pep2m failed to express LTD, whilst synapses that
were expressing strong LTD following low frequency stimulation of the Schaffer collaterals failed to
be further depressed by pcp2m. That these two methods of synaptic depression are mutually occluding
suggests that they use a common mechanism. No change in the kinetics of AMPA receptors was
observed, suggesting that LTD and pep2m depress the AMPA response by reducing the number of
functional receptors (Luthi ct al 1999).
It has been suggested that LTP is generated at individual synapses in an all-or-none manner
(Petersen et al 1998). Minimal stimulation intended to activate single synapses was paired with
postsynaptic depolarization to induce LTP. The majority of synapses showed one of three responses
when tested with a short pairing sequence followed by a long pairing sequence; potentiation in
response to the short sequence only, potentiation in response to the long sequence only or no
potentiation. Only one cell showed potentiation in response to both sequences. The short and long
sequences generated potentiation of similar magnitude indicating all-or-none LTP generation. That
some synapses required a longer pairing sequence indicates that they have different thresholds for
LTP induction.
This data can be interpreted in the light of the silent-synapse hypothesis. If indeed Petersen et
al were recniiling and potentiating single synapses then these already had functional AMPA receptors.
Indeed, additional AMPA receptors have been observed to migrate into active synapses following
LTP induction. This suggests that although the level of LTP generated in response to an induction
event may be all-or-none, such step-wise increases in potentiation may be repeated. The second
77
pairing sequence in the Petersen experiment was given within only a few minutes of the first, during
which time LTP expression would not have been established. If importation of AMPA receptors is the
key event in stabilizing LTP then giving a second pairing sequence after an hour or more may allow
further potentiation.
Potentiation at silent synapses necessitates activation of more than one synapse, since AMPA
receptor activation at another site is needed to depolarize the postsynaptic cell and allow NMDA
receptor activity. It is possible that individual synapses are only potentiated once, as implied by
Petersen et al, but that the increase in response generated by their technique was due to recruitment of
silent synapses. Tliis would suggest that AMPA receptors migrating into active synapses do not
become established in the postsynaptic membrane and do not contribute to LTP but that the all-or-
none expression of LTP is due to tire activation of an adjacent silent synapse.
Most studies have investigated silent synapses that lack functional postsynaptic AMPA
receptors. However, silent synapses may have functional receptors but fail to release neurotransmitter.
Late LTP is dependent on cAMP activity. LTP induced by cAMP leads to an increase in the level of
active presynaptic terminals shown by fluorescent dye (Fml-43), suggesting that late expression of
LTP may involve facilitation of neurotransmitter release from previously inactive synapses (Ma et al
1999).
Morphological changes
Recent studies have shown that morphological changes can occur rapidly and may be important for
LTP expression. Some active spines develop protrusions into the presynaptic bouton forming a
spinule, which may develop to such an extent that independent active zones are formed within the
same sjmapse, enhancing synaptic efficacy. These are known as perforated synapses. Electron
microscopy analysis of synapses following LTP induction shows an increase in the proportion of
perforated synapses by 5 minutes post-tetanus (Toni et al 1999).
The proportion of perforated synapses peaks by about thirty minutes and decays to baseline
levels within an hour. This decline is concommitant with an increase in the proportion of boutons
contacting multiple spines (Toni et al 1999). Three-dimensional reconstruction of neurones filled with
the fluorescent dye calcein shows formation of new spines within forty minutes post-tetanus (Engert
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and Boenlioeffcr 1999). In untetanized sections tlie majority of multiple spine boutons are contacted
by spines from different dendrites. In tetanized sections the number of multiple spine boutons
increases and a greater proportion involve spines arising from the same dendrite. The new spines had
a long neck, well developed postsynaptic density and were associated with vesicle-rich boutons
suggesting that they could be fully functional (Toni et al 1999). However, Shi et al suggest that new
AMPA receptors do not enter new spines (Shi et al 1999). Therefore, they may form silent synapses
and be a means of preventing saturation of LTP at a neuronal level rather than contributing to
potentiation resulting from the current induction events.
One electron microscopy study observed no significant change in synapse number or
morphology following LTP induction, however, tire authors acknowledged that their sample size was
small, and so did not argue strongly against the possible contribution of morphological changes to
LTP (Sorra & Harris 1998).
Guidance of morphological changes and stabilization of synapses may be regulated by the
HSPG, N-syndecan. During LTP, N-syndecan forms a complex with fyn tyrosine kinase that
accumulates in the cell membrane (Lauri et al 1999) where it would be available to mediate
interactions between the neurone and the extracellular matrix.
Receptor phosphorylation
Sire-family protein kinases can induce potentiation that occludes tetanic LTP induction (Huang & Hsin
1999a). The NMDA NR2B subunit is phosphorylatcd by tire sre tyrosine kinase during LTP, which
increases the conductance of NMDA receptors (Huang et al 2001). This is mediated by cell adhesion
kinase p/prolinc-rich tyrosine kinase 2 (CAKp/Pyk2) which is activated by PKC following increases
in intracellular Ca2+ concentration and binds sre tyrosine kinase, releasing it from autoinhibition. This
may facilitate Ca21 influx during early LTP and promote Ca2+ dependent mechanisms of expression
such as maintaining activity of CaMKIIa. Inliibition of CAKp/Pyk2 blocks LTP induction whilst
intracellular CAKp/Pyk2 perfusion CA1 pyramidal neurones induces potentiation that occludes
tetanic LTP induction (Huang et al 2001).
CaMKIIa can phosphorylate the AMPA receptor GluRl subunit (Barria et al 1997), which
increases the size of Na+/K+-mediatcd AMPA ESPCs. Other AMPAR subunits may also have
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phosphorylation sites with similar functions. Stabilization of CaMKIIa at the postsynaptic density by
binding the NMD A NR2B subunit may facilitate AMPA receptor phosphorylation (Leonard et al
1999).
PKA is activated 2 to 10 minutes following tetanization and may facilitate CaMKIIa activation
by decreasing protein phosphatase activity and so promoting autophosphorylation. LTP induction in
the dentate gyrus is also NMDA receptor dependent and probably involves autophosphorylation of
CaMKIIa.
NMDA-dcpcndent LTP expression involves activation of the mitogen activated protein kinase
ERK (Kanterewicz 2000). ERK activation may have various roles including activation of gene
expression, and so maybe relevant to the transition from early to late LTP.
LTD involves increased phosphatase activity that could theoretically reverse LTP-induced
receptor phosphorylation.
Glutamate release
Manabe and Nicoll argue that increased glutamate release is not a feature of CA1 LTP since the post-
tetanic decline in currents through persistently open NMDA receptor-linked channels followed the
same time course in tetanized and untetanized pathways (Manabe & Nicoll 1994). Whilst CA1 LTP
expression appears to be increasingly postsynaptic with time, in the dentate gyrus, a persistent
increase in glutamate release from the medial perforant pathway has been observed (Dolphin et al
1982, Bliss et al 1986, Errington et al 1987). Increase in glutamate release probability may result from
the phosphorylation of synaptic proteins such as rabphilin-3A, which is phosphorylated by PKA and
CaMKIIa (Fykse ct al 1995).
Retrograde messengers
Experimental generation of associative LTP in the CA1 by linking a weak input with an LTP-inducing
input, causes depression of PPF at synapses that receive only a weak input (Kleschevnikov et al
1997). This suggests that the probability of glutamate release is increased from these terminals even
though they were not subject to the LTP-inducing stimulus. Therefore, it is suggested that induction
events in dendritic spines lead to the release of a retrograde messenger that can modify the probability
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neurotransmitter release from the presynaptic terminal. The identity of this putative retrograde
messenger, required to coordinate presynaptic and postsynaptic changes, has not been resolved,
although nitric oxide, carbon monoxide and arachadonic acid are all possible candidates. Of these,
nitric oxide is a popular choice. Nitric oxide synthase can be activated by CaMKIIa. LTP is enhanced
by nitric oxide donors (Malen & Chapman 1997) mid impaired by nitric oxide synthase inhibitors
(Haley et al 1992). LTP induced by postsynaptic injection of CaMKIIa is not sensistive to nitric oxide
depletion (Ko & Kelly 1999a), which suggests that nitric oxide may maintain enhanced glutamate




There is controversy over whether mossy fibre LTP induction is pre or postsynaptic. Kapur et al
(1998) used two different stimuli and managed to isolate two forms of mossy fibre LTP. LTP induced
by HFS comprising of few long bursts seemed not to involve postsynaptic NMDA or L-type channels.
LTP induced by HFS comprising of many short bursts was also NMDA-independent but did require
influx of Ca2+ through postsynaptic L-type voltage dependent Ca2+ channels and was blocked by
nimodipine. Ycckcl ct al also tried to distinguish different mechanisms of LTP induction using
different stimulation protocols but they observed an increase in postsynaptic Ca2+ concentration
following brief HFS as well as following more prolonged stimulation. LTP induced by both protocols
was blocked by intracellular Ca2+ buffer. They found that the rise in intracellular Ca2+ arose from
intracellular stores and was dependent on mGluR activation (Yeckel et al 1999) This shows that this
form of LTP at least docs involve postsynaptic induction mechanisms, whilst it is possible that it is
generated alongside LTP with different mechanisms that are not postsynaptically driven. Mossy fibre
LTP does not involve activation of the mitogen-activated protein kinase ERK (Kanterewicz et al
2000). Lower frequency tetanization (25Hz) also induces mossy fibre LTP and this was not impeded
by mGluR blockade or Ca2T chelators (Mellor & Nicoll 2001).
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CA1 NMDA-independent LTP
CA1 LTP is usually defined as being NMDA dependent. Whilst NMDA receptors are involved in
CA1 LTP, NMDA antagonists have revealed an NMDA-independent component both in vitro (Grover
& Teyler 1990, Strieker et al 1999) and in vivo (Morgan & Teyler 1999). NMDA antagonists reveal
that about fifty per cent of the in vivo response is NMDA independent (Morgan and Teyler 1999).
Instead it is induced by Ca2+ influx through L-type voltage dependent calcium channels. The cascades
stimulated by these Wo forms of LTP are distinct. NMDA dependent LTP involves serine/threonine
kinase activity and mGluRl activity can modulate the LTP response. L-type voltage dependent
calcium channels LTP involves tyrosine kinase activity. Gamma-protein activity and the group 1
mGluRl and mG!uR5 (that are abundant on CA1 pyramidal cells) do not contribute to NMDA-
independent LTP induction however group 2 and group 3 mGluRs seem to be needed (Grover & Yan
1999).
Dentate gyrus NMDA-independent LTP
Dentate gyms LTP can also be induced independently of NMDA receptor activation by either
activating mGluR or stimulating Ca:+ influx through T-type voltage dependent calcium channels. All
these forms of DG LTP are impaired by MAPK inhibitors (Coogan et al 1999).Medial perforant
pathway-dentate gyrus synapses show NMDA-independent LTP and PPD. LTP induction by HFS was
attenuated by high concentrations of MAPK inhibitors (Coogan et al 1999). The mitogen activated
kinase p42 MAPK is involved in LTP expression. p38 MAPK, which can inhibit p42 MAPK activity,
is active during NMDA-independent LTD expression (Bolshakov et al 2000). Therefore, whilst
NMDA-dependcnt synaptic modification may be driven by relative activities of protein kinases and
phosphatases, NMDA-independent synaptic modification may be driven by the opposing actions of






Fischer rats were genetically modified to carry the human PS 1 gene with the Finnish M146V mutation
(Estibeiro, Edinburgh University). In the affected human family, this mutation causes AD that has an
especially early age of onset, which may facilitate the expression of AD-type abnormalities within the
lifetime of a rat.
Mice have been the animal of choice in the majority of transgenic studies into AD. Although
rats have a longer reproductive cycle, and so take longer to establish in transgenic lines, their
neurophysiology is better understood since their larger size makes them preferable for intricate in vivo
elecrophysiological studies.
In this transgenic line, the mutated human PS1 mRNA expression is 6 times greater than that of
the endogenous rat PS1 mRNA. The mutated protein is expressed at a low, but detectable level.
Mutated PS 1 is thought to cause AD by increasing the level of Ap42/43 expression. Unfortunately, the
Ap42/43 levels in these animals have not been quantified due to the lack of a commercially available
ELISA kits for rat Ap.
The rats were housed and bred in the Medical Faculty animal facility and monitored by trained
staff. Rats from second litters were preferably chosen for breeding. Heterozygote rats were mated with
wildtype partners to produce litters that gave approximately equal numbers of heterozygote and
wildtype offspring. Ageing of Edinburgh rats beyond 18 months was prevented by illness, in
particular the high incidence of tumours in rats approaching this age.
4.2 Genotyping offspring
4.21 Tagging and tail biopsy
Tail biopsies were taken from weaned offspring under general anaesthetic. Animals were
anaesthetised by halothane inhalation in an anaesthetic chamber until the withdrawl reflex was absent
in response to mild pinching of the hind paw. A tag was clipped to the ear of each animal bearing an
identification number. Half a centimetre was taken from the end of the tail using a razor blade and
placed in a microfuge tube labelled with the animal's tag number. The tail was pinched to minimize
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bleeding while a drop of tail glue was applied to the cut end to induce blood coagulation and promote
healing. The animal was then returned to their homecage where they recovered from the anaesthesia
within a few minutes. Animals were observed until fully recovered.
4.22 DNA extraction
Microfuge tubes containing the tail biopsies were placed on ice and 500pi of PK digestion buffer was
added to each. Samples were incubated at 55°C for about 36 hours after which they were spun for 10
minutes reducing any remaining solid material, which comprised mainly hair and bone, into a pellet.
The supernatant was removed and treated with 500pls isopropanol. The tube was gently swirled to
encourage the DNA to precipitate. The DNA was carefully picked out and the isopropanol drained off
before being transferred into TE. 1 pH7.5 (lOmM pH7.5 tris, O.lmM EDTA in sterile H20). This was
heated for 15 minutes at 60°C. To fully resuspend the DNA, the microfuge tubes were periodically
swirled. The samples were then stored at 4°C.
4.23 Southern blotting
Fifty microlitres of DNA solution was digested using 0.3pl EcoRl in 40pl lOx H- (500mM NaCl,
lOOmM Tris 7.5, lOOmM MgCl2, lOmM DTT, ImM spermidine and lg BSA) and incubated in a
water bath at 37°C overnight. The digests were heated to 67°C for 10 minutes after which l/w volume
NaAc and 2'A volume 100% EtOH was added. The digests were chilled at -20°C for 30 minutes to
precipitate the DNA. They were centrifuged for 15 minutes to recover the DNA. Having removed the
supernatant, the pellet was washed with 500pl 100% EtOH and centrifuged for a further 5 minutes.
The EtOH was removed and the microfuge tubes left open on the bench to allow the pellet to dry. The
DNA pellets were resuspended by heating in distilled water and Edye, which allowed the sample to be
visualized on the gel.
Agarose gel was prepared in lx TBE buffer with 5 pis ethidium bromide, a DNA binder. The
samples were loaded onto the gel and run at 150V for 1 to 2 hours. Once the marker had run about 2/3
of the way down the gel, the gel was photographed under ultraviolet light to expose how far the
samples had travelled, (poor sample mobility indicates incomplete DNA digestion by EcoRl). The gel
was treated with 0.4M HC1 for 15 minutes followed by 0.25M NaOH for 30 minutes. It was then
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stacked overnight on top of a NaOH reservoir and against a sheet of positively charged nylon. The gel
was exposed under ultraviolet light to ensure all of the DNA had transferred to the nylon sheet, which
was rinsed in 4 x SCC and allowed to dry.
The probe for human PS1 was heated in a bath of boiling water for 10 minutes to denature the
DNA into single strands. This was then cooled rapidly in an ice/water slurry to prevent reannealing of
the DNA probe. To the probe was added nonaprimer mix, cATP, cGTP, cTTP, Kienow enzyme and
the 32PdCTP radioactive marker. This was heated at 35°C for 30 minutes. EDTA was added and the
probe was heated again to 100°C for 10 minutes followed by rapid chilling in ice slimy. The nylon
sheet was treated with prehybridisation solution in SSC to occupy vacant DNA binding sites. This was
rotated slowly in a prehybridisation tube at 60°C for at least 15 minutes. The probe was added to the
prehybridisation tube, which was returned to the rotisserie for a further 2 hours. The nylon sheet was
then thoroughly washed at 65°C over an hour in gradually decreasing concentrations of SSC with 1%
SDS following which, it was removed and washed at room temperature with 2 x SSC. A geiger
counter was used throughout to be certain that all radioactive contamination was neutralized.
The nylon sheet, DNA side up, was placed in a photographic folder. In complete darkness, a
piece of film was placed in the exposing folder on top of the nylon sheet. The folder was sealed and
left at -70 °C for 20 to 24 hours to expose. The film was fully thawed and processed in an automatic
film developer (Konica SRX-101A). Tracks that were marked indicated the transgenic animals. Figure







Figure 4.1 Southern blot impression for samples from 14 rats.
The marker serves as a positive control. The positive tracks indicate the transgenic offspring.
The result for rat 581 was inconclusive and this sample was retested at a later date.
4.3 Recording chamber
An interface recording chamber as shown in figure 4.2 was used for all electrophysiological
experiments. Heated, oxygenated aCSF passed through outlet (B) and flowed over the mesh-covered
platform (E). The flow rate was high enough to allow a meniscus of aCSF to form around the slices
(D). Water vapour from outlet (A) bubbled with oxygen (G) also helped keep the slices moist and
oxygenated. aCSF was recycled to a heated, oxygenated reservoir (not shown). The temperature of
aCSF was measured using a thermal probe (C) near the aCSF outlet and was regulated by the heating
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element (H). The earth electrode (F) on tire platform gave a reference point for measuring voltage
changes at the recording electrode.
A
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Figure 4.2 Schematic diagram of slice chamber.
(A) Aerial view. (B) Side view in cross section.
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4.4 Preparation of hippocampal brain slices
Male Fischer rats were killed at 6 months or 18 months old by decapitation under halothane
anaesthesia. The brain was quickly and carefully removed and cooled in aCSF of composition (mM);
sucrose 252.0, KC1 2.5, NaH2P04 1.2, CaCl2 2.4, MgS04 10.0, NaHC03 26, D-glucose 10, which was
bubbled with 95% 02/5% C02 and maintained at <4°C. The brain was trimmed and fixed to a cutting
platform with cyanocryolite industrial superglue and supported against an agar block. Slices 400pm
thick were cut using a vibrotome (Campden Instruments). The hippocampus was trimmed and 4 slices
were transferred to the recording chamber where they were left to incubate for at least 1 hour at 30 to
31°C. To record from the CA1, the bath aCSF composition was (mM); NaCl 124.0, KC12.5, NaH2P04
1.2, CaCl2 2.4, MgS04 1.3, NaHC03 26, D-glucose 10. To record from the dentate gyrus, the aCSF
included lOOpM picrotoxin to depress GABAa inliibition and was adjusted to 4.0mM CaCl2 and
4.0mM MgS04 to prevent spontaneous synaptic activity. The flow rate was 1.5mls/minute.
At the end the pre-incubation period, slices were only used if the cell body layers were clearly
visible and the slices were not sinking into the supporting mesh.
4.5 Extracellular field potential recordings
Electrode positions are shown in figure 4.3. Micropipettes were pulled using a Model P-87 Flaming
Brown Micropipette puller (Sutter Instruments) using thin-walled (1.17mm inner diametre) filamented
borosilicate glass (Clark Instruments). To record extracellular field potentials in the CA1, a glass
recording electrode (5 to 10MF2) was placed into the stratum radiatum of the CA1 and a concentric
bipolar stimulating electrode was placed in the stratum lacunosum-molecularae of the CA3 to
stimulate the Schaffer collaterals. To record field potentials from dentate gyrus granule cells, the
stimulating electrode was placed on the perforant pathway at the apex of the granule cell body layer
and the recording electrode was placed in molecular layer of the dentate gyrus.
The perforant pathway divides as it enters the dentate gyrus into medial and lateral pathways.
All recordings were made in the medial pathway which can be identified by the expression of PPD
rather than PPF. All extracellular protocols were run using an LTP Program written by W.W.
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Anderson (University of Bristol, 1997). Data was collected and analysed online and offline using the
same program.
Figure 4.3 Electrode placement for extracellular field recording
Slices were deemed healthy if the fibre volley amplitude was less than 1/3 of the EPSP
amplitude and stimulation of the slice did not elicit epileptiform activity. Stimulus intensity was
increased until just subthreshold for generating a population spike. The rising slope of this maximal
EPSP was measured and recorded (figure 4.4). The stimulus intensity was then reduced in order to
generate a half-maximal EPSP as judged by slope magnitude.
The average amplitude, half width and rising slope of half-maximal field EPSPs were
calculated. Maximal field EPSPs were generated by gradually increasing the stimulus intensity until
evidence of a population spike was visible. Half-maximal field EPSPs were found by decreasing the
stimulus intensity until the rising slope value was half that recorded in the maximal field EPSP.
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Twenty consecutive field EPSPs were recorded from each slice. The field EPSP parameters measure
in control and transgenic groups were averaged and analysed using a t-test. All statistics were








Figure 4.4 Example of a maximum EPSP
EPSP showing the measurement of the slope and the typical size of the fibre volley.
Paired pulse data were collected by giving pairs of stimuli at interpulse intervals of 400, 350,
300, 250, 200, 150, 100, 75 and 50ms. Paired stimulation was repeated every 15 seconds and 4 sweeps
were averaged online at each interpulse interval. Paired pulse data were analysed using a repeat
measure 2-way ANOVA.
To record LTP, first a stable baseline was recorded for at least 30 minutes with test stimuli
given every 15 seconds. After 30 minutes of stable baseline had been recorded, a conditioning train
consisting of 100 pulses at 100Hz was applied to the stimulating electrode. To generate dentate gyrus
LTP, the stimulus intensity was doubled during the tetanus only. Test stimuli were given for an hour,
followed by a second identical conditioning train and a further 30 minutes of test stimuli. This was
repeated in 1 to 3 slices per day depending on the health of the slices. Reanalysis was performed if
necessary using the LTP Program. To analyze post-tetanic potentiation, an unpaired t-test was
performed on the values of the largest slope generated within 10 minutes of the conditioning train.
LTP was analyzed over the last 10 minutes of expression recorded, using a nested ANOVA (SPSS);
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LTP following the first conditioning train was analysed at the 80 to 89 minute interval and following
the second tetanus was analysed over tlie 111 to 120 minute interval.
4.6 Intracellular sharp electrode recording
Intracellular recordings were made in CA1 pyramidal cells from 18 month old rats. Micropipettes
were pulled from filamented borosilicate glass (30 to 70MH using thin wall glass or 80 to 150MQ
using thick wall glass). Electrodes were used if capable of passing more than InA of both positive and
negative current. All data were collected using Clampex 8 and analysed offline using Clampfit (both,
Axon Instruments Inc, 1999).
To make recordings, the tip of the electrode was place in the pyramidal cell body layer of the
CA1, the offset adjusted to OmV and the bridge current of the amplifier was balanced. The electrode
was advanced in 1 to 3 pm steps with a negative square current pulse being generated at 1Hz. As the
electrode approached a cell, the increased resistance at the tip was observed as an unbalancing of the
brigde. The Buzz feature of the amplifier was used to aid cell penetration. Negative holding current
was applied to promote sealing of the cell membrane. Once the membrane potential was stable, the
holding current was gradually removed and the offset value taken as the working membrane potential.
If the cell showed spontaneous activity, negative holding current was briefly reapplied. Cells were
only used if the resting membrane potential was stable at a minimum negative value of -60mV, the
action potentials were at least 60mV in amplitude and the membrane resistance was at least 20MQ.
The offset was also noted when the electrode was withdrawn to allow the true resting membrane
potential to be calculated. Data from cells where this showed the resting membrane potential to be
more positive than -60mV were discarded. All intracellular data were analysed using an unpaired t-
test or the Mann Whitney rank sum test if the data were not normally distributed.
4.61 Collection and analysis of data
Membrane resistance (Rn)
Square current pulses of 500ms duration were given via the recording electrode in 20pA steps from 35
to -205pA. This was repeated 13 times and the results were averaged. To calculate the membrane
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resistance, the input current was plotted against the voltage of the response with the slope being the
result. Cells with a membrane resistance lower than 20MQ were rejected. The resistance was
calculated using the initial voltage response to current injection, to minimize bias caused by rectifying
currents (figure 4.5).
Adaptation of action potential firing frequency
Two second-long pulses of current, starting from 20pA and increasing in 40pA steps, were injected
via the recording electrode to generate trains of action potentials. The current/frequency response were
calculated for the interspike intervals for action potentials 1 to 2 (first interspike interval), action
potentials 2 to 3 (second interspike interval) and by averaging the interspike intervals for the last 4
action potentials (steady state interval) (figure 4.6). Adaptation was analyzed by plotting the action

















Figure 4.5 Neuronal resistance
(A) The change in membrane resistance in response to current injection was measured
during the trasient (T) phase. (B) The slope of the current/voltage
plot gave the neuronal resistance.
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Figure 4.6 Action potential firing frequency adaptation
Response to a 700pA current pulse of (A) a typical slow-adapting neurone and (B) a typical
fast-adapting neurone. (C) Measurement of 1st, 2nd and steady-state firing frequencies
(trace shows first three and last four action potentials from the response shown in (A)).
The steady state firing frequency is calculated as the average interpulse interval of the
last 4 action potentials (n, n-1,n-2).
95
Action potential properties
One millisecond current pulses transmitted through the recording electrode were used to generate
single action potentials, which were averaged over 30 sweeps. The parametres measured were spike
amplitude, rise time, decay time, half width, and amplitudes of afterdepolarizing potentials or fast
afterhyperpolarizing potentials ifpresent (figure 4.7).
Medium and slow after-hyperpolarization
To measure the medium and slow AHPs, a 40Hz burst of current pulses transmitted through the
recording electrode, each producing an action potential, was generated on a 4 second sweep. The burst
generated 8, 12, 16 or 20 stimuli and the response was averaged over 30 sweeps. The medium AHP
amplitude was taken as the maximum level of hyperpolarization. The maximum of the slow AHP was
often obscured by the medium AHP and so the level of hyperpolarization 1 second after the end of the
end of the action potential burst was taken as a representative measurement of the slow AHP
amplitude (figure 4.8). By 1 second, the medium AHP no longer contributes to the hyperpolarization .
Synaptically evoked EPSP properties
A concentric bipolar stimulating electrode was placed in the stratum lacunosum-moleculare of the
CA3 to stimulate the Schaffer collaterals. The stimulus intensity was increased until an action
potential was generated with a 50% success rate. The amplitude of the maximum EPSP (recorded in
the absence of an action potential) was measured and the stimulus intensity was reduced until an
EPSP of half-maximal amplitude was generated. All subsequent procedures used this stimulus
intensity. To characterize the EPSP, 50 sweeps each generating 1 EPSP were averaged. The
amplitude, rise time, decay time and half width were recorded offline (figure 4.9).
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Figure 4.7 Action potential properties
(A) The action potential amplitude was measured from the resting membrane potential.
(B) The rise and decay times were measured from the peak of the action potential to the
resting membrane potential (or projected if an ADP extended the decay phase). The half
width was measured where the action potential had reached its half maximal amplitude.
(C) ADP and AHP amplitudes were measured from the resting membrane potential.
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action potential train (12 spikes)
500ms
4mV
Figure 4.8 Medium and slow after-hyperpolarization
After-hyperpolarization amplitude was measured from the resting membrane potential.
The mAHP maxima was the point of strongest hyperpolarization. The sAHP maxima
was usually masked by the mAHP and so was taken as the amplitude of hyperpolarization





Figure 4.9 EPSP properties
(A) Features of a typical mixed synaptic potential (B) Measurement of EPSP properties.
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Time constant (t)
A 0.5ms depolarizing current pulse transmitted via the recording electrode was used to calculate the
time constant. This pulse should be too small to activate voltage-dependent ion channels. About 300
sweeps were averaged for each cell. A curve with 2 exponentials consistently gave the best fit to the
membrane response, giving values for the first time constant (x0) and an equalizing time constant (xi).
If the potential of the entire neuronal membrane could be changed uniformally, then only 1 time
constant would be observed, which would be an accurate measure of the membrane time constant
(xm). However, current injection into the cell soma causes differential depolarization of the dendrites,
which generate equalizing time constants. x0 was used to describe the cells in this study, which tends
to be a slight overestimate of xm (Rail 1969) (figure 4.10).
100
0.2mV
region of fitted curve
10ms
Figure 4.10 Time constant
A curve was fitted to the cell response from the peak of the response to the point
where the membrane potential returned to baseline levels. Limits of the fitter region




The rats were deeply anaesthetised by intraperitoneal injection of 25% urethane (1.25g/kg body
weight). Full anaesthesia was determined by lack of withdrawl reflex on applying a strong pinch to the
hind paw.
The animal was piimed onto a polystyrene board, in a fume hood, ventral side uppermost with
its forelimbs splayed to present the thorax for dissection. A button-hole incision was made with blunt
scissors and the skin was cut to expose the thorax. The base of the sternum was held with forceps and
the ribs cut through on either side of the sternum, which was pinned to the polystyrene board to reveal
the thoracic cavity. The heart was held firmly but gently using toothed forceps and the apex of the left
ventrical snipped. A catheter was carefully inserted into the aorta and taped to the animal's body to
hold it in place. The right atrium was snipped to provide an outlet for perfusate. To flush blood from
the brain, heparinized phosphate buffered saline was pumped into the aorta for about 10 minutes.
Fixative (4% paraformaldehyde, 0.1% gluteraldehyde in 0.1M phosphate buffer, pH 7.4,) was then
pumped into the aorta for about 30 minutes. Successful infusion of the brain was suggested by
stiffening of the forelimbs and neck. The rat was decapitated and the brain removed and stored in
fixative overnight. The brain was transferred to 70% EtOH for at least 24 hours before being
automatically processed overnight and mounted in a wax block.
4.72 Slicing and preparing samples for water-based stain
The wax block was trimmed and mounted onto a chuck. Eight micrometre parasagital sections
containing the dorsal hippocampus were cut on a microtome (Glen Creston, Stanmore). About 160
sections were cut from one hemisphere of each animal. These were floated in a water bath at 40°C
until smooth and then floated onto microscope slides coated with gelatin with 4 sections per slide.
These were dried overnight at 36°C.
The sections were dewaxed by immersion in xylene for 20 to 30 minutes, dehydrated by
passage through EtOH (absolute, 90%, 70%) and washed in tap water. Every 5th slide was selected for
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each type of basic stain used to allow a representative spread of the hippocampus to be examined with
each of the staining regimens. About thirty sections from each animal were tested with each stain.
4.73 Histological staining
Haematoxylin and eosin
Heamatoxylin stains cell nuclei dark blue. Eosin stains cytoplasm pink. Combined haematoxylin and
eosin staining can expose faint irregularities in the neuropil indicating amyloid plaques and evidence
of NFTs through distorted, tadpole-shaped cell bodies.
Sections were immersed in filtered haematoxylin for 5 minutes and checked under a light
microscope. If necessary, they were differentiated with acid alcohol before washing with Scott's tap
water substitute for 3 minutes. The sections were washed for 3 minutes in tap water before immersion
in filtered eosin for 2 minutes and potassium alum for 2 minutes. The sections were dehydrated
through EtOH (70%, 90%, 95%, absolute) and cleared in xylene. DPX mountant was added drop-wise
over the sections and a coverslip fixed carefully on top to avoid damage to sections or trapping air
bubbles. The mountant hardened overnight.
Congo Red (Highman method)
Congo red stains amyloid plaques red, showing the dense amyloid core in mature plaques. The
plaques have green bifringence under polarized light. This is a traditional stain for AD amyloid
plaques that has now been supersceded by immunohistology and silver staining methods. It was used
here to give an initial indication of the presence of pathology, that could later be corroborated by the
use of more rigorous techniques.
Sections were immersed in a mordant of saturated picric acid for 15 minutes and washed well.
They were then immersed in 0.5% congo red in 50% EtOH for 15 minutes or more and differentiated
with 0.2% potassium hydroxide in 80% EtOH if necessary. The sections were then washed and the




The aim of this investigation was to characterize a new line of transgenic rats carrying the human PS1
gene with the AD-causing M146V mutation, with the intention of identifying abnormalities to support
the use of these animals as a model of AD and to suggest mechanisms by which PS1 mutations may
cause the deficits typical of AD. The study focussed on the hippocampus, which is a major target of
AD pathology. Since the hippocampus subserves some forms of memory, deficits in the physiology of
this structure could underlie some of the memory impairment indicative of AD. Synaptic plasticity
was investigated as a measure of hippocampal function and intracellular recordings were made from
CA1 pyramidal neurones as a means of elucidating the possible mechanisms of altered synaptic
plasticity in the transgenic animals. Basic histological staining was used to expose any AD-type






Extracellular recordings of field potentials and synaptic plasticity
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5.1 Extracellular field potentials
Extracellular field potentials generated in the CA1 and the dentate gyrus were analyzed in 6 and 18
month old animals. All fields showed a rapid rising phase and a slightly slower decay phase. In some
recordings, the fibre volley was evident (eg figure 5.1A control), although in many cases this was
obscured by the rising phase of the EPSP.
From each slice, the amplitude, rising slope and half width of 20 field EPSPs were measured.
The field EPSPs generated during the baseline of LTP experiments were used (see section 5.4). These
were half maximal field EPSPs. Maximal EPSPs were found by increasing the stimulus intensity until
a population spike was evident. The rising slope of the EPSP was measured and then the stimulus
intensity was reduced to generate an EPSPs with half the maximum slope value. The results are
summarized in table 5.1 at the end of this section.
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5.11 Field EPSP parameters in the CA1
Typical CA1 field EPSPs recorded in control and transgenic animals at 6 and 18 months old are
shown in figure 5.1A and B. Histograms comparing the mean amplitude, half width and slope in
control and transgenic animals are shown for animals aged approximately 6 months (figure 5.1C) and
18 months (figure 5. ID). All analyses were performed using the student's t-test on data averaged for
each animal.
There was no significant difference in the amplitude, half width or slope of field EPSPs
recorded in control and transgenic groups of animals aged 6 months (amplitude P=0.915; half width
P=0.344; slope P=0.961; control n=4 rats, transgenic n=3 rats). In 18 month old animals there was
also no significant difference in the amplitude, half-width or slope of field EPSPs recorded in control
and transgenic groups (amplitude P=0.632; half width P=0.489; slope P=0.658; control n=6 rats,
transgenic n=6 rats).
The field EPSPs shown in figure 5.1A and B were chosen to represent as close as possible the
mean amplitude and slope parameters of their group. The field EPSPs generated at 18 months were
visibly larger in both the control and transgenic groups. Repeat measure analysis showed the
amplitude and slope, but not the half width of the field EPSPs, to be highly significantly increased at
18 months in both control (amplitude P<0.010 p(i_228)=9.239; slope P<0.01 F(ij228)=9.847; half width
P=0.943 F(1j228)=0.005) and transgenic (amplitude P=0.021 F(i,228)=6.993; slope P=0.031
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Figure 5.1 CA1 field EPSP properties
Examples of CA1 field EPSPs recorded from (A) 6 month and (B) 18 month old animals.
The upper traces were recorded from control animals and the lower traces were recorded
from transgenic animals. Histograms show the mean amplitude, half width and slope values
measured in (C) 6 month and (D) 18 month animals (control - black, transgenic - white).
There was no significant difference between control and transgenic groups in the Held
EPSP amplitude, half width or slope values (t-test. 6 months; amplitude P-0.915, half
width P=0.344 , slope P=0.961; control n=4 rats, transgenic n=3 rats. 18 months;






5.12 Field EPSP parameters in the dentate gyrus
Typical field EPSPs recorded in the dentate gyrus of control and transgenic animals at 6 and IB
months old are shown in figure 5.2A and B. Histograms comparing the amplitude, half width and
slope mean in control and transgenic animals are shown at 6 months (figure 5.2C) and 18 months
(figure 5.2D). All statistical analyses were performed using the student's t-test on tire average EPSP
values for each animal.
At 6 months, there was no significant difference in the amplitude, half width or slope of field
EPSPs recorded in control and transgenic groups (amplitude P=0.252; half width P=0.730; slope
P=0.741; control n=3 rats, transgenic n=4 rats). Unlike the CA1 field potentials, at 18 months there
was a significant difference in the amplitude, and slope but not half width of field EPSPs recorded in
control and transgenic groups in the dentate gyrus (amplitude P=0.048; slope P=0.030; half width
P=0.690; control n=9 rats, transgenic n=4 rats).
The field EPSPs shown in figure 5.2A and B were again chosen to represent as close as
possible the mean amplitude and slope parameters of their group. The field EPSPs generated in the
transgenic group at 18 months were visibly larger than those generated at 6 months, but there was
little apparent age-related change in field EPSP size in the control group. T-test analysis showed die
amplitude and slope, but not the half width of the field EPSPs recorded in the transgenic group to be
significandy increased at 18 months (amplitude P<0.05 F(i,265)=5.833; slope P<0.01 F(i>265)=l 1-722;
half width P=0.697 F(1265)=0.158). There was no age-related change in any of the three parameters in
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Figure 5.2 Dentate Gyrus field EPSP properties
Examples of DG field EPSPs recorded at (A) 6 months and (B) 18 months.
Histograms show the mean amplitude, half width and slope values ± SEM measured
in (CJ6 month and (D) 18 month animals (black - control, white - transgenic).
At 6 months, there was no significant difference in the field EPSP amplitude, half width
or slope values measured in the control and transgenic groups (t-test. Amplitude
P=0.252 half width P=0.730, slope P=0.741; control n=3 rats, transgenic n=4 rats).
However, at 18 months, the transgenic groups generated field EPSPs with significantly
greater amplitude and slope (but not half width) values (amplitude P=0.048; slope
P=0.030; half width P=0.690; control n=9 rats, transgenic n=4 rats).
transgenic
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Table 5.1 Properties of excitatory postsynaptic field potentials
Control Transgenic P and F values
(mean ± SEM) (mean ± SEM)
CA1 6 months
Amplitude (mV) 0.905 ±0.023 1.039 ±0.051 P=0.915
n=4 n=3
Half width (ms) 6.903 ±0.075 7.256 ±0.167 P=0.344
n=4 n=3
Slope (mV/ms) -0.354 ±0.009 -0.398 ±0.014 P=0.961
n=4 n=3
Dentate gyrus 6 months
Amplitude (mV) 1.726 ±0.061 2.355 ±0.029 P=0.252
n=3 n=4
Half width (ms) 4.853 ±0.055 5.474 ±0.094 P=0.730
n=3 n=4
Slope (mV/ms) -0.947 ±0.027 -1.087 ±0.190 P=0.741
n=3 n=4
CA1 18 months
Amplitude (mV) 1.618 ±0.036 1.872 ±0.041 P=0.632
n=6 n=6
Half width (ms) 6.923 ±0.104 6.770 ± 0.095 P=0.489
n=6 n=6
Slope (mV/ms) -0.584 ±0.010 -0.658 ±0.015 P=0.658
n=6 n=6
Dentate gyrus 18 months
Amplitude (mV) 2.557 ±0.040 3.406 ±0.065 P=0.048*
n=9 n=4
Half width (ms) 5.407 ±0.062 5.362 ±0.038 P=0.690
n=9 n=4
Slope (mV/ms) -1.395 ±0.033 -1.939 ±0.040 P=0.030*
n=9 n=4
All statistics were performed using the t-test.
Sample sizes; n=number of animals.
* Statistically significant P<0.05.
5.2 Paired pulse plasticity
Paired pulse plasticity of the field EPSP was studied in the CA1 and dentate gyrus. Pairs of stimuli
with interpulse intervals from 50 to 400ms were used to generate paired pulse facilitation (PPF) in
Schaffer collateral/CAl pyramidal cell synapses and paired pulse depression (PPD) in medial
perforant pathway/dentate gyrus granule cell synapses. The level of facilitation or depression is given
as a ratio, calculated by dividing the conditioned field EPSP slope by the conditioning field EPSP
slope.
5.21 Paired pulse facilitation in the CA1
PPF in die CA1 was strongest in response to shorter interpulse intervals, and decreased in a
non-linear manner as the interpulse interval was lengthened. PPF was expressed at all interpulse
intervals tested. Representative examples of field EPSPs from control and transgenic groups
demonstrating PPF in response to stimuli with a 50ms interpulse interval are shown at both 6 months
(figure 5.3A and B) and 18 months (figure 5.4 A and B). The relationship between PPF and interpulse
interval recorded at 6 months in slices from control and transgenic animals is shown in figure 5.3C. At
6 months, there was no significant difference in the strength of PPF recorded in control and transgenic
groups (2-way repeat measure ANOVA. P=0.996 F(U28)=0.0000258; control n=9 slices from 4
animals, transgenic n=9 slices from 5 animals).
The change in PPF with interpulse interval recorded at 18 months in slices from control and
transgenic animals is shown in Figure 5.4C. Typical PPF responses in control and transgenic groups
are shown in figure 5.4A and B). At 18 months, there was also no significant difference in the strength
of PPF recorded in control and transgenic groups (2-way repeat measure ANOVA. P=0.465
A(i,i44)=0.558; control n=10 slices from 5 animals, transgenic n=10 slices from 5 animals).
The strength of PPF was compared at 6 and 18 months within experimental groups (figure 5.5).
This revealed an increase in the strength of PPF with age in both control (2-way repeat measure
ANOVA. P<0.01 Fi,i36j=13.539; 6 months n=9 slices from 4 animals, 18 months n=10 slices from 5
animals) and transgenic groups (2-way repeat measure ANOVA. P0.001 F(ij136)=29.362; 6 months
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Figure 5.3 Paired pulse facilitation in the CA1 at 6 months
Examples of PPF in the CA1 of (A) control and (B) transgenic animals at 6 months.
Examples were chosen to show representative PPF strength. (C) shows the change
in PPF magnitude with interpulse interval. (Black - control, white - transgenic).
There was no significant difference in the strength of PPF generated by control and
transgenic groups in the CA1 at 6 months (2-way repeat measure ANOVA. P=0.996
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Figure 5.4 Paired pulse facilitation in the CA1 at 18 months
Examples of PPF in the CA1 of (A) control and (B) transgenic animals at 18 months.
Examples were chosen to show representative PPF strength. (C) shows the change
in PPF magnitude with interpulse interval. (Black - control, white - transgenic).
There was no significant difference in the strength of PPF generated by control and
transgenic groups in the CA1 at 18 months (2-way repeat measure ANOVA. P=0.465
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Figure 5.5 Age-dependent changes in CA1 PPF strength
The change in PPF magnitude with age is shown for (A) control and (B) transgenic
groups (6 months - black, 18 months - white). In both cases, there was a significant
increase in the strength of PPF with age, which was especially prevalent at smaller
interpulse intervals (2-way repeat measure ANOVA. Control P=0.002 F(1136)=13.539, 6
months n=9 slices from 4 animals, 18 months n=10 slices from 5 animals). Transgenic
(2-way repeat measure ANOVA. P<0.001 F(1136)=29.362; 6 months n=9 slices from 5
animals, 18 months n=10 slices from 5 animals).
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5.22 Paired pulse depression in the dentate gyrus
The change in PPD with interpulse interval recorded in the dentate gyrus showed a triphasic response
to the range of interpulse intervals used. PPD was strongest at 50ms, but fell rapidly as the interpulse
interval increased to 150ms, where PPD was weakest. At the longer interpulse intervals (200-400ms)
PPD strength was increased and established a plateau. PPD was expressed at all interpulse intervals
tested. Representative examples of field EPSPs from control and transgenic groups demonstrating
PPD in response to stimuli with a 50 ms interpulse interval are shown for both 6 months (figure 5.6A
and B) and 18 months (figure 5.7 A and B). The triphasic pattern of PPD activity was observed at both
6 months (figure 5.6C) and 18 months (figure 5.7C).
At 6 months, there was no significant difference in the strength of PPD recorded in control and
transgenic groups (2-way repeat measure ANOVA. P=0.144 F(1j72)=2.566; control n=4 slices from 4
animals, transgenic n=7 slices from 4 animals). However, there was a consistent trend towards
stronger PPD in the transgenic group at 6 months and the all-pairwise multiple comparison procedures
(Tukey Test) showed a highly significant difference between control and transgenic groups at the
50ms interpulse interval only (50 ms p<0.01; 75ms p=0.067; 100ms p=0.084; 150ms p=0.214; 200ms
p=0.364; 250ms p=0.471; 300ms p=0.411; 350ms p=0.506; 400ms p=0.559). At 18 months, there was
also no significant difference in the strength of PPD recorded in control and transgenic animals (2-
way repeat measure ANOVA. P=0.401 A(i>272)=0.725; control n=24 slices from 10 animals, transgenic
n=12 slices from 4 animals).
The strength of PPD was compared in 6 month and 18 month groups (figure 5.8). Unlike PPF,
PPD showed no age-related change in strength in control and transgenic groups (2-way repeat
measure ANOVA. Control; P=0.384 /'o.2ox)=0.784; 6 months n=4 slices from 4 animals, 18 months
n=24 slices from 10 animals. Transgenic; P=0.113 /rn,i36)=2.796; 6 months n=7 slices from 4 animals,
18 months n=12 slices from 4 animals).
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Figure 5.6 Paired pulse depression in the dentate gyrus at 6 months
Examples of PPD in the dentate gyrus of (A) control and (B) transgenic animals at
6 months, generated with a 50ms interpulse interval. Examples were chosen to show
representative PPD strength. (C) shows the change in PPD magnitude with interpulse
interval (Black - control, white - transgenic).
There was no significant difference in the strength of PPD generated in control and
transgenic groups in the dentate gyrus at 6 months (2-way repeat measure ANOVA.
P=0.144 F(172)=2.566; control n=4 slices from 4 animals, transgenic n=7 slices from 4
animals) however, the aii-pairwise multiple comparison procedure (Tukey test) showed
























Figure 5.7 Paired pulse depression in the dentate gyrus at 18 months
Examples of PPD in the dentate gyrus of (A) control and (B) transgenic animals at
18 months, generated with a 50ms interpulse interval. Examples were chosen to show
representative PPD strength. (C) shows the change in PPD magnitude with interpulse
interval (black - control, white - transgenic).
There was no significant difference in the strength of PPD generated in control and
transgenic groups in the dentate gyrus at 18 months (2-way repeat measure ANOVA.
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Figure 5.8 Age-dependent change in dentate gyrus PPD strength
The comparison of PPD magnitude generated at 6 months and 18 months is shown for
(A) control and (B) transgenic groups (black - 6 months, white -18 months). There was no
significant age-dependent change in PPD strength in either control or transgenic groups.
(2-way repeat measure ANOVA. Control; P=0.384 F(1208)=0.784; 6 months n=4 slices from
4 animals, 18 months n=24 slices from 10 animals. Transgenic; P=0.113 F(1136)=2.796; 6
months n-7 slices from 4 animals, 18 months n=12 slices from 4 animals).
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5.3 Post-tetanic potentiation
Postetanic potentiation of the field EPSP was induced using a 1 second 100Hz high frequency
stimulation train (HFS) and monitored by measuring the field EPSP slope in response to test stimuli
given every 15 seconds. The field EPSP slope value increased rapidly in response to the HFS and was
maximal within 5 minutes, before decaying more gradually into the STP/early LTP phase of
potentiation.. The increase in EPSP slope was expressed as a percentage change from baseline (pre-
HFS) values. The amplitude of PTP was taken as the largest increase in EPSP slope generated within
5 minutes of the HFS. The latency was the time (in seconds) from the end of the HFS to the maximal
PTP response. PTP amplitude and latency values are summarized in Table 5.2 at the end of section
5.3.
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5.31 Post-tetanic potentiation in the CA1
HFS consistently generated strong PTP in the CA1 in both control and transgenic groups at 6 and 18
months. Figure 5.9A shows the typical pattern of PTP development in the CA1 recorded from a 6
month old control animal. Histograms of the mean PTP peak amplitude and latency values are shown
for control and transgenic groups at 6 months (figure 5.9B) and 18 months (figure 5.9C).
The mean (± SEM) PTP amplitude at 6 months was 160.531% ± 27.446 in the control group
and 158.602% ± 16.853 in the transgenic group. The mean PTP amplitude at 18 months was
140.683% ± 17.366 in the control group and 128.519% ± 17.523 in the transgenic group. PTP
amplitude varied greatly. At 6 months the range of amplitude values was 90.734 to 251.671% in the
control group and 87.087 to 207.519% in the transgenic group. At 18 months the range of amplitude
values was 64.547 to 206.044% in the control group and 64.941 to 212.864% in the transgenic group.
There was no significant difference in the mean PTP amplitude generated in control and transgenic
groups at either 6 months (t-test; P=0.951 control n=6 transgenic n=8) or 18 months (t-test; P=0.636
control n=7 transgenic n=9).
In the CA1, PTP reached maximum within 60s of the HFS in both control and transgenic
groups (range; 6 months control 30-60s, transgenic 15-60s. 18 months control 15-60s, transgenic 15-
45s). Since test stimuli were given every 15s the resolution of PTP latency was low. There was no
significant difference in the PTP latencies recorded in control and transgenic groups at 6 months (t-
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Figure 5.9 Post-tetanic potentiation in the CA1
(A) shows a typical response to a tetanizing stimulus train (large arrow) recorded in
a 6 month old control animal. PTP is demonstrated by the sharp peak following the
tetanus. Histograms show the mean (± SEM) PTP amplitude and latency values at
(B) 6 months and (C) 18 months (black - control, white - transgenic).
There was no significant difference in the mean PTP amplitude or latency recorded in
control and transgenic groups at 6 months (t-test: amplitude; P=0.951 control n=6
transgenic n=8. Latency; P=0.108 control n=6 transgenic n=8) or 18 months (t-test:
amplitude; P=0.636 control n=7 transgenic n=9. Latency; P=0.139 control n=7
transgenic n=9).
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5.31 Post-tetanic potentiation in the dentate gyrus
High frequency stimulation consistently generated PTP in the DG in both control and transgenic
groups at 6 and 18 months. PTP generated in the dentate gyrus was weaker and took longer to reach
peak levels than PTP generated in the CA1. An example of the pattern of PTP development in the
dentate gyrus (recorded at 6 months from a control animal) is shown in figure 5.10A. Histograms of
the mean PTP peak amplitude and latency values are shown for control and transgenic groups at 6
months (figure 5.10B) and 18 months (figure 5.10C).
The mean (± SEM) PTP amplitude at 6 months was 98.036% ± 12.345 in the control group and
104.868% ± 9.393 in the transgenic group. The mean PTP amplitude at 18 months was 102.173% ±
15.165 in the control group and 106.319% ± 15.247 in the transgenic group. As in the CA1, PTP
amplitude varied greatly in the dentate gyrus. At 6 months the range of amplitude values was 65.354
to 136.892% in the control group and 79.925 to 144.574% in the transgenic group. At 18 months the
range of amplitude values was 33.563 to 302.033% in the control group and 15.247 to 200.061% in
the transgenic group. There was no significant difference in the mean PTP amplitude generated hi
control and transgenic groups at either 6 months (t-test; P=0.664 control n=5 transgenic n=6) or 18
months (t-test; P=0.859 control n=17 transgenic n=10).
In the DG, PTP was maximal within 3 minutes of the HFS in both control and transgenic
groups (range: 6 months control. 30 to 165s, transgenic 30 to 135s; 18 months control 45 to 270s,
transgenic 60 to 270s). There was no significant difference in the PTP latencies recorded in control
and transgenic groups at 6 months (t-test P=0.477 control n=5 transgenic n=6) or 18 months (t-test











































Figure 5.10 Post-tetanic potentiation in the dentate gyrus
(A) shows a typical response to a tetanizing stimulus train (large arrow) recorded in the
dentate gyrus ofa 6 month old control animal. PTP is demonstrated by the peak following
the tetanus. Histograms show the mean (± SEM) PTP amplitude and latency values at
(B) 6 months and (C) 18 months (black - control, white - transgenic).
There was no significant difference in the mean PTP amplitude or latency recorded in
control and transgenic groups at 6 months (t-test: amplitude; P=0.664 control n=5
transgenic n=6. Latency P=0.477 control n=5 transgenic n=6) or 18 months (t-test:
amplitude; P=0.859 control n=17 transgenic n=10. Latency P-0.303 control n=17
transgenic n=10).
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Table 5.2 Post-tetanic potentiation amplitude and time to peak latency
Control Transgenic P values
(mean ± SEM) (mean ± SEM)
CA1
6 months
PTP amplitude"!" 160.531 ± 27.446 158.602 ± 16.853 P=0.951
n=6 n=8
Latency (s) 52.5 ± 12.55 39.375 ± 13.742 P=0.108
n=6 n=8
18 months
PTP amplitudet 140.683 ± 17.366 128.519 ± 17.523 P=0.636
n=7 n=9




PTP amplitudet 98.036 ± 12.345 104.869 ± 9.393 P=0.644
n=5 n=6
Latency (s) 90.00 ± 22.25 70.00 ± 16.28 P=0.477
n=5 n=6
18 months
PTP amplitudet 102.173 ± 15.165 106.319 ± 15.247 P=0.859
n=17 n=10
Latency (s) 111.18 ± 16.273 136.50 ± 22.743 P=0.303
n=17 n=10
All statistics performed using the t-test.
tPTP amplitude is expressed as the per cent increase in field EPSP slope from pre-tetanized values.




Long-term potentiation (LTP) was generated in the Schaffer collateral/CAl pathway and the medial
perforant pathway/dentate gyrus pathway. A stable baseline was recorded for 30 minutes before using
a 1 second, 100Hz high frequency tetanizing stimulus (HFS) to generate LTP. A second identical HFS
was given an hour after the first. The field EPSP slope values measured during the baseline were
averaged offline and all slope values were normalized as a percentage of the baseline slope value.
Slope measurements made at 81 to 90 minutes were averaged to analyze the strength of LTP
expression, and an increase of 10% or more above baseline values were accepted as LTP. To assess
differences between groups, slope measurements made over the same 81-90 minute interval were
analyzed by nested ANOVA. Further increase in synaptic strength following the second HFS was
measured offline at 111-120 minutes.
5.41 Long-term potentiation in Schaffer-collateral/CAl pathway
Figure 5.11 shows example of field EPSPs recorded in the CA1 of slices from 6 and 18 month old
animals before and after HFS. Figures 5.12A and B show recordings from the CA1 for control and
transgenic groups at 6 months and 18 months respectively. LTP was evoked by HFS at the time point
indicated by the arrows. At 6 months, both control and transgenic groups showed the same qualitative
response to the HFS; rapid PTP generation, which quickly decayed into the early-LTP phase, with
stable LTP usually established within 1 hour. The strength of LTP expression varied greatly. At 6
months, the mean (± SEM) LTP expression level values were 22.64% ± 6.277 (control) and 18.029%
± 2.257 (transgenic) with ranges of 11.499 to 53.554% in the control group and 10.442 to 26.692% in
tire transgenic group. There was no significant difference in the strength of LTP expression recorded
in control and transgenic groups at 6 months (nested ANOVA; P=0.519 P=0.444 control n=3,
transgenic n=4). Figure 5.13 shows scatter plots of the relationship between the percentage of LTP
and the baseline EPSP slope and stimulus intensity. No correlation was found to suggest that the
increase in LTP recorded in the transgenic group was due to baseline effects (Pearson correlations;
Control LTP and EPSP slope P=0.873, LTP and stimulus intensity /M). 139, transgenic LTP and
EPSP slope P=0.131, LTP and stimulus intensity P=0.367).
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Figure 5.11 Field EPSPs in the CA1 before and after HFS
Traces are shown of EPSPs recorded from slices of 6 month (A-D) and 18 month (E-H)
old animals. (A), (B), (E) & (F) were recorded from control and (C), (D), (G) & (H) were
recorded from transgenic animals. The traces on the left were recorded during the baseline.
The traces on the right were recorded at 55 minutes following the HFS. The slope of fields
recorded after the HFS were all potentiated.

















Figure 5.12 Long-term potentiation in the CA1
LTP recorded in the CA1 of control (black) and transgenic (white) animals at (A) 6
months and (B) 18 months old. The Schaffer collaterals were tetanized at 30 and 90
minutes (arrows). (A) LTP recorded in slices from 6 month old transgenic rats was not
significantly different from that recorded in slices from control rats (nested ANOVA;
P=0.519 F(1 gg =0.444, control n=3 rats, transgenic n=4 rats.)
(B) LTP recorded in slices from 18 month old transgenic rats was significantly greater
than that recorded in slices from control rats (nested ANOVA; P=0.011 F(1126)=7.560
control n=6 rats, transgenic n=6 rats).
The second HFS generated further potentiation of between 10.077 and 45.347% (x=24.687% ±
4.781) in the control group and between 16.014 and 37.018 (x=24.223% ± 2.861) in the transgenic
group. Although the transgenic group still showed stronger LTP, there was no statistically significant
difference in either the total level of LTP expression in the control and transgenic groups (nested
ANOVA; P=0.227, A(i,99j=L635), or in the further increase in LTP expression measured in the two
groups (t-test; P=0.938).
At 18 months, the control group showed the same qualitative response to the HFS as was
described in the 6 month old animals. However, the LTP generated in the transgenic group showed a
striking qualitative difference (figure 5.14B). Instead of showing the gradual decrease in potentiation
following the end of the PTP phase, the level of potentiation in the transgenic group actually increased
slightly. This increase rapidly stabilized into a robust plateau of LTP expression that was established
within 10 minutes following the HFS. This was in stark contrast to the gradual decline of potentiation
that was observed in the control group that takes usually 30 minutes to establish a stable level of LTP
expression. There was a significant difference in the level of potentiation recorded for the first 20
minutes following HFS (2-way repeat measure ANOVA; P<0.001, F=22.117.). There was a
statistically significant interaction between genotype and time (P0.001, F=4.066). The strength of
LTP expression varied from 23.484 to 53.912% in the control group (x=39.674% ± 4.448) and from
37.467 to 117.700% in the transgenic group (x=65.301% ± 8.413). The level of LTP expression 51-60
minutes following HFS was significantly greater in the transgenic group (nested ANOVA; P=0.011
F(i,i26)=7.560 control n=6 rats, transgenic n=6 rats).
The second HFS generated further potentiation of between 9.872 and 38.346% (x=17.229% ±
6.898) in the control group and between 0.354 and 72.397% (x=21.362% ± 7.191) in the transgenic
group. In one control experiment, the second HFS caused an 18.44% depotentiation of LTP
expression. There a statistically significant difference in the total level of LTP expression in control
and transgenic groups following the second FIFS (nested ANOVA; P=0.002 F(ljl26)=11.662), although
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Figure 5.13 Correlations between percentage of CA1 LTP and baseline properties
Scatter plots show the relationship between percentage of LTP and average baseline EPSP
slope (A) and stimulus intensity (B) in control (black circles) and transgenic (open circles)
18 month groups.
There was no significant correlation between the percentage of LTP and the baseline EPSP
slope or stimulus intensity (Pearson correlations; Control LTP and EPSP slope P=0.873,
LTP and stimulus intensity P=0.139, transgenic LTP and EPSP slope P=0.131, LTP and
stimulus intensity P=0.367).
5.42 Long-term potentiation in medialperforant pathway/dentate gyruspathway
Figure 5.14 shows example of field EPSPs recorded in the DG of slices from 6 and 18 month old
animals before and after HFS. Figures 5.15A and B show LTP recorded in the CA1 for control and
transgenic groups at 6 months and 18 months respectively. At 6 and 18 months, both control and
transgenic groups showed the same qualitative response to the HFS; PTP decayed into the early-LTP
phase, with stable LTP usually being established within 1 hour.
The strength of LTP expression varied greatly. At 6 months, the mean (± SEM) LTP
expression level values were 40.323% ± 5.885 (control) and 40.666% ± 6.338 (transgenic) with ranges
of 27.385 to 59.179% in the control group and 25.611 to 63.302% in the transgenic group. There was
no significant difference in the strength of LTP expression recorded in control and transgenic groups
at 6 months (nested ANOVA; P=0.7.21, F(190)=0.136 control n=4 rats, transgenic n=4 rats ). At 18
months, the mean (± SEM) LTP expression level values were 42.214 ± 5.585% (control) and 49.636 ±
10.122% (transgenic) with ranges of 14.813 to 96.864% in the control group and 21.706 to 122.448%
in the transgenic group. There was no significant difference in the strength of LTP expression
recorded in control and transgenic groups at 18 months (nested ANOVA; P=0.055, F(U26)=4.368
control n=9 rats, transgenic n=4 rats ).
At 6 months, the second HFS generated further potentiation of between 0.53 and 41.25%
(x=19.417% ± 8.559) in the control group and between 2.49 and 29.93% (x=20.699% ± 3.926) in the
transgenic group. One slice in the control group showed 1.56% depotentiation. There was no
statistically significant difference in the total level of LTP expression in control and transgenic groups
following the second HFS (nested ANOVA; P=0.817 P(19o)=0.056), or in the level of further increase
in LTP expression (t-test; P=0.888). At 18 months, the second HFS generated further potentiation of
between 3.17 and 46.08% (x=14.499% ± 4.164) in the control group and between 0.300 and 57.700%
(x=27.339% ± 4.876) in the transgenic group. Three slices in the control group showed 0.14, 1.41 and
19.97% depotentiation of LTP expression following the second F1FS. There was no statistically
significant difference in the total level of LTP expression in control and transgenic groups following
the second FIFS (nested ANOVA; P=0.061 F(i,i26)=4.149), or in the further increase in LTP expression
(t-test; P=0.063) although this result was marginal and there was a trend towards stronger LTP
expression in the transgenic group noticable after the second HFS.
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Figure 5.14 Field EPSPs in the DG before and after HFS
Traces are shown of EPSPs recorded from slices of 6 month (A-D) and 18 month
(E-H) old animals. (A), (B), (E) & (F) were recorded from control and (C), (D), (G)
& (H) were recorded from transgenic animals. The traces on the left were recorded
during the baseline. The traces on the right were recorded at 55 minutes following
the HFS. The slope of fields recorded after the HFS were all potentiated.































































Figure 5.15 Long-term potentiation in the dentate gyrus
LTP recorded in slices from control (black) and transgenic (white) animals at (A) 6
months and (B) 18 months. The perforant pathway was tetanized at 30 and 90 minutes
(arrows). There was no significant difference in the level of LTP generated by slices from
control and transgenic animals at either 6 or 18 months (nested ANOVA; 6 months:
P=0.721 Fp qo)=0■ I36- Control n=4 rats, transgenic n=4 rats.
18 months: P=0.055 Fp 216)~4.368. Control n=9 rats, transgenic n=4 rats).
Part II
Intracellular recordings from CA1 pyramidal neurones in 18 month old
rats
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Sharp electrode intracellular recordings were made from CA1 pyramidal neurones in 18 month old
control and transgenic rats. The limited number of animals available prevented an intracellular
investigation in 6 month old animals. Of the fifty-three animals available for intracellular study, 12
became ill and had to be killed without use (most commonly due to tumours) and twenty-two yielded
slices that were not healthy enough to make successful intracellular recordings. This left nineteen
animals that yielded healthy slices from which recordings were successfully made. Cells were
accepted for analysis if the resting membrane potential had a negative value of at least -60mV,
generated action potentials with amplitudes of at least 60mV and had a membrane resistance of more
than 20MQ. The findings of this study are summarized in table 5.3 at the end of part II.
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5.5 Basic membrane properties of CA1 pyramidal neurones
5.51 Resting membrane potential
The provisional value for the resting membrane potential was recorded from impaled cells and
adjusted if necessary if the voltage registered at the recording electrode when withdrawn from the
neurone was not zero, to give the true resting membrane potential.
Figure 5.16 shows the frequency distribution of resting membrane potential values recorded in
control and transgenic groups. The resting membrane potential values ranged from -60 to -87.5mV in
the control group (x=-66.49mV ± 1.23) and -60 to -83.20mV in the transgenic groups (x=-63.39mV ±
0.61). The resting membrane potential values recorded in the control and transgenic groups was not
significantly different (Mann-Whitney rank sum test; P=0.513 control n=36, transgenic n=54).
5.52 Membrane resistance
Hyperpolarizing and depolarizing current pulses were injected into neurones and the resulting change
in membrane potential was recorded. Figure 5.17A shows the membrane responses to current
injection. The membrane potential response was measured in the early part of the sweep to avoid bias
of the result by rectifying voltage gated currents. Also to minimize bias caused by voltage activated
currents, only responses to hyperpolarizing pulses of between -5 and -125pA were included in the
analysis. The current voltage relationship was plotted as shown in figure 5.17B and the value of the
slope is the membrane resistance.
Membrane resistance values ranged from 22.757 to 82.168MQ in the control group
(x=38.39MQ ± 2.19) and 20.030 to 74.078MQ in the transgenic group (x=40.18MQ ± 1.94) (figure
5.17C). The mean (± SEM) membrane resistance values are shown in figure 5.17D. The difference in
membrane resistance values recorded in neurones from control and transgenic groups was not
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Figure 5.16 Resting membrane potential
(A) Frequency distribution of resting membrane potential values in control and transgenic
groups. Values are grouped into 1mV bins. (B) Mean resting membrane potential values
( ± SEM). The difference between values recorded in control and transgenic groups was
not statistically significant (Mann-Whitney rank sum test P=0.513. Control; x = -66.46mV








































Figure 5.17 Membrane resistance
(A) Membrane response to current pulses rangeing from -205 to 35pA. (B) The
membrane responses to hyperpolarizing current pulses to -130pA were plotted to
calculate the membrane resistance. (C) Frequency distribution of membrane
resistance values in control and transgenic groups. (D) Comparing the mean
membrane resistance values (± SEM). The difference in membrane resistance
values in the control and transgenic groups was not statistically significant
(t-test; P=0.549, control n=33, transgenic n=50).
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5.53 Time constant
A 0.5ms hyperpolarizing current pulse was used to generate a passive membrane response, to which a
curve was fitted to calculate the neuronal time constant (figure 5.18A). Time constant values ranged
from 7.427 to 59.824ms in the control group and from 11.229 to 67.177ms in the transgenic group.
The frequency distributions are shown in figure 5.18B. Figure 5.18C shows the mean (±SEM) time
constant values recorded in the control (x=30.62ms ± 2.41) and transgenic (x=27.81ms ± 1.79)
groups. The difference in time constant values recorded in control and transgenic groups was not
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Figure 5.18 Time constant
(A) Membrane response to a 0.5ms hyperpolarizing current pulse. (B) Frequency
distribution of time constant values recorded in the control (black) and transgenic
(white) groups. Time constant values are grouped into 5ms bins. (C) Comparing the
mean (± SEM) of the time constant values. The difference in time constant values
recorded in the control and transgenic groups was not statistically significant (t-test;
P=0.343 control n=28, transgenic n=41).
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5.6 Action potential properties
Action potentials were generated by injecting depolarizing current into the neurone. The amplitude,
rise time, decay time and half width of five action potentials were measured and the average gave
representative values for each cell. An example of an action potential is shown in figure 5.19A.
Action potential amplitude values ranged from 64.46 to 79.80mV in the control group
(x=72.867mV ± 0.686) and from 60.22 to 82.46mV in the transgenic group (x=71.703mV ± 0.772).
The frequency distributions of amplitude values are shown in figure 5.19B and the mean values (±
SEM) are shown in figure 5.19C. The difference in action potential amplitudes recorded in the control
and transgenic groups was not statistically significant (Mann-Whitney rank sum test; P=0.465, control
n=29 transgenic n=51).
Action potential rise time values ranged from 0.40 to 0.76ms in the control group (x=0.59ms ±
0.013) and from 0.44 to 0.76ms in the transgenic group (x=0.59ms ± 0.012). The frequency
distributions are shown in figure 5.20A and the mean values (± SEM) are shown in figure 5.20B. The
difference in action potential rise time recorded in the control and transgenic groups was not
statistically significant (Mann-Whitney rank sum test; P=0.877, control n=29 transgenic n=51).
Action potential decay time values ranged from 0.84 to 1.46ms in the control group
(x=l.078ms ± 0.023) and from 0.68 to 1.50ms in the transgenic group (x=l.068ms ± 0.024). The
frequency distributions are shown in figure 5.20C and the mean values (± SEM) are shown in figure
5.20D. The difference in action potential decay time recorded in the control and transgenic groups was
not statistically significant (t-test; P=0.778, control n=29 transgenic n=51).
Action potential half width values ranged from 0.76 to 0.98ms in the control group (x=0.851ms
± 0.010) and from 0.70 to 1.50ms in the transgenic group (x=0.869ms ± 0.011). The frequency
distributions are shown in figure 5.20E and the mean values (± SEM) are shown in figure 5.20F. The
difference in action potential half width recorded in the control and transgenic groups was not
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Figure 5.19 Action potential amplitude
(A) Action potential induced by a single depolarizing current pulse. (B) Frequency
distribution of action potential amplitude values in control (black) and transgenic
(white) groups. Action potential amplitude values are grouped in 1mV bins. (C)
Mean (± SEM) amplitude values.
The difference in action potential amplitude values measured in control and
transgenic groups was not statistically significant (Mann-Whitney rank sum





















































Figure 5.20 Action potential rise time, decay time and half width
Frequency distribution graphs are shown for action potential (A) rise time, (C) decay time
and (E) half width in control (black) and transgenic (white) groups. Action potential rise time
and fall time values are grouped into 0.05ms bins and half width values are grouped into
0.02ms bins. Mean (± SEM) values are plotted for (B) rise time, (D) decay time and (F)
half width.
There was no significant difference in the action potential rise time (Mann-Whitney rank
sum test P=0.877) decay time (t-test P=0.778) or half width (t-test P=0.264) measured in
control and transgenic groups (control n=31, transgenic n=52).
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An afterdepolarizing potential (ADP) followed single action potentials in 18 out of 31 (58%)
control cells and 22 out of 52 (42%) transgenic cells. An example of both ADP and fAHP responses in
a control cell is shown in figure 5.21 A. Afterdepolarizing potential amplitudes ranged from 0.20 to
13.64mV (x=4.51mV ± 0.84) in the control group and from 0.11 to 11.06mV (x=4.058mV ± 0.612) in
the transgenic group. Figure 5.2 IB shows frequency distributions of ADP amplitudes. The mean
(±SEM) ADP amplitude values are shown in figure 5.21C. The difference in ADP amplitudes
recorded in control and transgenic groups was not statistically significant (t-test; P=0.661 control
n=18, transgenic n=22).
A fast afterhyperpolarizing potential (fAHP) followed the action potential in 21 out of 31
(67%) control cells and 34 out of 52 (65%) transgenic cells. Fast afterhyperpolarizing potential
amplitudes ranged from 0.260 to 3.803mV (x=1.503mV ± 0.350) in the control group and from 0.140
to 8.480mV (x=1.271mV ± 0.267) in the transgenic group. Figure 5.21D shows frequency
distributions of fAHP amplitudes. The mean (±SEM) fAHP amplitude values are shown in figure
5.22E. The difference in ADP amplitudes recorded in control and transgenic groups was not
statistically significant (Mann-Whitney rank sum test; P=0.562 control n=21. transgenic n=34).
Single action potentials were followed by an fAHP and an ADP in 15 out of 31 (48%)
control neurones and 22 out of 52 (42%) transgenic neurones (figure 5.21A). No aflerpotential was
observed following action potentials in 9 out of 31 (29%) control and 20 out of 52 (38%) transgenic
neurones. There was no significant difference in the numbers of neurones showing an ADP, fAHP.






















































Figure 5.21 Action potential afterdepolarizing and fast hyperpoiarizing potentials
(A) Both a small ADP and a fAHP followed the action potential in this cell. Frequency
distributions ofADPs (B) and fAHPs (D) in control (black) and transgenic (white) groups.
Values were grouped into 1mV (ADP) and 0.5mV (fAHP) bins. The mean (± SEM) values
are shown for the (C) ADP and (E) fAHP.
The difference in ADP and fAHP values recorded in control and transgenic groups was
not statistically significant (ADP: t-test; P=0.661, control n=18 transgenic n=22. fAHP:
Mann-Whitney rank sum test; P=0.562. control n=21 transgenic n=34.)
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5.7 EPSP properties
EPSPs in CA1 pyramidal neurones were generated by stimulation of the Schaffer collaterals in the
stratum radiatum. For consistancy between cells and animals, measurements were made from half
maximal EPSPs. To obtain synaptically generated half maximal EPSPs, the stimulus intensity was
increased until an action potential was generated in response to 50% of stimuli. The amplitude was
measured and the stimulus intensity decreased to obtain an EPSP with a half maximal amplitude
value. Superimposed examples of EPSPs recorded in control and transgenic groups is shown in figure
5.22A.
EPSP amplitude values ranged from 2.181 to 11.369mV in the control group (x=5.704mV ±
0.512) and from 2.681 to 11.107mV in the transgenic group (x=5.995mV ± 0.369). The frequency
distributions of amplitude values are shown in figure 5.22B and the mean values (± SEM) are shown
in figure 5.22C. The difference in EPSP amplitudes recorded in the control and transgenic groups was
not statistically significant (t-test; E=0.638, control n=22 transgenic n=30).
EPSP rise time values ranged from 3.5 to 13.2ms in the control group (x=5.65ms ± 0.49) and
from 3.3 to 9.4ms in the transgenic group (x=6.03ms ± 0.34). The frequency distribution of rise time
values is shown in figure 5.23A and the mean values (± SEM) are shown in figure 5.23B. The
difference in EPSP rise time recorded in the control and transgenic groups was not statistically
significant (Mann-Whitney rank sum test; P=0.251, control n=22 transgenic n=30).
EPSP decay time values ranged from 3.60 to 101.40ms in the control group (x= 19.659ms ±
4.901) and from 3.0 to 84.1ms in the transgenic group (x=30.70ms ± 4.50). The frequency
distributions of EPSP decay time values is shown in figure 5.23C and the mean values (± SEM) are
shown in figure 5.23D. The difference in EPSP decay time recorded in the control and transgenic
groups was not statistically significant (Mann-Whitney rank sum test; E=0.060, control n=22
transgenic n=30) although there was a trend towards a longer decay time in the transgenic group.
EPSP half width values ranged from 4.30 to 45.60ms in the control group (x=10.718ms ±
1.964) and from 4.10 to 37.49ms in the transgenic group (x=14.85ms ± 1.50). The frequency
distribution of half width values is shown in figure 5.23E and the mean values (± SEM) are shown in
figure 5.23F. The action potential half width recorded in the transgenic groups was significantly
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longer than that recorded in the control group (Mann-Whitney rank sum test; P=0.016, control n=22
transgenic n=30).
Figure 5.24 shows scatter plots of EPSP properties against resting membrane potential. There
was no significant correlation between resting membrane potentian and EPSP amplitude, rise time,
decay time or half-width in either control or transgenic groups. (Pearson correlation. Control; resting
membrane potential and EPSP amplitude P=0.699, EPSP rise time P=0.069, EPSP decay time
P=0.198 and EPSP 1/2 width P=0.189. Transgenic; resting membrane potential and EPSP amplitude
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Figure 5.22 EPSP amplitude
(A) Examples of synaptically generated EPSPs in control and transgenic groups,
showing the increase half width in the transgenic group. (B) Frequency distribution
of EPSP amplitudes in control (black) and transgenic (white) groups. (C) Mean (±
SEM) amplitudes; there was no significant difference in the mean EPSP amplitudes
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Figure 5.23 EPSP rise time, decay time and half width
Distribution graphs are shown for EPSP (A) rise time, (C) decay time and (E) half width
in control (black) and transgenic (white) groups. Values are grouped into (rise time) 0.5ms,
(decay time) 5ms and (half width) 1ms bins. Mean (± SEM) values are plotted for (B) rise
time, (D) decay time and (F) half width.
There was no significant difference in the EPSP rise time (P=0.251) or fall time (P=0.060)
values recorded in control and transgenic groups. The EPSP half width values recorded in
the transgenic group were significantly longer (P=0.016). (All statistics using Mann-Whitney
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Figure 5.24 Resting membrane potential and EPSP properties
Scatter plots show the relationship between the resting membrane potential and
(A) EPSP amplitude, (B) EPSP rise time, (C) EPSP decay time and (D) EPSP
half width in control (black circles) and transgenic (open circles) groups. There
was no significant correlation between resting membrane potential and EPSP
properties in control or transgenic groups.
Control; resting membrane potential and (A) EPSP amplitude P=0.699, (B) EPSP
rise time P=0.069, (C) EPSP decay time P=0.198 and (D) EPSP 1/2 width P=0.189.
Transgenic; resting membrane potential and (A) EPSP amplitude P=0.123,
(B) EPSP rise time P=0.175, (C) EPSP decay time P=0.113 and (D) EPSP 1/2
width P=0.232 (Pearson correlation).
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5.8 Action potential firing frequency
Depolarizing current pulses of between 20 and 780pA were used to investigate the current/firing
frequency relationship and firing frequency adaptation of action potentials. Neurones either showed
rapid adaptation to silence or established a steady state of firing that persisted for the duration of the 2
second long current pulse. Neurones are referred to as rapidly or slowly adapting on the basis of these
firing patterns. Examples of both types of response are shown in figure 5.25. Neurones showing
persistent firing properties were used to investigate potential differences between the control and
transgenic groups. Persistent firing was observed in 14 out of 29 (48.3%) control neurones and 31 out
of 53 (58.5%) transgenic neurones.
Action potential frequencies were measured for spikes 1 and 2 (1st interspike interval), spikes
2 and 3 (2nd interspike interval) and averaged over the last 4 spike in the train (steady state). The
relationship of these values with change in current strength is shown in figure 5.26. The action
potential firing frequency over the 1st interpulse interval was not significantly different in control and
transgenic groups (2-way repeat measure ANOVA; P=0.906 F(i>6o7)=0.014. Control n=14, transgenic
n=31). The maximum firing frequencies were 77.31Hz ± 4.36 (range 45.05 to 116.28Hz) in the
control group and 70.05Hz ± 7.32 (range 25.00 to 138.89Hz) in the transgenic group. The action
potential firing frequency over the 2nd interpulse interval was not significantly different in control and
transgenic groups (2-way repeat measure ANOVA; P=0.730 ,=0.120. Control n=14, transgenic
n=30). The maximum firing frequencies were 62.36Hz ± 4.35 (range 28.57 to 81.97Hz) in the control
group and 58.84Hz ± 5.91 (range 17.73 to 106.38Hz) in the transgenic group. The action potential
firing frequency at steady state was not significantly different in control and transgenic groups (2-way
repeat measure ANOVA; P=0.554 F(i>437)=0.356. Control n=14, transgenic n=25). The maximum
firing frequencies were 5.71Hz ± 0.97 (range 1.69 to 11.56Hz) in the control group and 7.72Hz ± 1.09






Figure 5.25 Action potential firing patterns
Responses to a 700pA depolarizing current pulse are shown for slowly and rapidly adapting
neurones. (A) shows action potential firing frequency adaptation to a steady state that
persisted for the 2 second duration of the sweep. (B) shows rapid adaptation to silence.
The two types of response were observed in neurones from both control and transgenic
groups (control; adaptation to silence 15/29 neurones, persistent firing 14/29 neurones.
Transgenic; adaptation to silence 22/53 neurones, persistent Tiring 31/53 neurones). There
was no significant difference in the number of rapidly and slowly adapting neurones in the
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Figure 5.26 Current - action potential firing frequency relationship
Current-frequency plots are shown for the (A) 1st, (B) 2nd and (C) steady state spike
intervals. The difference in action potential firing frequency in control and transgenic
groups was not significant at any of the intervals measured (2-way repeat measure
ANOVA; 1st interspike interval P=0.906 F(16Q7=0.014 control n=14 transgenic n=31.
2nd interspike interval P=0.730 F(1671)=0.120 control n=14 transgenic n=30. Steady
state P=0.554 F(1437)=0.356 control n-14 transgenic n=25).
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A plot of action potential firing frequency adaptation in control and transgenic cells in response
to a 660pA depolarizing current pulse is shown in figure 5.27. The first interval frequency values were
64.74Hz ± 5.16 in the control group (range 36.50 to 108.70Hz) and 64.49Hz ± 5.15 in the transgenic
group (range 15.48 to 108.70Hz). The final interval frequency values were 13.73Hz ± 2.67 in the
control group (range 2.67 to 16.39Hz) and 15.25Hz ± 1.96 in the transgenic group (range 1.95 to
19.16Hz). Neurones from both control and transgenic groups reached a plateau firing frequency by
about the 8th interspike interval. There was no significant difference in the firing frequency values
recorded in the control and transgenic groups at any interval (t-test; P values ranged from 0.181 to
0.992).
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Figure 5.27 Action potential firing frequency adaptation
Trains of action potentials were generated using a 660pA current pulse. Both control
(black) and transgenic (white) neurones showed rapid adaptation, reaching a steady
state firing frequency by the 8th interspike interval. There was no significant difference
in adaptation in control and transgenic groups (t-tests performed at each interval. P
values ranged from 0.181 to 0.992).
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5.9 Medium and slow afterhyperpolarization
Hippocampal pyramidal neurones show periods of membrane hyperpolarization following bursts of
action potentials (APs). To investigate if these hyperpolarizations were altered in the transgenic rats,
burst of 8, 12, 16 and 20 action potentials APs were evoked to generate medium and slow
afterdepolarizations (mAHP and sAHP). The mAHP last for less than 1 second and its amplitude was
taken as the maximal level of hyperpolarization following tire burst. The sAHP lasts for upto 4
seconds. The peak amplitude of the sAHP was often obscured by the mAHP and so the level of
hyperpolarization recorded 1 second following the end of the burst was taken as a representative value
for the sAHP amplitude. Figure 5.28 shows examples of mAHPs and sAHPs generated in neurones
from control and transgenic animals.
The mAHP amplitude varied greatly with control values ranging from 1.300 to 7.825mV
following an 8 AP burst (x=4.082mV ± 0.282), 1.738 to 8.43 lmV following a 12 AP burst
(x=5.173mV ± 0.336), 1.825 to 8.881mV following a 16 AP burst (x=5.297mV ± 0.349) and 1.806 to
9.050mV following a 20 AP burst (x=5.170mV ± 0.369) (figure 5.30B. C. D &E). Ranges in the
transgenic group were 1.138 to 8.738mV following an 8 AP burst (x=3.830mV ± 0.228), 1.463 to
9.481mV following a 12 AP burst (x=4.557mV ± 0.249), 1.863 to 10.838mV following a 16 AP burst
(x=4.794mV ± 0.319) and 1.931 to 11.450mV following a 20 AP burst (x=5.039mV ± 0.311). The
change in mAHP amplitude with the number of APs in the conditioning burst is shown in figure
5.29A. The mAHP amplitude generated following a 12 AP burst was significantly greater than that
generated following an 8 AP burst in both control and transgenic groups (t-test; control /J=0.()15, 8 AP
burst n=36, 12 AP burst n=32. Transgenic P=0.034, 8 AP burst n=46, 12 AP burst n=44). The
increase in the mAHP amplitude generated by 16 AP bursts and 20 AP bursts was not significantly
greater than that generated by 12 AP bursts in either control or transgenic groups (t-test; control 12 &
16 AP bursts P=0.798, 12 & 20 AP bursts P=0.804, 16 AP bursts n=32, 20 APs n=25. Transgenic 12
& 16 AP bursts ,P=0.557, 12 & 20 AP bursts P=0.586, 16 AP bursts n=44, 20 AP bursts n=38). The
difference in mAHP amplitude generated in control and transgenic groups was not significant (t-test; 8
AP burst P=0.485, 12 AP burst P=0.137, 16 AP burst P=0.295, 20 AP burst P=0.788).
157
The sAHP amplitude varied greatly with control values ranging from 0.600 to 7.363mV
following an 8 AP burst (x=3.471mV ± 0.268), 0.931 to 7.575mV following a 12 AP burst
(x=4.230mV ± 0.325), 1.306 to 7.856mV following a 16 AP burst (x=4.158mV ± 0.320) and 1.100 to
7.869mV following a 20 AP burst (x=4.214mV ± 0.375) (figure 5.3 IB, C, D &E). Ranges in the
transgenic group were 0.894 to 8.350mV following an 8 AP burst (x=3.178mV ± 0.224), 0.969 to
8.456mV following a 12 AP burst (x=3.603mV ± 0.231), 1.219 to 9.738mV following a 16 AP burst
(x=3.679mV ± 0.292) and 1.056 to 10.588mV following a 20 AP burst (x=3.829mV ± 0.290). The
relationship between sAHP amplitude and the number of APs in the conditioning burst is shown in
figure 5.30A. The increase in the sAHP amplitude generated by 12, 16 and 20 AP bursts was not
significantly greater than that generated by 8 AP bursts in either control or transgenic groups (t-test;
control comparing 8 & 12 AP bursts P=0.074, 8 & 16 AP bursts P=0.102. 8 & 20 AP bursts P=0.103.
Transgenic comparing 8 & 12 AP bursts P=0.190, 8 & 16 AP bursts P=0. 171. 8 & 20 AP bursts
P=0.075). The difference in sAHP amplitude generated in control and transgenic groups was not
significant (t-test; 8 AP bursts P=0.402, 12 AP bursts P=0.110, 16 AP bursts P=0.276, 20 AP bursts
P=0.415).
Figures 5.32 and 5.33 show scatter plots of slow and medium AHP amplitudes respectively
against resting membrane potential for control and transgenic groups. There was no significant
correlation between the medium AHP amplitude and resting membrane potential (Pearson correlation:
Control; mAHP8 P=0.056, mAHP12 P=0.082, mAHP16 P=0.098, mAHP20 P=Q. 140. Transgenic;
mAHP8 P=0.213, mAHP12 P=0.319, mAHP16 P=0.196, mAHP20 P=0.150). There was no
significant correlation between the slow AHP amplitude and resting membrane potential (Pearson
correlation: Control; sAHP8 P=0.036, sAHP12 P=0.072, sAHP16 P=0.090, sAHP20 P=0.075.










Figure 5.28 Medium and slow afterhyperpolarization
Medium and slow afterhyperpolarizing responses to a train of
20 action potentials are shown for control and transgenic groups.
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Figure 5.29 Medium AHP amplitude
(A) The amplitude of the mAHP increased significantly when the number of action
potentials (APs) in the conditioning train was increased from 8 to 12 (t-test; control
P=0.015 8 APs n=36 12 APs n=32. Transgenic P=0.034, 8 APs n=46 12 APs n=44.)
The difference in mAHP amplitude generated by 12 APs and 16 or 20 APs was not
statistically significant (t-test; control 12 & 16 APs P=0.798, 12 & 20 APs P=0.804,
16 APs n=32, 20 APs n=25. Transgenic 12 & 16 APs P=0.557, 12 & 20 APs P=0.586, 16
APs n=44, 20 APs n=38). The difference in mAHP amplitude generated in control and
transgenic groups was not significant (t-test; 8 APs P=0.485, 12 APs P=0.137, 16 APs
P=0.295, 20 APs P=0.788). Frequency distributions are shown for mAHP amplitudes
generated in control and transgenic groups in response to (B) 8, (C) 12, (D) 16 & (E) 20
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Figure 5.30 Slow afterhyperpolarization amplitude
(A) The amplitude of the slow AHP increased when the number of conditioning action
potentials (APs) was increased from 8, but this was not significant (t-test control comparing
8 & 12 APs P-0.074, 8 & 16 APs P=0.102, 8 & 20 APs P=0.103. Transgenic comparing 8
& 12 APs P=0.190, 8 & 16 APs P=0.171, 8 & 20 APs P=0.075.)
The difference in sAHP generated in control and transgenic groups was not statistically
significant (t-test; 8 APs P=0.402, 12 APs P=0.110, 16 APs P=0.276. Mann-Whitney rank
sum test; 20 APs P-0.395). Frequency distributions are shown for the sAHP amplitudes
generated in control and transgenic groups in response to (B) 8, (C) 12, (D) 16 and (E)
20 APs.(Control 8 APs n=36, 12 AP2 n=30, 16 APs n=32, 20 APs n=25. Transgenic 8 APs
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Figure 5.31 Medium AHP amplitude and resting membrane potential
Scatter plots show the relationship between the resting membrane potential and the
medium AHP amplitude following a train of (A) 8, (B) 12, (C) 16 and (D) 20 action
potentials in control (black circles) and transgenic (open circles) groups.
There was no significant correlation between the resting membrane potential and the
medium AHP amplitude in control (mAHP8 P=0.056, mAHP12 P=0.082, mAHP16
P=0.098, mAHP20 P=0.140) or transgenic (mAHP8 P=0.213, mAHP12 P=0.319,
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Figure 5.32 Slow AHP amplitude and resting membrane potential
Scatter plots show the relationship between the resting membrane potential and the
slow AHP amplitude following a train of (A) 8, (B) 12, (C) 16 and (D) 20 action
potentials in control (black circles) and transgenic (open circles) groups.
There was no significant correlation between the resting membrane potential and the
slow AHP amplitude in control (sAHP8 P=0.036, SAHP12 P=0.072, SAHP16
P=0.090, SAHP20 P-0.075) or transgenic (sAHP8 P=0.700, SAHP12 P=0.804,
sAHP16 P=0.489, sAHP20 P=0.458) groups (Pearson correlation).
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RMP resting membrane potential. Rm membrane resistance. ADP after-depolarizing potential. f,m,s
AHP slow, medium, fast hyperpolarizing potentials. APs action potentials,






Parasaggital section of rat brain including transverse sections of the hippocampus were fixed in
paraformaldehyde and stained with haematoxylin and eosin or congo red. Human cortex from an
Alzheimer's disease subject was stained alongside the rat sections as a positive control.
Both haematoxylin and eosin and congo red stains successfully demonstrated the presence of
pathology in the human AD tissue. Figure 5.34 shows an amyloid plaque in human AD cortex stained
with haematoxylin and eosin at x200 magnification. An amyloid plaque stained with congo red
observed under x400 magnification is shown illuminated with normal light (figure 5.35A) and
showing biffingence when viewed under polarized light (figure 5.35B). Congo red staining also
showed accumulation of neurofibrillary tangles in pyramidal cell bodies at x400 magnification (figure
5.36).
Between 25 and 50 sections were examined from 3 control and 5 transgenic rats. No signs of
amyloid plaque formation were observed in any of the sections whether stained using haematoxylin
and eosin or congo red. Examination of congo red-stained sections under polarized light gave no
evidence for the presence of amyloid plaques. Figure 5.37 shows part of the CA1 in a section from a
transgenic rat at xlOO magnification stained with haematoxylin and eosin demonstrating the complete
lack of pathology. Similarly, examples of CA1 hippocampal sections from the same transgenic rat are
shown stained with congo red at lOOx magnification illuminated with normal (figure 5.38A) and
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Figure 5.34 Human AD cortex sections showing amyloid plaques stained with H & E
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Figure 5.35 Human AD cortex sections showing amyloid plaques stained with congo
red
Photographs of the same plaque revealed using congo red staining observed at x400
magnification under (A) normal light and (B) polarized light.
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Figure 5.36 Human AD cortex sections showing neurofbrillary tangles
Photographs of neurofibrillary tangles revealed using congo red staining observed at x400












Figure 5.37 M146V rat hippocampus section stained with haematoxylin and eosin
Sections of rat hippocampus stained with haematoxyllin and eosin, observed at x100
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Figure 5.38 M146V rat hippocampus section stained with congo red
Sections of rat hippocampus stained with congo red, observed at x100 magnification showed





Fischer rats were genetically engineered to express the human PS1 protein carrying the familial
Alzheimer's disease-causing Ml46V mutation. Using electrophysiological and histological
techniques, the suitability of these transgenic rats to be used as a model for Alzheimer's disease was
assessed.
6.1 Summary of Results
The strength of LTP expression was increased in the PSlMi46v rat in both an age-dependent and
pathway-specific manner. The increase in LTP strength was only observed in the Schaffer
collateral/CAl pathway in aged animals. Paired pulse plasticity and post-tetanic potentiation were
unchanged in this pathway. There was no change in perforant pathway/dentate gyrus synaptic
plasticity, even in aged animals.
PPF in the CA1 was stronger in aged animals in both control and transgenic groups. This age-
dependent change in PPF strength was not observed in the DG.
The amplitude and rising slope of field EPSPs recorded in the dentate gyrus were elevated in
the transgenic rats.
Intracellular recordings revealed no differences in the basic membrane properties and non-
synaptically driven activity in CA1 pyramidal neurones. Ffowever, synaptically evoked EPSPs did
have an increased half width. Since there was no trend towards an increase in the EPSP rise time or
amplitude, this was most likely attributable to the increased, (though not statistically significant)
duration of the decay time.
No evidence of amyloid plaques was seen in the congo red or haemotoxylin and eosin stained
sections of brain from the PSlMi46v rat. Sections from the cortex of a human AD subject did show
evidence of plaques and tangles when processed alongside the PSlMi46v rat tissue. The absence of
amyloid deposition was confirmed by immunohistological staining of slices from the same animals
(Professor Ironside and co-workers, CJD Unit, Western General Hospital, Edinburgh).
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6.2 Elevated LTP expression
Elevated LTP expression, as observed in the aged PSlMi46v rat, has been reported in the CA1 of
transgenic mouse models carrying PS1 mutations (Barrow et al 2000, Parent et al 1999, Zaman et al
2000). Animal models of AD using APPP mutations have shown a decrease in LTP expression levels
(Moechers et al 1999, Chapman et al 1999) although older mice have shown a reversal to elevated
LTP expression (Larson et al 1999). Mutations to both proteins lead to altered APPP processing,
which has suggested that changes in the abundance of different ApPP cleavage products constitutes a
common mechanism by which all known FAD-causing mutations act. However, whilst APPP
mutations such as the Swedish mutation (concentrated around the P-secretase cleavage site) promote
P-secretase processing, leading to an upregulation of both AP40 and Ap42, with a concomitant decrease
in the neuroprotective sApPPa, PS1 mutations, along with APPP mutations concentrated around the
y-secretase cleavage site such as the London mutation) cause selective upregulation of Ap42 without
generating a significant change in the level of other cleavage products (Dewachter et al 2000, Xia et al
1998). This is consistent with the observed (though not yet characterized) role of PS1 in y-secretase
activity and suggests that it is the ratio of Ap42/Ap4o rather than the absolute level of Ap that is
pathogenic in AD induced by PS 1 mutations. Although the differences in LTP response to APPP and
PS1 mutations could be due to difference in the way they alter APPP processing, it is also possible
that PS1 mutations can disrupt normal neurophysiology by mechanisms unrelated to APPP processing
pathways to initiate AD progression.
PS1 levels are usually tightly regulated, and whilst ApPP can be overexpressed at high levels,
significant upregulation of PS1 is difficult to achieve, suggesting that even small changes in PS1
levels can perturb normal cellular physiology. PS1 mutations A246E and M146L lead to an increase
in levels of N- and C-terminal fragments, which seems to be due to increased stability of fragments
from the mutated protein (Lee et al 1997). Therefore, FAD mutations in PS1 may allow subtle
changes in PS1 activity by impairing clearance of excess protein, suggesting a possible pathogenic
gain of function.
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Lack of altered CA1 PPF recorded in brain slices showing enhanced LTP expression has been
reported in other PS1 models (Parent et al 1999, Zaman et al 2000). The lack of altered PPF in the
CA1 of the aged PS1MI46V rat suggests that the enhanced LTP expression was not caused by changes
in Ca2+ homeostasis in the CA3 pyramidal neurone axon terminals.
PTP was also not altered in the PSlMi46v rat, suggesting that enhanced LTP expression was not
caused by abnormal Ca2+ buffering by presynaptic mitochondria or by altered numbers of
mitochondria.
Intracellularly recorded EPSP parametres have not been investigated in other PS1 models of
AD. Both NMDA receptor and GAB A receptor mediated currents contribute strongly to the late phase
of the EPSP and so it is possible that the increased half width observed in the PSlMi46v rat represents
either enhanced NMDA activity or depressed GABAergic activity. The contribution of NMDA
currents to the EPSP was measured in a PS 1 AE9 transgenic mouse and was unchanged with respect
to the control group (Zaman et al 2000), suggesting that PS1 mutations do not influence NMDA
activity.
An increase in EPSP half width has been observed in the conditioned response during paired
pulse facilitation and this has been attributed to inhibition of GABAergic interneurones by GABA
released during the first pulse acting on presynaptic GABAb receptors (Nathan et al 1990).
GABAergic activity also influences CA1 LTP induction; inhibiting GABAa transmission with
picrotoxin enhances LTP expression (Wigstrom & Gustafsson 1985) and enhancing GABAa
transmission with benzodiazepines decreased LTP expression (Del Cerro et al 1992).
The importance of GABAergic activity in modulating LTP is also indicated by a study of how
choice of cutting solution during the preparation of hippocampal brain slices affects subsequent LTP
generation. Cutting slices in a solution that replaced NaCl with sucrose helped to preserve neurones
against anoxic damage during slicing. Slices cut in sucrose-substituted aCSF expressed weaker LTP
and this was attributed to better preservation of GABAergic interneurones (Kuenzi et al 2000).
Anoxia, which is unavoidable during preparation of brain slices, leads to neuronal depolarization and
excitotoxicity, which has been attributed to influx of CF and cations. This draws water into the cell,
which causes swelling and cell lysis. The NaCl/sucrose substitution in the cutting solution preserves
neuronal stability and allows more reliable preparation of healthy slices from adult tissue (Aghajanian
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& Rasmusen 1989). Therefore, enhanced GABAb mediated suppression of GABAergic interneurones
could potentiate facilitation of postsynaptic responses to HFS and so explain the increase in LTP
expression in the PSlMi46v rat. However, the time course of GABAB-mediated autoinhibition is too
slow to explain the increase in EPSP half width.
GABAa currents were also measured in the AE9 mouse and rather than being depressed,
GABAa activity was actually increased (Zaman et al 1999). They observed that blocking GABAa
with picrotoxin in slices from control animals enhanced CA1 LTP to levels comparable to the
transgenic group. However, transgenic slices perfused with picrotoxin failed to show additional LTP
expression, suggesting that the modulation of LTP by GABAa and by the PS1 mutation act
independently on a common pathway.
The authors suggested that the link between the effects of the PS1 mutation and enhanced
GABAa activity on LTP expression could be Ca2+ homeostasis. Enhanced Ca2+ responses to
depolarization and A(3 have been recorded in PC12 cells transfected with PSlL286v (Guo et al 1996),
cells from PS1 FAD transgenic animals (Guo et al 1998) and fibroblasts from affected human subjects
(Etcheberrigaray et al 1998). This led to increased neuronal vulnerability to apoptosis (Guo et al 1998,
Begley et al 1999). The adverse effects of PS1 mutations were alleviated using intracellular Ca2+
buffers and inhibitors of Ca2+-induced Ca2+ release from intracellular stores (Begley et al 1999).
Zamen et al suggested that the PS1 mutation causes enhanced release of Ca2+ from intracellular stores
in response to Ca2+ influx through NMDA receptors and that the observed increase in GABAa
currents was an (inadequate) compensatory reaction to the resulting increase in neuronal excitability
(Zaman et al 2000). They also suggested that the PS 1-induced increase in intracellular Ca2+ levels may
promote Ap production, as has been induced by promoting Ca2+ release from intracellular stores in
cultured cells (Querfurth & Selkoe 1994).
Two recently published papers have addressed the question of how PS1FAd causes altered Ca2
homeostasis (Leissring et al 2000, Yoo et al 2000). Both studied the effects of PS1FAd on the
regulation of endoplasmic reticulum (ER) Ca2+ stores. Before the results of these papers are discussed,
the proposed mechanisms of ER Ca2+ homeostasis will be outlined.
Receptor activity at the cell membrane can result in release of Ca2+ from the endoplasmic
reticulum by two mechanisms. G-protein coupled receptors that activate PKC cause release of IP3,
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which activates Ca2+ channel linked receptors (IP3R) in the ER membrane. A second Ca2+ channel
linked receptor, ryanodine (RyR), is activated by Ca2+ and mediates Ca2+-induced Ca2+ release.
Stimulation of these receptors induces a biphasic pattern of Ca2+ activity; the initial peak caused by
release from the ER is followed by a second peak, which is due to Ca2+ influx through store-activated
calcium channels (SOCC) in the plasma membrane and serves to replenish ER Ca2+ levels. This
second peak can be induced in the absence of receptor activation by artificially depleting ER Ca2+
stores with thapsigargin, indicating that this response is independent of second messenger cascades
initiated by receptor activation and is induced solely by the drop in ER Ca2+ levels. This direct
coupling between ER Ca2+ depletion and influx of extracellular Ca2+ is known as capacitative calcium
entry (CCE) (Putney et al 1986). The precise mechanisms are still to be elucidated and the SOCC has
not been isolated, (although the resulting current, Icrac has been characterized electrophysiologically),
however, recent research has discounted many of the theories formerly proposed and has allowed a
clearer understanding of the events involved.
Evidence supports the theory that coupling involves direct physical interaction between the ER
and the plasma membrane (Ma et al 2000). The proteins involved in this interaction are SOCC in the
plasma membrane and IP,Rin the ER membrane, although in its coupling role, IP3R does not bind IP3.
IP3R is believed to interact with and cause conformational change in the SOCC, which allows direct
influx of extracellular Ca2+ into the ER. IP3R is morphologically suited for this putative role since it
has an intraluminal C-terminal domain, which could monitor ER Ca2+ levels, and a cytosolic N-
terminal domain that is large enough to span the gap between the ER and the plasma membrane, and
so could interact with SOCC.
Cells expressing FAD PS1 are associated with depressed CCE activity (Leissring et al 2000,
Yoo et al 2000). Cells in which PS1 is absent or non-functional have increased CCE activity (Yoo et
al 2000), which suggests that PS1 is a modulator of CCE and that the depression of CCE activity in
cells carrying FAD PS1 reflects a gain of function. Ffowever, Leissring et al observed that the level of
Ca2+ in the ER was strongly elevated in cells carrying PSlMi46v and that treatment with thapsigargin to
deplete ER Ca2+ stores elicited a normal CCE response, indicating that CCE mechanisms are not
impaired (Leissring et al 2000). Therefore, the CCE underactivity associated with FAD PS1 is
probably due to insufficient Ca2 depletion during neuronal activity to create a drive for coupling
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rather than dysfunction of the pairing mechanism. This suggests that the initial deleterious event
caused by FAD PS1 is elevated ER Ca2+ concentration. Although the mechanisms causing this are yet
to be determined it has been observed that RyR mRNA and protein levels are elevated in the brains of
mice expressing PS1mi4«v or PS1U86V. This is accompanied by an increased Ca2+ response to caffeine
(which binds RyR), susceptibility to excitotoxicity and apoptosis (Chan et al 2000).
Yoo et al also observed that normal cells in which CCE was inhibited using SKF96365 showed
increased A(3 production, and that this required the expression of functional PS1 (Yoo et al 2000).
Therefore, the elevated Ap42 levels that are associated with cells carrying FAD PS1 are likely to be a
response to CCE depression. This may even be a protective compensatory response. Animal models of
FAD PS1, including the PS1mi46v rat, all show enhanced LTP expression, which could potentially
saturate synaptic capacity for plastic change. Intracerebroventricular injection of Ap42 into rat brain
has been shown to promote CA1 LTD expression and can depotentiate LTP if applied within 10
minutes of an LTP-inducing tetanus (Kim et al 2001). Hippocampal slices perfused with Ap40, which
is downregulated in FAD PS1, show elevated LTP expression (Wu et al 1995) whilst perfusion with
the active AP25.35 fragment depresses LTP (Freir et al 2001). Therefore, the increased ratio of
AP42/Ap^o in cells expressing FAD PS1 may reflect a bias towards the synaptic plasticity-suppressing
longer isoform, intended to protect against saturation of synaptic plasticity and excitotoxicity.
The CCE studies used cultured fibroblasts and neurones from neonatal (Leissring et al 2000) or
embryonic (Yoo et al 2000) mice carrying the M146V or M146L mutations, showing that Ca2f
homeostasis dysfunction is an early and probably an initiating event in FAD PS1 pathogenesis. This
suggests that the development of AD symptoms and pathology in human cases is a result of years of
physiological changes intended to compensate for the effects of, but failure to reverse, elevated Ca2+
levels. These compensatory mechanisms eventually generate deleterious side-effects possibly initiated
by the accumulation of Ap, as detailed in the introduction. Given the importance of Ca2+ in cellular
physiology, the extent of the spectrum of systems, including inflammatory responses, mitochondria,
tau function, APPP processing, metal ion regulation and oxidant clearance, which present deficits in
AD cases is certainly not surprising.
These observations support a possible role for enhanced Ca2+ activity in the generation of
elevated LTP in the PSlMi46v rat. The elevated Ca2+ response may also lead to the increase in EPSP
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half width since GABA responses are suppressed by high Ca2 levels, leading to decrease in the
duration, but not amplitude of IPSCs (Koninck & Mody 1996).
6.3 Phenotypic change in LTP expression
CA1 LTP in slices from transgenic rats was not only enhanced but showed a consistent difference in
the pattern of development. The usual response to high frequency tetanization is an initially powerful
post-tetanic potentiation which declines exponentially into early LTP. The level of potentiation
gradually falls for often over thirty minutes before a stable level of LTP expression is established.
LTP in the CA1 of aged transgenic rats showed normal PTP but rather than showing a gradually
declining early LTP phase, the postsynaptic response increased in strength briefly and slightly before
reliably establishing a robust plateau of LTP expression within 15 minutes. This phenotypic change
suggests that the observed increase in LTP involves an increased potency of early LTP expression
mechanisms and is not merely caused by facilitation of induction by a lowered threshold for LTP or
enhancement of the Ca2+ response increasing the probability that the threshold is reached, (although
these may contribute, or even be necessary for the later effects).
The rapid stabilization of LTP expression level may be due to altered activity of NMDA and
AMPA receptors following the tetanus. Blockade of NMDA receptors following tetanization leads to
enhanced stability of the AMPA receptor response to test stimuli with a time course that is similar to
that seen for the stabilization of LTP expression in the PS1mi46v rat (Xiao et al 1996). This leads to the
possibility that NMDAR activity in the PSlMi46v rat following tetanus is unusually low and the
changes in LTP expression pattern and strength are mediated by a lack of decay in AMPA receptor
activity. This conflicts with the idea proposed in chapter 3 that enhanced NMDA receptor activity by
PKC-dependent src tyrosine kinase phosphorylation of NR2B (Huang & Hsin 1999a) facilitates
establishment of LTP. Instead, it suggests that such NMDA receptor-enhancing mechanisms may
negatively regulate the expression level of LTP and their impairment would be a possible explanation
for the observations in the PS1M146V rat. Zamen et al failed to show a change in the NMDA receptor
contribution to the EPSP in the PS1AE9 mouse model during 4-pulse bursts at 100 Hertz (Zaman et al
2000). There are several possible explanations for this discrepancy. It is possible that altered NMDA
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receptor activity would only be apparent following prolonged tetanic stimulation, such as the 100-
pulse 100 Hertz stimulation used in the PSlMi«v rat study. Also, the response to APV antagonism of
NMDA receptor activity in the control group showed a large variance, suggesting a larger sample
would be needed to reveal potential differences in NMDA activity in the PS 1 ae9 mouse. Alternatively,
it is possible that the PSlMi46v mutation has a different effect on neurophysiology. This is possible
since the PS1AE9 mutation prevents PS1 cleavage and so the pathogenic species is full length PS1
rather than the persistent C- and N-terminal fragments generated by other PS1 mutations. However, if
the lack of change in NMDA receptor activity is confirmed, then other mechanisms must be
responsible for the observed phenotypic changes in LTP expression pattern. An extensive (though not
exhaustive) search of the literature failed to find reports of manipulations that had generated elevated
LTP in conjunction with phenotypic changes mimicking those observed in the PS1mi46v rat and so
current research fails to suggest alternative mechanisms.
6.4 Amyoid-beta production
Cells from subjects carrying PS1 mutations show upregulation of Ap42 production. The levels of A(342
and A(340 in the PSImi^v rat were not assayed due to the lack of a commercially available ELISA kit
for rodent Ap protein. However, mouse models of FAD PS1 mutations that have been tested all show
an increase in the Ap42 levels in the absence of significant changes in the level of total Ap (Duff et al
1996, Citron et al 1997). The increase in Ap42 expression in these mice was not determined by the
level of mutated PS1 protein expression, which suggests that the low level of human PS1 protein
detected in the PS1M146V rat does not preclude the possibility of significant Ap42 upregulation. Indeed,
the ability of the PSImi^v rat to replicate the changes in synaptic plasticity observed in the mouse
models suggests that upregulation of Ap42 will eventually be confirmed.
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6.5 Enhanced LTP and memory
The hippocampus is important for spatial memory in rodents. Procedures that interfere with normal
dorsal hippocampal function lead to impaired performance in behavioural tests such as the water maze
and the T-maze (McDonald et al 1998, Hock et al 1998).
T-maze testing of spatial memory was attempted in the aged PS1M146V rat. However, both
control and transgenic rats failed to perform sufficiently well during extensive pretraining (lasting
over a week) to proceed with experiments. Both control and transgenic rats showed poor exploratory
behaviour, which seemed to be due to nervousness in the new environment. They typically took a long
time to begin exploring the maze and spent the majority of their time cowering. They showed head
swaying behaviour, suggesting fear. They did eat the food reward, which was scattered throughout the
maze, but only after a long delay (sometimes over an hour) even when the food was found quickly.
The same food rewards were consumed readily when presented to the rats in their home cage. Better
performance might have been achieved by pretraining the animals at an earlier age to familiarize them
with the maze environment.
Enhance performance in spatial memory tasks has been observed in conjunction with elevated
LTP expression (Madani et al 1999, Routtenberg et al 2000). However, current theory on synaptic
plasticity and its possible role in memory formation, can also support the possibility of impaired
memory formation in response to enhanced LTP expression. Memory encoding is thought to involve
not only potentiation at strongly activated synapses but also depotentiation at weakly activated
synapses, as a means of improving memory pattern resolution. Therefore, inappropriate
overexpression of LTP (as generated by LTP expression in an unusually large number of the activated
synapses) may impair pattern discrimination. It may also lead to saturation of synaptic capacity for
plastic change, although saturation was not observed in the PSlMi46v rat when just 2 episodes of
tetanic stimulation were used.
Impaired memory in response to treatments that elevate LTP expression levels have been
observed. Mice lacking the protein tyrosine phosphatase 8 receptor show elevated LTP expression
levels but have impaired memory when tested in the water maze, T-maze or radial arm maze (Uetani
et ai 2000). Transverse rat hippocampal slices perfused with Ap40 showed elevated LTP expression
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(Wu et al 1995), but intracerebral injection of Ap resulted in impaired performance of treated rats in
the radial arm maze test (Yamaguchi & Kawashima 2001). Mutation of the postsynaptic density-95
protein enhanced long-term potentiation in mice but impaired learning in a water maze (Migaud et al
1998). Although selective inhibition of postsynaptic GABAb receptors using CGP 35348 facilitated
LTP generated by HFS in a dose dependent manner, the change in performance of mice in a spatial
delayed nonmatch-to-sample task following intraperitoneal injections of CGP 35348 did not follow
the dose response relationship of altered LTP expression (Staubli et al 1999).
Therefore, it is possible that the increased LTP expression in the PSlMi46v rat may not have
correlated with improved memory and learning in behavioural tests, but may have been an
inappropriate increase in synaptic strength that could actually disrupt memory formation. Behavioural
tests have been performed on mice carrying FAD PS1 mutations and failed to show a difference in
performance at 6 or 9 months old (Janus et al 2000b).
6.6 Ca2+ dependent events recorded intracellularly
The Ca2+ explanation of the elevated LTP response in the PSlMi46v rat was not supported by the
intracellular study. AHPs and action potential firing frequency adaptation are Ca2+ dependent events
(mediated by Ca2'-dependent K currents) and these were unchanged in the PS1m146v rat. If Ca2+
responses were enhanced in these animals, the expected intracellular observations would be larger
AHPs and more rapid action potential firing frequency adaptation.
A possible explanation is that cells with significantly higher Ca2+ responses were less viable
due to excitotoxicity and did not tolerate impalement by sharp electrodes. However, these neurones
would have been available to contribute to extracellular field recordings. An increase in the medium
and slow AHP amplitudes have been reported in CA3 pyramidal neurones of two lines of mice
carrying different PS 1 mutations (Barrow et al 2000), although it should be noted that the sample sizes
used were extremely low (control n=4 cells, PS1mi46l n=3 and PS1M146V n=4 cells).
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6.7 Enhanced PPF expression in the CA1 of aged rats
The observed increase in PPF expression in the CA1 of both control and transgenic groups is contrary
to a previously published study that showed a decrease in PPF expression in 16 month old rats
compared to 2 month old rats (Papatheodoropoulos & Kostopoulos 1998), however, they assessed
PPF based on field EPSP area rather than slope.
At single synapses, stronger PPF is associated with a smaller conditioning response
(Debanne et al 1996), however, the amplitude of field EPSPs was increased in the older rats. This
suggests that the stronger PPF recorded in the old rats may be due to increased level of synaptic
coupling that has been observed between both CA1 pyramidal neurones and dentate gyrus granule
cells in the aged hippocampus (Barnes et al 1987).
6.8 Enhanced field EPSP amplitude and slope in the dentate gyrus
The amplitude and slope of field EPSPs recorded in the dentate gyrus were increased in aged
transgenic rats. This is contrary to a previous report of decreased fEPSP slope recorded from aged rat
dentate gyrus granule cells (Levkovitz & Segal 1998). However, this did not lead to a change in
dentate gyrus LTP or PPD expression levels. Since recordings in the dentate gyrus were made in the
presence of picrotoxin, it is unlikely that the age related changes were due to a decrease in intrinsic
GABA release. Also, changes in GABA receptor activity would be unlikely to affect the rising slope
of the field EPSP. This suggests that the increase in field EPSP slope and amplitude may be mediated
by increased AMPA and/or NMDA receptor activity. Alternatively, there could be a change in the
pattern of synaptic input onto granule cell dendrites resulting in greater uniformity in the parts of the
dendritic tree that receive synaptic input, which could cause the increased fEPSP slope and amplitude
by decreased variability in the time course of EPSP generation throughout the population of activated
cells.
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6.9 Absence of amyloid plaques
The lack of amyloid deposition in animal models of PS1 FAD has been previously reported (Chui et al
1999, Lamb et al 1999). Cerebral amyloid deposition is commonly observed in the brain from elderly
human subjects but is not seen in aged rodent brain. Rodent A(3 differs from human A(3 in at least 2
residues (Podlisny et al 1991). Human Ap seems to aggregate more readily than rodent Ap; human Ap
is aggregated in the presence of Cull, especially in acidic conditions, whilst rat Ap (and human Ap in
which histidine residues had been substituted to mimic the species differences in amino acid
sequence) failed to aggregate under these conditions (Atwood et al 1998). Transgenic rats expressing
FAD ApPP mutations do show amyloid deposition and this is likely to be due to the presence of
human ApPP.
6.10 Choice of control group
The control animals used in this study do not express human PS1, therefore it is possible that the
observed difference in the transgenic group are due to upregulation of PS1 and are independent of the
mutation. PS1 upregulation is difficult to achieve since its expression level is tightly regulated.
Therefore, even small changes in PS1 activity could be physiologically important and upregulated PS1
could be the reason for the differences in electrophysiology observed in the PSlMi46v rat. Increased
PS1 expression can saturate PS1 cleavage (Borchelt et al 1996) and so it is possible the changes
observed here are induced by elevated full-length PS1, which is physiologically active (Levitan et al
1996).
This discrepancy could be controlled by using a control group that expresses wild-type human
PS1, however the control and experimental lines would then need to be bred independently, which
could introduce genetic drift and false positive results. Using non-transgenic controls allowed
transgenic animals to be compared with their littermates and removed the risk of errors due to genetic
drift. Mating of the control and transgenic rats gave litters that were about fifty per cent control and
fifty per cent transgenic hemizygotes. The use of hemizygotes was appropriate since this is the
genotype of human subjects.
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However, enhanced LTP expression has been observed when animals expressing FAD PS1 are
compared with controls that carry human wild-type PS1 suggesting that the increase in LTP is induced
by the mutation (Duff et al 1996, Zaman et al 2000). Zaman et al used both non-transgenic and wild-
type human PS1 transgenic control groups, and these showed no significant differences in their
electrophysiology (Zaman et al 2000). A PSlMi46V mouse model has provided a particularly rigorous
model of AD since the human gene was inserted using knock-in techniques, which simultaneously
ablates the endogenous mouse PS1 (Guo et al 1999a). This allowed the human protein to be expressed
not only at the level normally exhibited by endogenous mouse PS1 but also preserved the site-
specificity of expression. These observations support the PS1 mutation and not altered PS1 expression
levels as the source of the changes observed in the PSlMi46v rat.
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Conclusion
The PSlMi46v rat has successfully demonstrated some important features of AD. The increase in LTP
expression indicates that the level of transgenic protein expression, although small, was sufficient to
generate strongly significant physiological change. The literature suggests that this increase was due
to altered Ca2+ homeostasis, which seems to be an early and possibly causative event in AD
pathogenesis, at least in PS1 FAD cases. Although the levels of A(342 were not investigated in these
animals, other PS1 models of AD have shown a selective increase in Ap42. The PSlMi46v rat has
shown elevated LTP expression as seen in other PS1 models in which elevated Ap42 has been
measured. It has been suggested that the increase in LTP expression is caused by elevated Ca2+ levels
and elevated Ca2+ levels can lead to increased Ap42 production. The elevated expression of LTP in the
PS1M146V rat therefore suggests that altered APPP processing will also be demonstrated in this model.
In addition, the change in LTP expression was both age-dependent and site-specific with a pattern that
was consistent with human AD progression.
The observations made in the PSlMi46v rat were consistent with those that have been reported
for mice carrying PS1FAD. However, the rats showed an additional stark qualitative difference in the
pattern, as well as amplitude, of CA1 LTP expression in the aged animals. This may reflect specific
abnormalities in the interaction of STP/LTP and further research will be needed to identify the
mechanisms involved. Depression of NMDA receptor activity during early LTP expression can
facilitate LTP strength, suggesting a possible focus for further investigation.
Although no evidence of plaques or tangles were observed, this is in line with other similar
studies. Cross-breeding the PSlMi46V rat with transgenic animals expressing A(IPPfad, wildtype
human A(3PP or human tau protein may allow the species differences that have prevented these
pathologies to develop to be overcome. Cross-breeding could also possibly reduce the incidence of
tumour development in animals approaching 18 months and so allow older animals to be studied.
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Appendix I
Criteria for Clinical Diagnosis of Alzheimer's Disease
I The criteria for the clinical diagnosis of PROBABLE Alzheimer's disease include:
dementia established by clinical examination and documented by the Mini-Mental Test, Blessed
Dementia Scale, or some similar examination, and confirmed by neuropsychological test;
deficits in two or more areas of cognition;
progressive worsening of memory and other cognitive functions;
no disturbance of consciousness;
onset between ages 40 and 90, most often after age 65; and
absence of systemic disorders or other brain diseases that in and of themselves could account for
the progressive deficits in memory and cognition.
II The diagnosis of PROBABLE Alzheimer's disease is supported by:
progressive deterioration of specific cognitive functions such as language (aphasia), motor skills
(apraxia), and perception (agnosia);
impaired activities of daily living and altered patterns of behavior;
family history of similar disorders, particularly if confirmed neuropathologically; and
laboratory results of normal lumbar puncture as evaluated by standard techniques,
normal pattern of nonspecific changes in EEG, such as increased slow-wave activity, and
evidence of cerebral atrophy on CT with progression documented by serial observation.
III Other clinical features consistent with the diagnosis of PROBABLE Alzheimer's disease, after
exclusion of causes of dementia other than Alzheimer's disease, include:
plateaus in the course of progression of the illness;
associated symptoms of depression, insomnia, incontinence, delusions, illusions, hallucinations,
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catastrophic verbal, emotional, or physical outbursts, sexual disorders, and weight loss;
other neurologic abnormalities in some patients, especially with more advanced disease and
including motor signs such as increased muscle tone, myoclonus, or gait disorder;
seizures in advanced disease; and
CT normal for age.
IV Features that make the diagnosis of PROBABLE Alzheimer's disease uncertain or unlikely
include:
sudden, apoplectic onset;
focal neurologic findings such as hemiparesis, sensory loss, visual field deficits, and incoordination
early in the course of the illness; and
seizures or gait disturbances at the onset or very early in the course of the illness.
V Clinical diagnosis of POSSIBLE Alzheimer's disease:
may be made on the basis of the dementia syndrome, in the absence of other neurologic,
psychiatric, or systemic disorders sufficient to produce dementia, which is not considered to be the
cause of the dementia; and
should be used in research studies when a single, gradually progressive severe cognitive deficit is
identified in the absence of other identifiable cause.
VI Criteria for diagnosis of DEFINITE Alzheimer's disease are;
the clinical criteria for probable Alzheimer's disease; and
histopathologic evidence obtained from biopsy or autopsy.
VII Classification of Alzheimer's disease for research purposes should specify features that may
differentiate subtypes of the disorder, such as:
familial occurrence;
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onset before age of 65;
presence of trisomy-21; and
coexistence of other relevant conditions such as Parkinson's disease.
(Reproduced with permission; Lippincott, Williams & Wilkins, Philadelphia)
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